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Summary of Thesis 
Human nuclear receptor (NR) superfamily represents an important group of regulating 
factors of a large number of physiologically important target genes. In this project, we 
hypothesized that the phenotype of non-synonymous single nucleotide polymorphisms 
(nsSNPs) of NRs and their target genes could be predicted using computational approaches 
and that herbal compounds regulated CYP3A4 via pregnane X receptor (PXR) mediated 
pathway. To test this hypothesis, we have: a) predicted the potential functional impact of 
nsSNPs of human NR genes using a bioinformatic approach; b) predicted the phenotype of 
nsSNPs in human ATP-binding cassette (ABC) transporters using an identical bioinformatic 
approach; and c) investigated the effects of a panel of herbal compounds on the activity of 
PXR and the expression of its target gene CYP3A4 in cell lines derived from human colon and 
liver tumors. 
 
Firstly, we employed two algorithms, Sorting Intolerant from Tolerant (SIFT) and 
Polymorphism Phenotyping (PolyPhen) to predict the impact of non-synonymous SNPs 
(nsSNPs) on NR activities and disease susceptibility. We identified 442 nsSNPs in a 
systematic screening of 48 human NR genes. Using SIFT, of 442 amino acid substitutions, 
289 (65.38%) were classified as “intolerant”. The PolyPhen program classified 269 (60.86%) 
of them as “probably damaging” or “possibly damaging”. The results from the two 
algorithms were in concordance. Among the 442 mutations, 229 of them have been 
functionally characterized. SIFT predicted 192 of these nsSNPs as “intolerant”, resulting in a 
correct prediction rate of 83.84%, while PolyPhen gave a prediction rate of 76.86%. For 216 
nsSNPs of the androgen receptor gene, 149 nsSNPs have been functionally studied and most 
(121) of them resulted in a reduction of receptor activity. SIFT sorted 187 out of 216 as 
“intolerant” (86.57%) and PolyPhen identified 159 out of 216 as “potentially intolerant” 
(73.61%). These results indicate that both SIFT and PolyPhen are useful and efficient tools to 
predict the functional effects of nsSNPs of human NR genes. 
 
Secondly, we predict the phenotypical impact of nsSNPs of human ABC transporter genes 
and the predicted results were further validated by phenotypical data from site-directed 
mutagenesis and clinical genetic studies. One thousand and six hundred thirty two nsSNPs 
were found from 49 human ABC transporter genes. Using the PolyPhen and SIFT algorithms, 
41.8-53.6% of nsSNPs in ABC transporter genes were predicted to have an impact on protein 
function. The prediction accuracy was up to 63-85% when compared with known 
 vi
phenotypical data from in vivo and in vitro studies. There was a significant concordance 
between the prediction results using SIFT and PolyPhen. Of nsSNPs predicted as deleterious, 
the prediction scores by SIFT and PolyPhen were significantly related to the number of 
nsSNPs with known phenotypes confirmed by experimental and human studies. The amino 
acid substitution variants are supposed to be the pathogenetic basis of increased susceptibility 
to certain diseases with Mendelian or complex inheritance, altered drug resistance and 
altered drug clearance and response. 
 
Finally, we investigated the effect of an array of compounds isolated from commonly used 
Chinese herbal medicines on the activity of PXR using a luciferase reporter gene assay in 
transiently transfected HepG2 and Huh7 cells, two cell lines derived from human liver tumor. 
The effect of herbal compounds on the expression of PXR and its target gene CYP3A4 in 
human intestinal LS174T cells was further determined using real-time PCR and Western blot 
analysis. The study found that praeruptorin A and C, salvianolic acid B, sodium danshensu, 
and protocatechuic aldehyde significantly transactivated the CYP3A4 reporter gene construct 
in both PXR-transfected HepG2 and Huh7 cells. Cryptotanshinone, emodin, morin, and 
tanshinone IIA significantly transactivated CYP3A4 reporter gene construct in 
PXR-transfected HepG2 cells, but not in PXR-transfected Huh7 cells. The PXR mRNA 
expression in LS174T cells was significantly induced by physcion, protocatechuic aldehyde, 
salvianolic acid B, and sodium danshensu. However, epifriedelanol, morin, praeruptorin D, 
mulberroside A, tanshinone I, and tanshinone IIA significantly down-regulated the 
expression of PXR mRNA in LS174T cells. Furthermore, emodin, physcion, praeruptorin C 
and E, protocatechuic aldehyde, rhein, salvianolic acid B, and sodium danshensu 
significantly induced CYP3A4 mRNA expression in human intestinal LS174T cells. 
 
These findings suggest that: a) predicting the phenotypic consequence of nsSNPs in human 
NRs and their target genes ABC transporters using computational algorithms may provide 
further understanding of genetic differences in susceptibility to diseases and drug response 
and would be useful hints for further genotype-phenotype studies; and b) herbal medicines 
can significantly regulate PXR and its target gene CYP3A4 and this has important implication 
in herb-drug interactions. Further benchmarking studies are warranted to verify our 
prediction data for NRs and their target genes ABC transporters and to explore the clinical 
impact of herb-CYP interactions via the PXR-mediated pathway. 
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CHAPTER 1 GENERAL INTRODUCTION 
 
1.1 The surperfamily of human NRs 
In June 1905, Ernest Starling defined the word ‘hormone’ as “the chemical messengers 
spreading from cell to cell along the blood stream, may coordinate the activities and growth 
of different parts of the body” [1]. Subsequently, Edward C. Kendall and Tadeus Reichstein 
isolated and determined the structures of cortisone and thyroxine hormones in 1929 [2], but 
their mediators remained elusive until the first NR was identified biochemically by Jensen 
and Jacobsen in 1961 [3]. However, untill 1985, Ronald M. Evans and his colleagues cloned 
first NR cDNA encoding the human glucocorticoid receptor (GR, NR3C1) [4] and the Pierre 
Chambon and Geoffrey Greene laboratories cloned the estrogen receptor (ER) (that was the α 
subtype, NR3A1) [5]. Since then, NRs have become recognized as a superfamily involving an 
immense diversity of biological functions from development to apoptosis [6, 7]. 
 
Now NRs are well-known key transcriptional factors that regulate crucial gene networks 
which involve important physiological functions such as embryonic development, organ 
physiology, cell growth, differentiation, and homeostasis [8, 9]. NRs are a group of soluble 
proteins that can bind to specific elements of target genes. Fourty eight members have been 
identified through sequencing of the human genome. Each receptor has vital and specific 
roles in the regulation of many biologically important processes such as growth, 
development, and homeostasis [6]. Dysfunction of NR signaling leads to proliferative, 
reproductive and metabolic diseases such as cancer, infertility, obesity and diabetes [10]. 
 
According to the ligand combining, human NRs can be divided into two classes, liganded 
receptors and orphan receptors. The liganded receptors can respond directly to a large variety 
of hormonal, metabolic substances and xenobiotcs. Upon binding with ligands, this type of 
receptors can change their conformation and dynamic behavior, and regulate the recruitment 
of coregulators and chromatin-modifying machineries, a key component of NR signaling. 
Ultimately, liganded NRs bind to specific site of target gene DNA and therefore enhance the 
recruitment and/or function of the general transcription machinery to transcript into mRNA 
[11]. The orphan receptors have no defined ligands [12]. Some orphan receptors for which 
regulatory ligands have not been identified or may not exist are referred to as “true orphan 
receptors”; and some for which candidate ligands have only recently identified are referred to 
as “adopted orphan receptors” [6].  
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NRs modulate transcription through several distinct mechanisms, which include both 
activation and repression activities. These activities, making NRs signaling extremely 
complex, can be genomic or nongenomic and ligand-dependent or -independent, and can 
activate or repress gene transcription, release gene repression, or transrepress gene 
expression [6]. NRs can also be the targets of other signaling pathways that modify the 
receptor post-translationally and affect its function [2, 13]. In general, NRs in the form of 
homo- or heterodimers act on target gene response elements (REs). Many gene whose 
transcription are NR-dependent have been reported to contain NR REs in their promoters. 
Meanwhile, many genes whose transcription modulated by NRs lack REs in their promoters 
or other regulatory elements, suggesting that the regulation of transcription by NRs are 
multi-leveled and complex [14-16].  
 
1.2 Nomenclature and classification of NRs  
In 1990s, researchers worked in this field had described more than 300 sequences of NRs 
using an increasingly complex nomenclature. Some genes have several names, especially for 
orphan receptors. The surplus names became a barrier for understanding of newly acquired 
knowledge to researchers. For this reason, NRs Nomenclature Committee based on sequence 
alignment and phylogenetic tree construction has classified the human NR superfamily into 
following seven evolutionary subfamilies (Table 1-1) [17].  
 
• Subfamily 1, thyroid hormone receptor (TR)-like, a large group contains the 
receptors TRs, retinoic acid receptors (RARs), vitamin D receptor (VDR/NR1I1), 
and peroxisome proliferators-activated receptors (PPARs), as well as orphan 
receptors such as RAR-related orphan receptors (RORs), Rev-erbs, constitutive 
androstane receptor (CAR/NR1I3), pregnane X receptor (PXR/NR1I2), liver X 
receptors (LXRs), and others.  
• Subfamily 2, retinoid X receptor-like subfamily, includes retinoid X receptors 
(RXRs), chicken ovalbumin upstream promoter-transcription factor (COUP-TF), 
and hepatocyte nuclear factor (HNF-4).  
• Subfamily 3, estrogen receptor (ER)-like, includes the steroid receptors ERs, GR, 
progesterone receptor (PR), and androgen receptor (AR) as well as the 
estrogen-related receptors (ERRs).  
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• Subfamily 4, nerve growth factor IB-like, contains the nerve growth factor-induced 
clone B group of orphan receptors (NGFI-B/NR4A1), NR related receptor 1 
(NURR1/NR4A2), and neuron-derived orphan receptor 1 (NOR1/NR4A3). 
• Subfamily 5, steroidogenic factor-like, includes the steroidogenic factor 1 (NR5A1) 
and the receptors related to the Drosophila FTZ-F1.  
• Subfamily 6, germ cell nuclear factor (GCNF)-like, contains only the GCNF1 
receptor (NR6A1), which does not fit well into any other subfamilies.  
• Subfamily 0 includes DAX1 (NR0B1) and SHP (NR0B2).  
 
Table 1-1. Human NR superfamily. 
Subfamily Name Group Name Name 
Abbrevi
- 
ation 
Nomen-
clature
Gene 
Name 
Typical 
Ligands 
Throid hormone 
receptor-α TRα NR1A1 THRA 
Thyroid 
hormones A
Throid 
hormone 
receptor Throid hormone receptor-β TRβ NR1A2 THRB 
Thyroid 
hormones 
Retinoic acid 
receptor-α RARα NR1B1 RARA 
Retinoic acid
Retinoic acid 
receptor-β RARβ NR1B2 RARB 
Retinoic acidB
Retinoic 
acid 
receptor Retinoic acid 
receptor-γ RARγ NR1B3 RARG 
Retinoic acid
Peroxisome 
proliferator- 
activated 
receptor-α 
PPARα NR1C1 PPARA 
Fatty acids, 
leukotriene 
B4, fibrates 
Peroxisome 
proliferator- 
activated 
receptor-β/δ 
PPARβ/
δ NR1C2 PPARD 
Fatty acids 
C
Peroxisome 
proliferator
s 
-activated 
receptor Peroxisome 
proliferator- 
activated 
receptor-γ 
PPARγ NR1C3 PPARG 
Fatty acids, 
prostaglan_ 
din J2, 
thiazolidi- 
nediones 
Reverse erbA-α Rev-erbα NR1D1 NR1D1 
Orphan 
D Reverse erbA Reverse erbA-β Rev-erbβ NR1D2 NR1D2 
Orphan 
RAR-related 
orphan receptor-α RORα NR1F1 RORA 
Cholesterol, 
cholesteryl 
sulfate 
RAR-related 
orphan receptor-β RORβ NR1F2 RORB 
Retinoic acidE
RAR-relate
d orphan 
receptor 
RAR-related 
orphan receptor-γ RORγ NR1F3 RORC 
Orphan 
Liver X 
receptor-α LXRα NR1H3 NR1H3 
Oxysterols, 
T0901317, 
GW3965 
Liver X 
receptor-β LXRβ NR1H2 NR1H2 
Oxysterols, 
T0901317, 
GW3965 
1 Thyroid Hormone 
Receptor-like 
F
Liver X 
receptor-lik
e 
Farnesoid X 
receptor-α FXRα NR1H4 NR1H4 
Bile acids, 
fexaramine 
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Farnesoid X 
receptor-β FXRβ* NR1H5 - 
Lanosterol 
Vitamin D 
receptor VDR NR1I1 VDR 
Vitamin D, 
1,25-dihydro
xyvitamin D3
Pregnane X 
receptor PXR NR1I2 NR1I2 
Xenobiotics, 
16α-cyanopr
egnenolone 
G
Vitamin D 
receptor-lik
e 
Constitutive 
androstane 
receptor 
CAR NR1I3 NR1I3 
Xenobiotics, 
phenobarbital
X
NRs with 
two DNA 
binding 
domains 
 2DBD- NR**   
 
Hepatocyte 
nuclear factor 4-α HNF4α NR2A1 HNF4A 
Orphan 
A
Hepatocyte 
nuclear 
factor 4 Hepatocyte nuclear factor 4-γ HNF4γ NR2A2 HNF4G 
Orphan 
Retinoid X 
receptor-α RXRα NR2B1 RXRA 
Retinoic acid
Retinoid X 
receptor-β RXRβ NR2B2 RXRB 
Retinoic acidB Retinoid X receptor 
Retinoid X 
receptor-γ RXRγ NR2B3 RXRG 
Retinoic acid
Testicular 
receptor 2 TR2 NR2C1 NR2C1 
Orphan 
C Testicular receptor Testicular 
receptor 4 TR4 NR2C2 NR2C2 
Orphan 
Tailless receptor TLX NR2E1 NR2E1 Orphan 
E TLX/PNR Photoreceptor-spe
cific NR PNR NR2E3 NR2E3 
Orphan 
Chicken 
ovalbumin 
upstream 
promoter-transcri
ption factor 
COUP-
TFI NR2F1 NR2F1 
Orphan 
Chicken 
ovalbumin 
upstream 
promoter- 
transcription 
factor 
COUP-
TFII NR2F2 NR2F2 
Orphan 
2 Retinoid X receptor-like 
F COUP/EAR 
ErbA2-related 
gene-2 EAR2 NR2F6 NR2F6 
Orphan 
Estrogen 
receptor-α ERα NR3A1 ESR1 
Estradiol-17β
, tamoxifen, 
raloxifene 
A Estrogen receptor Estrogen 
receptor-β ERβ NR3A2 ESR2 
Estradiol-17β
, various 
synthetic 
compounds 
Estrogen- 
related receptor-α ERRα NR3B1 ESRRA 
Orphan 
Estrogen-related 
receptor-β ERRβ NR3B2 ESRRB 
DES, 4-OH 
tamoxifen B
Estrogen-re
lated 
receptor Estrogen-related 
receptor-γ ERRγ NR3B3 ESRRG 
DES, 4-OH 
tamoxifen 
Glucocorticoid 
receptor GR NR3C1 NR3C1 
RU486, 
dexamethaso
ne, cortisol. 
Mineralocorticoid 
receptor MR NR3C2 NR3C2 
Aldosterone, 
spirolactone. 
3 Estrogen receptor-like 
C 3-Ketosteroid receptors 
Progesterone PR NR3C3 PGR Progesterone, 
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receptor RU486, 
medroxyprog
esterone 
acetate,  
Androgen 
receptor AR NR3C4 AR 
Testosterone, 
flutamide 
Nerve growth 
factor IB NGFI-B NR4A1 NR4A1 
Orphan 
NR related 1 NURR1 NR4A2 NR4A2 Orphan 4 
Nerve 
Growth 
Factor 
IB-like 
 
A NGFIB/NURR1/NOR1 Neuron-derived 
orphan receptor 1 NOR1 NR4A3 NR4A3 
Orphan 
Steroidogenic 
factor 1 SF1 NR5A1 NR5A1 
SPH, PIP2, 
PIP3 5 Steroidogenic Factor-like A SF1/LRH1 Liver receptor 
homolog-1 LRH-1 NR5A2 NR5A2 
Orphan 
6 
Germ Cell 
Nuclear 
Factor-like 
A GCNF Germ cell nuclear factor GCNF NR6A1 NR6A1 
Orphan 
DSS-AHC critical 
region on 
chromosome X, 
gene 1 
DAX-1 NR0B1 NR0B1 
Orphan 
0 Miscellaneous A DAX/SHP 
Small 
heterodimer 
partner 
SHP NR0B2 NR0B2 
Orphan 
*FXRβ is a pseudogene in human but is a functional lanosterol receptor in mouse [18]. 
**A novel member [16]. 
 
For each subfamily, several groups are often defined. A group often contains highly related 
genes with paralogous relationship in vertebrates (e.g., RARA, RARB, and RARG). For 
example, NR1A1 (TRα) means NR superfamily, subfamily 1, group A, and member 1. 
Besides, the term ‘isoform’ is reserved for different gene products originating from the same 
gene due to alternative promoter usage or splicing, or alternative initiation of translation [6, 
14]. 
 
1.3 Structural features of human NRs 
In the superfamily, all NRs are classified according to their conserved structural domains. In 
general, NRs exhibit a typical modular structure that consists of five to six homologic 
domains that are nominated A to F, from the N-terminal to the C-terminal end (Figure 1-1) 
[14].  
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Figure 1-1. General structural and functional organization of NRs. Top – Schematic illustration 1D 
structure and function of amino acid sequence of NRs. The evolutionarily conserved regions C and 
E are indicated as boxes, and a dark green bar represents the divergent A/B, D, and F regions. 
Domain functions are given. Bottom showed 3D structures of the DNA-binding domain and 
ligand-binding domain of the NRs. The structures shown are of the estrogen receptor. Experimental 
structures of N-terminal domain (A/B), hinge region (D), and C-terminal domain (F) have not been 
determined therefore are represented by red, purple, and orange dashed lines, respectively. Modified 
from Boghog2 at website (http://en.wikipedia.org/wiki/File:Nuclear_Receptor_Structure.png).  
 
1.3.1 The DNA-binding domain and D region 
The central C region is the DNA-binding domain (DBD) that is the most highly conserved 
domain shared by all NRs with the exception of two divergent members: dosage-specific sex 
reversal-adrenal hypoplasia congenita critical region on the X chromosome-1 (DAX1) and 
short heterodimeric partner (SHP) (Figure 1-1). Though DBD-containing receptors can bind 
to hormone response elements (HREs), specific DNA sequences are also found in promoters 
and enhancers of NR target genes [19]. The DBD consists of a highly conserved 66-residue 
core which has two typical cysteine-rich zinc finger motifs. The short sequence motifs 
referred to as P-box and DR-box within the first zinc finger play a very important role in 
determining the sequence specificity of the receptor-DNA binding response element [6]. 
Another short amino acid sequence motif is D box, which controls the half-site spacing. The 
C E AD
A/B D F
DNA binding
domain (DBD)
Ligand binding
domain (LBD)
DNA
Ligand
AF-1
Isoform-specific AF-2Hinge
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DBD is also the target of post-translational modifications. It is also involved in nuclear 
localization and functions in interactions with transcription factors and coactivators [20].  
 
The D region is thought to be a flexible domain that connects the DBD with the LBD. It 
influences intracellular trafficking and subcellular distribution and allow rotation of the DBD. 
Therefore, it might permit the DBDs and the LBDs to adopt different conformations. This 
domain also harbors a nuclear localization signal or at least some elements of a functional 
nuclear localization signal.  
 
1.3.2 The ligand-binding domain (LBD) and activation function 2 (AF-2) 
The E region is LBD which exhibits a less conserved than the DBD (Figure 1-1). LBD 
mediates ligand binding and dimerization and contains a ligand-dependent transactivation 
function. Currently, the LBD crystal structures of all classic liganded receptors and adopted 
orphan receptors have been determined. These structures were solved with LBDs alone or in 
complex with agonists or antagonists, some with peptides corresponding to fragments of 
transcriptional coactivators or corepressors, and in the form of monomers, dimers, or 
tetramers. 
 
The LBD forms a defined globular structure in which 11-12 α-helices (H) are arranged 
together in an antiparallel, three-layered sandwich, which also includes 2-4 β-strands (s1-s2) 
[14]. This framework structure is constant for most NRs and positions of all the helices 
except for those that are in contact with the ligand are very similar. In all holo-structures, the 
cognate ligand binds to a hydrophobic cavity buried within the core of the LBD. Thus, the 
ligand becomes an integral part of the hydrophobic core of the holo-receptor stabilising its 
three dimensional structures [6].  
 
The three-dimensional structures of LBD contains four surfaces: 1) a dimerization surface, 
which mediates combining with partner LBDs, 2) the ligand-binding pocket (LBP), which 
interacts with diverse lipophilic small molecules, 3) a coregulator binding surface, which 
binds to regulatory protein complexes that modulate transcriptional activity positively or 
negatively, and 4) an activation function helix, termed AF-2, which mediates ligand 
dependent transactivation [21].  
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Within the most carboxy terminal part of LBDs contain an amphipathic α-helix, which is 
essential for the ligand-dependent transactivation of transcription and coactivator recruitment, 
named activation function 2 (AF-2) core motif. It has been demonstrated that AF-2 formed 
from C-terminal helix 12 and controls the ability of LDBs to activate transcription [22].  
 
1.3.3 The A/B region and AF-1  
The A-B domain is highly variable in sequence between various NRs and poorly defined. 
This region contains another domain important for transcriptional activation of NRs is 
ligand-independent activation function 1 (AF-1) (Figure 1-1). The AF-1 region is the least 
conserved among unclear receptors both in size and sequence. No crystal structure of an A/B 
domain has been elucidated so far.  In contrast to the other activation function (AF-2) 
located in the LBD of liganded NRs, AF-1 function in a promoter-context and/or cell-type 
specific manner. The transcriptional activation of AF-1 is normally very weak, but it does 
synergize with AF-2 to produce a more robust upregulation of gene expression. It has been 
demonstrated that both individual activation functions AF-1 and AF-2 can act cooperatively 
to recruit transcriptional modulators such as NR coactivator 1 (NCoA1) and TIF2 [6].  
 
In addition, this N-terminal region can interact with cofactors such as coactivators or other 
transcription factors. These features may be related to cell type, DBD, and promoter 
specificity of the AF-1 activity [23]. 
 
1.4 Molecular mechanism of NR action 
NRs are key transcription regulatory factors that regulate DNA-binding transcription factors. 
NR-mediated transcriptional regulation can be either DNA-dependent (cis-regulation) or 
DNA-independent (trans-regulation). In the case of cis-regulation, NRs activate or repress 
their target gene by binding directly to the positive or negative response elements [6]. 
Trans-regulation of gene transcription is mediated by binding of NR to other DNA-binding 
transcription factors. This type of NR regulation seems to be mostly negative to transcription.  
 
Several distinct mechanisms are involved in the regulation by NRs, which may lead to 
activation or repression transcription activities. After site-specific DNA binding, the final 
transcriptional activity depends on the set of associated proteins, the so-called coactivators 
and corepressors, interacting with them. These coregulators are not exclusive to NRs and are 
used in a similar manner by numerous other DNA-binding transcription factors [24].  
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1.4.1 Transcription activation 
The eukaryotic DNA is packed into a condensed chromatin structure which exerts a crucial 
influence on transcription by limiting the access of promoter sequences to the transcription 
machinery and organizing genomic information for the coordinated regulation of genome 
expression [25].   
 
One of the special features of nuclear receptors distinguishing them from other 
sequence-specific transcription factors is their ability to access their binding sites in the 
repressive chromatin context [26]. Upon binding to their response elements, NRs switch the 
function of these transcription factors from an inactive to active state by inducing a 
conformational change in the LBD of the receptor [27]. This specific conformation allows 
the second step of NR’s activation that corresponds to the recruitment of coregulatory 
complexes, which contain chromatin-modifying enzymes required for transcription. These 
specific modifications of histone termini generate a more open chromatin structure 
permissive for transcription initiation. The ultimate action on target genes is to enhance the 
recruitment and/or function of the general transcription machinery [28].  
 
1.4.2 Transcription repression 
Most NRs that permanently reside in the nucleus such as TR, RAR, and VDR as well as many 
orphan receptors are able to recognise their response elements in the absence of ligand and 
actively inhibit transcription. Repression is mediated by interaction with transcriptional 
corepressors such as NR corepressor (NCoR) and silencing mediator for retinoid and thyroid 
hormone receptors (SMRT) that are originally identified as components of a complex 
involved in repression associated with RAR and TR [29]. The C-terminal part of NCoR and 
SMRT contains a region that specifically recognizes and binds to a hydrophobic groove in 
the surface of the LBD of RAR and TR, as well as LBD of steroid hormone receptors bound 
to certain antagonists. NCoR and SMRT posses several conserved repression domains, 
which provide the interacting surfaces for histone deacetylases (HDACs) or components of 
HDAC-containing complexes like Sin3A. The main cellular function of HDACs is to remove 
acetyl moieties from the specific lysines on histone tails, thereby counteracting to HAT 
activity and inducing chromatin condensation over the target promoter. The loss of 
acetylation leads to the increased positive charge of lysine that favors a closed nucleosomal 
structure and reduces the affinity of coactivators containing bromodomains. NCoR and 
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SMRT can actively contribute to the repression process since it has been shown that the 
enzymatic activity of HDAC3 requires interaction with a region of both NCoR and SMRT, 
referred to as the deacetylase-activating domain, located in the amino terminus of these two 
corepressors [30]. 
 
In general, unliganded NRs preferentially interact with corepressors to mediate repression, 
whereas liganded receptors are transcriptional activators owing to their ability to recruit 
coactivator proteins. Nevertheless, exceptions have been identified. Some corepressors, 
exemplified by ligand-dependent nuclear-receptor corepressor, receptor-interacting 
protein-140, and receptor with estrogen-receptor activity, can bind to NRs in a 
ligand-dependent manner and compete with coactivators by displacing them [14]. 
 
1.4.3 Post-translation modification 
NR-mediated transcription regulation includes transcriptional and post-transcription 
modulation. Various signal transduction pathways can regulate the interactions of NRs with 
specific coregulator, modulate their activity, or affect the distribution between nuclear and 
cytoplasmic compartment. Although association of NRs with coregulators is tightly 
controlled by ligand-binding, it has been demonstrated that cell signalling events can directly 
regulate the association of NRs with cofactors [31, 32].  
 
Phosphorylation of specific amino acid residues, which lie mainly within the amino-terminal 
A/B region, also in both DBD and LBD, enhances their transcriptional activation. Other 
types of post-translational modification, such as acetylation, sumoylation, and methylation, 
potentially constitute an important cellular integration mechanism [33]. These different 
modes of regulation reveal an unexpected complexity of the dynamics of NR-mediated 
transcription.  
 
Beside, modifications of coregulators, such as coactivators and corepressors, have been 
reported. Phosphorylation may enhance interaction of coactivators with NRs, efficiency to 
recruit HAT complexes, and enzymatic activity. In contrast, phosphorylation of corepressors 
NCoR and SMRT subsequent to the activation of mitogen-activated protein kinases 
(MAPKs), AKT/PKB and casein kinase-2 has been shown to induce their redistribution from 
the nucleus to the cytoplasm and to correlate with inhibition of their interaction with NRs 
[14]. 
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1.4.4 Mechanistic classes  
NRs may be classified into following four types based on the mechanism of regulating the 
transcription of target genes:  
 
1) Type I NRs which include members of subfamily 3, such as AR, ERs, GR, and PR. They 
bind with ligands in the cytosol, resulting in the dissociation of heat shock proteins, 
homo-dimerization, translocation (i.e., active transport) from the cytoplasm into the nucleus, 
and then binding to specific sequences of DNA known as hormone response elements 
(HREs). Type I NRs bind to HREs consisting of two half-sites separated by a variable length 
of DNA, and the second half-site has a sequence inverted from the first (inverted repeat). The 
NR/DNA complex then recruits other proteins that transcribe DNA downstream from the 
HRE into mRNA and eventually protein, which causes a change in cell function.  
 
2) Type II NRs which include principally subfamily 1, such as RAR, RXR and TR. In 
contrast to type I NRs, type II NRs stay in the nucleus regardless of the ligand binding status, 
and in addition bind as heterodimers (usually with RXR) to DNA. In the absence of ligand, 
type II NRs are often complexed with corepressor proteins. Ligand binding to the NR causes 
dissociation of corepressor and recruitment of coactivator proteins. Additional proteins 
including RNA polymerase are then recruited to the NR/DNA complex that transcribe DNA 
into mRNA.  
 
3) The members of subfamily II belong to type III NRs which are orphan receptors and their 
ligands still unknown. Type III NRs are similar to type I, binding to DNA as homodimers. 
However, type III NRs bind to direct repeat instead of inverted repeat HREs. 
 
4) Type IV NRs bind either as monomers or dimers, but only a single DNA binding domain 
of the receptor binds to a single half-site HRE. Examples of type IV receptors are found in 
most of the NR subfamilies [13]. 
 
1.5 Target genes 
A number of target genes of NRs have been identified. For example, a large group of genes, 
such as CYP11B2, CYP11A1, CYP17, NR0B1, and NR0B2, have been identified for SF-1 
target genes [13]. SF-1 is a major regulator of cholesterol metabolism in steroidogenic cells 
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as it stimulates the expression of nearly all factors involved in cholesterol mobilization and 
steroid hormone biosynthesis. SF-1 acts on many genes to promote differentiation of the 
male phenotype [13]. The main target genes of human NR superfamily are summarized in 
Table 1-2. 
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Table 1-2. Main target genes and mutant phenotypes of human NRs. 
Name  Main Target Genes Main Human Disease (Mutant 
Phenotype) 
Coactivator Corepressor 
TRα -- -- NCOA1, NCOA2, NCOA3, 
PPARBP, CREBBP, p300 
[34-37]. 
NCOR1, NCOR2, 
SMRT, HDAC, mSin3 
[36, 38]. 
TRβ -- Resistance to thyroid hormones [36]. NCOA1, NCOA2, NCOA3, 
PPARBP, CREBBP, p300 [34, 
37, 39]. 
NCOR1, NCOR2, 
SMRT, HDAC, mSin3 
[28, 38]. 
RARα     
RARβ     
RARγ     
PPARα Activated: liver fatty acid binding protein [40, 41], 
CPTI [40]. 
Arteriosclerosis [42].  PPARBP, NCOA6, BFE, 
CREBBP, CITED2, NCOA1, 
NCOA3, PGC-1α, SW12/SNF2, 
PPARGC1B [43-48]. 
NRIP1, NCOR1 [41, 
49]. 
PPARβ Activated: FIAF.  Atherosclerosis (controversial) [50]. NCOA1, NCOA3, NCOA6, 
PGC-1α [43, 44, 51]. 
NCOR1, NCOR2 [52, 
53]. 
PPARγ Activated: BCRP [54]; Repressed: BCRP [54]. Obesity and insulin resistance [55]; insulin 
resistance [42, 55, 56]; type II diabetes 
mellitus and hypertension [56]; syndrome X 
or metabolic syndrome [56]; atherosclerosis 
[42]; colon cancer [57]; prostate cancer [58]; 
thyroid tumors [59]. 
PGC-2, ARA-70, PGC-1α, 
PPARGC1B, CREBBP, CITED2, 
ERAP140, PPARBP, PRMT-2, 
PIMT, p300, NCOA1, NCOA2, 
NCOA3, NCOA6, SWI/SNF, 
PDIP [43, 60-65]. 
NRIP1, SAF-B, TAZ, 
NCOR1, NCOR2 [41, 
52, 65, 66]. 
Rev-erbα Repressed: Rev-erbα [67], ApoCIII [68], Baml1. - NCOA5. NCOR1, C1d, HDAC3, 
NCOA5. 
Rev-erbβ Repressed: Rev-erbα [69], N-Myc. - NCOA5. NCOR1, NCOA5. 
RORα Activated: N-Myc [69], ApoA5, laminin B1 [69], 
fibrinogen β, Rev-erbα gene. 
- NCOA2, PPARBP, EP300. NCOR1, NCOR2, HR 
[69].  
RORβ Activated: Bmal1.  NCOA1. Nrip2, HR. 
RORγ - - NCOA1 [69]. HR. 
LXRα Activated: ABCA1 [70], ABCG1 [71], SREBP1c 
[72], APOCI/IV/II [73], APOE [74], APOD [75], 
CETP [76], LPL [77], PLTP [78], FAS [79], 
GLUT4 [80]. 
-- NCOA1, p300, TRRAP, 
GRIP1/TIF2, PGC1b [81-84]. 
NCOR1, NCOR2 [85]. 
LXRβ Activated: ABCA1 [72], ABCG1 [71], SREBP1c 
[72], APOCI/IV/II [73], APOE [74], CETP [76], 
FAS [79], GLUT4 [80]. 
-- NCOA1, p300 [86]. NCOR1, NCOR2 [85]. 
FXRα Activated: FGF19, SHP, BSEP [87], IBABP [88], -- -- -- 
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MDR3, MRP2 [89], CYP3A4 [90], SULT2A1 [91], 
OATP1B3, OATP8 [92], BACS, ApoCII, C3, 
PDK4 [93], PLTP, PPARα, αA-crystallin, 
fibrinogen, kininogen, syndecan-1, VPAC1, OSTα, 
OSTβ; repressed: CYP7A1, ABAT, APOAI, 
ApoCIII, hepatic lipase, VLDLR [88]. 
VDR Activated: CYP3A4 [94-96], SULT2A1 [97]. Vitamin D-dependent rickets type II [88]. -- -- 
PXR Activated: CYP genes [98], CYP3A4 [99], 
CYP2B6 [100], CYP2C9 [101], MDR1 [102], 
MRP2 [103], UGT1A1 [104, 105], SULT2A1 
[106], OATP-A [107], GST [108]. 
Breast cancer [88];  NCOA1, NRIP1, PGC-1, 
FOXO1, GRIP1. 
SHP, NCOR2. 
CAR Activated: CYP genes [109], CYP3A4 [110], 
CYP2C9, [101], CYP2C19 [111], CYP2B6 [104, 
110], UGT1A1 [112], MDR1 [113], MRP2 [103], 
MRP4 [114]. 
-- NCOA1, PPARBP, PGC-1. -- 
HNF4α Activated: ApoC3, ApoB, HNK1A, PEPCK, 
CYP3A4. 
Early/Late-onset type 2 diabetes; MODY1 
[115]; factor VII deficiency; hemophilia B 
Leyden [69]. 
NCOA1, NCOA2, CREBBP, 
PPARGC1A, PPARGC1B, 
PPARBP.  
NCOR2. 
HNF4γ Activated: HNK-1α [69], AKR1C4.  -- -- 
RXRα -- -- NCOA1, NCOA 2, NCOA3, 
PGC-1α, TBP, PPARBP, 
TAFII110, TAFII28, CREBBP, 
p300. 
-- 
RXRβ -- -- NCOA1, NCOA2, NCOA3. -- 
RXRγ -- -- NCOA1, NCOA2, NCOA3. -- 
TR2 Activated: CNTFRα [116], aldolase A; repressed: 
HRH1, EPO [69].  
-- -- NRIP1, HDAC3, 
HDAC4. 
TR4 Activated: HIV1-LTR, LHcgR [117], steroid 
21-hydoxylase, CNTFRα [69], ApoE. 
-- -- TRA16, TIP27. 
TLX Activated: RARβ [69]; Repressed: PAX2 [69].  -- -- -- 
PNR Activated: Rhodopsin; repressed: S-cone opsin, 
M-con opsin. 
Enhanced S-cone syndrome; Retinitis 
pigmentosa; Goldmann-Favre syndrome 
[118].  
-- -- 
COUP-TFI Activated: PEPCK [119], TF [69]; repressed: 
CYP3A1 [69]. 
- BCL11B1, NCOA1, CREBBP. NCOR1, NCOR2, 
BCL11A. 
COUP-TFII Activated: CYP7A, arrestin; repressed: Apo AI 
[120]. 
- BCL11B, SQSTM1.   NCOR1, NCOR2, 
BCL11A . 
EAR2 Repressed: LH receptor, GRIK5, oxytocin [69]. - NCOA1 [121].   -- 
ERα Activated: pS2, GR [122], cathepsin D [123]. Breast cancer [124]; endometrial cancer 
[125]; obesity [126]; insulin resistance and 
NCOA1, NCOA2, NCOA3, 
CREBBP, PPARBP, P68, SRA. 
NCOR1, NRIP1.  
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diabetes [126]. 
ERβ Activated: pS2, GR [122], cathepsin D [123]. -- NCOA1, NCOA2, NCOA3, 
CREBBP, PPARBP, P68, SRA. 
NCOR1, NRIP1.  
ERRα Activated: MCAD [127], osteopontin, lactoferrin, 
TRα [69], ApoA4. 
Osteoporosis; obesity [128]. PNRC2, PPARGC1A, NCOA3, 
NCOA2, NCOA1, PNCR. 
-- 
ERRβ -- -- PNRC, NCOA3, NCOA1, 
NCOA2. 
-- 
ERRγ Activated: ERRα, MAOA, MAOB. -- PNRC2, PPARGC1A, 
PPARGC1B, NCOA1, TLE1.  
-- 
GR Activated: PEPCK-C, CYP3A4 [129], CYP2C9 
[130], CYP2C19 [111], NTCP [131], lipocortin-1; 
repressed: PEPCK-C, IL-8, TNF-α. 
Glucocorticoid resistance [132]; 
glucocorticoid hypersensitivity; asthma; 
acute childhood lymphoblastic leukemia. 
CREBBP, NCOA2, MTI-II, 
PPARBP. 
BAG1. 
MR Activated: Enac [133].  Hypertension; pseudohypoaldosteronism 
type 1.  
NCOA1, PGC-1α, ELL. NCOR1, NCOA 2, 
PIAS1. 
PR Activated: FSHβ, Stat5A, 11β-hydroxysteroid 
dehydrogenase genes.  
  
Pseudocorpus luteum insufficiency; breast 
cancer [134]; endometriosis [135]; 
endometrial cancer. 
NCOA1, NCOA 3, CREBBP, 
SRA1, JDP2. 
NCOR2. 
AR Activated: PSA, SC. Prostate cancer [136]; androgen insensitivity 
syndrome; Kennedy’s disease [137]; 
Klinefelter’s syndrome [138]. 
RNF14, NCOA2&4, Fhl2, 
TGFB1I1, RAN. 
-- 
NGFI-B Activated: POMC, INSL3 [69]. -- NCOA1, NCOA2, NCOA3, 
EP300, PPARBP.  
-- 
NURR1 -- Parkinson’s disease.  NCOA1, NCOA 2, NCOA3, 
CREBBP, PPARBP, P68, SRA. 
NCOR1, NRIP1. 
NOR1 Activated: POMC. EMC, extraskeletal myxoid 
chondrosarcoma. 
SIX3, PPARBP, EP300, NCOA2, 
PCAF. 
-- 
SF1 Activated: CYP11A1, CYP17, MC2R. Adrenocortical insufficiency; sex reversal, 
XY, with adrenal failure.  
CREBBP, NCOA1, NCOA2, 
EDF1, PNRC2. 
NCOR2. 
LRH-1 Activated: CYP11A1, ApoA1 [139], StAR, 
ABCG5/ABCG8 [140]. 
-- NCOA1, NCOA3, EP300, 
NCOA62, EDF1. 
Prox1.  
GCNF Repressed: Oct4 [69]. -- RAP80.  NCOR1, NCOR2. 
DAX-1 Repressed: DAX-1, StAR. Hypogonadotropic hypogonadism; a 
truncated DAX-1 protein16; DSS syndrome; 
X-linked adrenal hypoplasia congenital. 
-- NCOR1, NORR2, 
COPS2. 
SHP Repressed: CYP7A1, NTCP, ACOX1, PEPCK 
[69], ABCA1.  
Obesity (in relation with MODY). -- HDAC1, HDAC3, 
Sin3A, CREBBP, 
NCOR1, NCOR2.  
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1.5.1 Main target genes related to drug metabolism 
1.5.1.1 CYP3A4 
The cytochrome P450 (CYP) represents a large and diverse group of enzymes named CYP 
superfamily. The function of most CYP enzymes is to catalyze the oxidation of organic 
substances. The substrates of CYP enzymes include metabolic intermediates such as lipids and 
steroidal hormones and xenobiotic substances such as drugs and toxic chemicals. Human CYP1A, 
2A, 2B, 2C, 2E, and 3A are inducible [141]. 
 
The human CYP3A subfamily contains four members, namely CYP3A4, 3A5, 3A7 and 3A43. 
CYP3A4 is the most abundantly expressed CYP and has been implicated in the metabolism of 
more than 50% of current therapeutic drugs [142]. CYP3A4 is highly expressed in liver and small 
intestine that are key sites of drug disposition.  Several DNA binding sites have been identified in 
the 5’-flanking region of human CYP3A4 gene. One is located at approximately -150 bp region of 
the proximal promoter, and other two sites are found between -7733 and -7672 bp of the distal 
enhancer region of human CYP3A4 gene, termed as xenobiotic-responssive enhancer module 
(XREM) which consist of two hexaetric half-site [AG(G/T)TCA] made up a direct repeat with a 
three-nucleotide spacing (DR3) and an evert repeat separated by 6 bp referred to as ER6. All three 
DNA binding site are requied for PXR activation [143, 144].  
 
The interindividual variability in CYP3A4 drug-metabolizing activity has been estimated to be 
between 5- and 20-fold [145]. Variability in CYP3A4 expression and/or activity has a dramatic 
effect on the clinical response to many drugs. CYP3A4 expression is regulated by a number of 
NRs, including PXR, CAR, GR, HNF4α, FXR, and VDR. The intestinal and hepatic expression of 
CYP3A4 is highly dependent on the activity of PXR which is localized in the cytoplasm.  
 
PXR is a very promiscuous receptor which can be activated by a large number of structurally 
unrelated compounds including rifampicin, hyperforin and paclitaxel, and is referred as the 
“master” regulator of CYPs [141]. It is now known that many clinically relevant drug interactions 
involving the upregulation of CYP3A4 are mediated through the action of PXR. In addition, PXR 
may also determine basal CYP3A4 activity [146]. Most recently, Istrate et al. [147] have found 
that COUP-TFI, COUP-TFII, LXRα, TRα1 and TRβ bind efficiently to the proximal promoter 
ER6 and distal xenobiotic-responsive enhancer module DR3 motifs of CYP3A4. CAR is also 
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capable of activating CYP3A4 in vitro and in vivo [148]. Transient transfection of HepG2 cells 
with human CAR results in an increased expression of CYP3A4 mRNA. 
 
HNF4α is a critical determinant of PXR- and CAR-mediated induction of CYP3A4 [144]. It has 
been shown that the inductive response of PXR on CYP3A4 expression in vitro requires the 
presence of HNF4α. HNF4α binds immediately upstream of the PXR and CAR response elements 
in a CYP3A4 gene enhancer. In vivo, fetal and adult mice with conditionally deleted hepatic 
HNF4α have absent or reduced inducible expression of CYP3A. These results, along with the 
high expression of HNF4α in tissues crucial to drug metabolism (liver and small intestine), 
suggest that HNF4α is an important modulator of PXR- and CAR-mediated transcriptional 
activity and therefore of CYP3A4-mediated drug metabolism.  
 
GR may also have an impact on CYP3A4 expression. Studies with cultured human hepatocytes 
revealed that GR agonist dexamethasone induces PXR expression and results in CYP3A4 
induction [129]. Furthermore, induction of the CAR gene and protein expression by 
submicromolar concentrations of dexamethasone are accompanied by increased CYP3A4 
expression. Such an effect could be abrogated by the GR antagonist RU-486. Therefore, at a low 
(submicromolar) concentration, dexamethasone triggers GR signaling to induce the expression of 
PXR and CAR, whereas at high concentrations (supramicromolar), dexamethasone can activate 
PXR directly.  
 
FXR, also known as the bile acid receptor, is expressed in liver, intestine, kidney, and vascular 
endothelium. In addition to their role in intestinal lipid absorption, bile acids have recently been 
implicated as signaling molecules that activate gene transcription via binding to NRs. Gnerre et al. 
[149] have found that FXR agonists chenodeoxycholate (CDCA) and GW4064 increase 
expression of CYP3A4, and this inductive effect is independent of PXR. The results of these 
studies suggest that bile acid homeostatic mechanisms converge with xenobiotic elimination 
pathways.  
 
In addition, VDR has been implicated in the regulation of CYP3A4 [150]. Lithocholic acid 
promotes DNA strand breaks, DNA adduct formation, and inhibition of DNA repair enzymes and 
has been shown to cause colon cancer in experimental animals. Interestingly, lithocholic acid can 
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function as a ligand for the VDR and thereby induce CYP3A4, which promotes its own 
detoxification, and possibly limit the carcinogenic effects of this bile acid.  
 
1.5.1.2 CYP2C9, 2C19, and 2B6 
CYP2C9 is the second most abundantly expressed CYP that makes up about 18% of the 
cytochrome P450 proteins in human liver microsomes. About 100 therapeutic drugs are 
metabolized by CYP2C9, including drugs with a narrow therapeutic index such as warfarin and 
phenytoin and other routinely prescribed drugs such as acenocoumarol, tolbutamide, losartan, 
glipizide, and some nonsteroidal anti-inflammatory drugs. By contrast, extrahepatic CYP2C9 
often metabolizes important endogenous compound such as 5-hydroxytryptamine, arachidonic 
acid, and linoleic acid.  
 
CYP2C9 induction likely explains some variation in interindividual responses to warfarin [151]. 
Like CYP3A4, PXR, CAR, and GR have been implicated in regulating CYP2C9 expression. Chen 
et al. [152] have reported that PXR mediates the induction of CYP2C9 by rifampin, hyperforin, 
and phenobarbital. Glucocorticoid response element and a CAR response element have been 
identified in the promoter region of the CYP2C9 gene, suggesting that induction of CYP2C9 by 
dexamethasone and phenobarbital is likely mediated by GR and CAR, respectively. Besides, 
HNF4α may play a role in the regulation of CYP2C9 expression [153].  
 
CYP2C19 is also an important human drug-metabolizing enzyme and most abundantly expressed 
in the liver. CYP2C19 is known to metabolize many xenobiotics including the proton pump 
inhibitor omeprazole, anxiolytics such as diazepam, and the β-blocker propanolol. CYP2C19 
expression is regulated by NRs, and the degree of interindividual variability in drug metabolism 
may be due to its regulated expression. Chen et al. [111] have found a CAR/PXR response 
element and a GR response element in the promoter of CYP2C19. Previous studies have shown 
that CYP2C19 is also induced by the prototypical PXR ligands rifampin and ritonavir [154]. 
Thereby, it is likely that PXR plays an important role in regulating CYP2C19 expression.  
 
CYP2B6 is responsible for the oxidative metabolism of many drugs such as bupropion, 
cyclophosphamide, and efavirenz. CYP2B6 expression is induced by the prototypical CAR ligand 
phenobarbital. Chang et al. [155] have found there is a significant correlation between levels of 
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CYP2B6 and both CAR and PXR mRNA levels in 12 human liver samples. They found a 
278-fold variability in human CYP2B6 mRNA, 240-fold variability in CAR mRNA, and 27-fold 
variability in PXR. 
 
1.5.1.3 UDP-glucuronosyltransferase (UGT) 1A1 
UGTs are the most important Phase II (conjugative) enzymes that have been the subject of 
increasing scientific enquiry since the mid-to-late 1990s. UGTs catalyze the conjugation of 
glucuronic acid with xenobiotics to enhance their hydrophilicity and thus facilitate renal and 
biliary excretion. The catalysis reaction is the most important pathway for the human body's 
elimination of the top 200 drugs. The UGT1A1 isoform is an enzyme of the glucuronidation 
pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and 
drugs, into water-soluble, excretable metabolites [156]. UGT1A1 expressed in liver, small 
intestine, colon, stomach, and bile ducts. 
 
UGT1A1 induction has been shown to be mediated by the NRs PXR, CAR, and aryl hydrocarbon 
receptor (AhR) [157]. UGT1A1 is part of a complex locus that encodes several 
UDP-glucuronosyltransferases. This complex locus includes thirteen unique alternate first exons 
followed by four common exons. Except for four alternate first exons are pseudogenes, each 
alternate first exons may be spliced to the four common exons. Each first exon encodes the 
substrate binding site, and is regulated by its own promoter. The activity of UGT has been shown 
to vary 6- to 15-fold in liver microsomes and 10- to 100-fold in intestinal microsomes. 
Gardner-Stephen et al. [105] have found that only two in 3 PXR splice variants of human liver 
regulate UGT1A1 expression, indicating that tissue-dependent splice variation may lead to 
differential gene expression between organs.   
 
1.5.1.4 Glutathione S-transferases (GSTs) 
GSTs are a family of phase II drug-metabolizing enzymes that are considered important for 
cellular drug detoxification. GSTs catalyze the conjugation of reduced glutathione to electrophilic 
centers on a wide variety of xenobiotics and metabolites and play critical role in protecting the cell 
from oxidative and environmental stress and are also an important determinant of cellular 
resistance to drugs during chemotherapy. GSTs may also bind toxins and act as transporting 
proteins.  
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According to their amino acid sequence, GSTs are classified into α, μ, ω, θ, ξ, and π classes. 
Cytosolic GSTs are dimeric both subunits being from the same class, although not necessarily 
identical. The studies in the transgenic mice revealed that hepatic GST activity was related to 
PXR [158]. GSTα, π, and μ are possibly regulated by PXR in human, although studies confirming 
the PXR action on GST regulation are still lacking [157].  
 
1.5.1.5 Sulfotransferases (SULTs) 
SULTs are a supergene family of phase II drug-metabolizing enzymes that catalyze a sulfate 
group from a donor molecule, such as 3'-phosphoadenosine-5' phosphosulfate (PAPS), to an 
acceptor such as xenobiotics, steroids, and bile acids with sulfate, thus facilitating their 
detoxification and excretion. SULTs are regulated by several NRs. PXR and FXR may also have a 
role in regulating SULT2A1. VDR has been shown capable of transcriptionally regulating human 
SULT2A1 when transfected into HepG2 and Caco-2 cell lines [157].  
 
1.5.2 Regulation of main target genes related to drug transport  
Drug transporters mediate the influx of xenobiotics into the cell or facilitate their extrusion from 
inside the cell to the extracellular compartment. More recently, drug transporters have also been 
implicated as determinants of drug disposition. Ligand activated transcription factors within the 
NR superfamily appear to be critical to the coordinate expression of drug-metabolizing enzymes 
and drug transporters in organs such as the intestine and liver.  
 
Several ABC transporters are regulated by NRs. P-glycoprotein (P-gp/MDR1/ABCB1) is an ABC 
transporter encoded by the multidrug resistance 1 (MDR1/ABCB1) gene. P-gp is an efflux 
transporter that extrudes hydrophobic xenobiotics from the intracellular to extracellular 
compartment. The transcription of ABCB1 is also regulated by PXR and also by CAR. 
PXR-dependent induction of P-gp by rifampin and other known PXR ligands has been 
demonstrated [102].  
 
Multidrug resistance protein 2 (MRP2/ABCC2) is an efflux transporter expressed in liver, 
intestine, and kidney. The expression of ABCC2 is regulated by the NRs PXR, CAR, and FXR. 
Increased MRP2/ABCC2 expression has been noted following treatment with ligands for PXR 
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(e.g. rifampicin and hyperforin), FXR (chenodeoxycholic acid), and by the CAR activator 
Phenobarbital [103]. MRP4/ABCC4 is an efflux transporter in liver that transports conjugated 
steroids and bile acids from hepatocytes back into blood. Whether MRP4 is regulated by CAR in 
humans is currently unknown and warrants further investigation. Besides, the bile salt export 
pump (BSEP/ABCB11), breast cancer resistance protein (BCRP/ABCG2), the Na+ 
taurocholate-transporting polypeptide (NTCP/SLC10A1), organic anion-transporting 
polypeptide 1B3 (OATP1B3/SLCO1B3), and OATP1A2/SLCO1A2) are regulated by FXR, PXR 
and PPARγ [157].  
 
1.6 Mutations of the NRs and functional consequences  
1.6.1 Types of Mutations 
Mutations are changes in the deoxyribonucleic acid sequence of DNA of a cell's genome and are 
caused by radiation, viruses, transposons and mutagenic chemicals, as well as errors that occur 
during meiosis or DNA replication. Mutations in the structure of genes can be classified two 
classes: 1) large-scale mutations and 2) small-scale mutations. Large-scale mutation is the 
changes occur in the structure and numbers of chromosomes. The number change of 
chromosomes including euploidy and aneuploidy. The chromosome structural changes include 
amplification, deletions, chromosomal translocations and chromosomal inversions. Small-scale 
mutation is change occur in one or a few nucleotides including point mutation, insertion, and 
deletion. 
 
A kind of most common mutation is SNP which is DNA sequence variation occurring when a 
single nucleotide in the genome. For example, two sequenced DNA fragments from different 
individuals, AGCTTCGA to AGCCTCGA, contain a difference in a single nucleotide. We say 
that there are two alleles: T and C. Almost all common SNPs have only two alleles. Single 
nucleotide polymorphisms may fall within coding sequences of genes, non-coding regions of 
genes, or in the intergenic regions between genes. SNPs within a coding sequence will not 
necessarily change the amino acid sequence of the protein that is produced, due to degeneracy of 
the genetic code. A SNP in which both forms lead to the same polypeptide sequence is termed 
synonymous (sometimes called a silent mutation) — if a different polypeptide sequence is 
produced they are nonsynonymous. A nonsynonymous change may either be missense or 
nonsense, where a missense change results in a different amino acid, while a nonsense change 
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results in a premature stop codon. SNPs that are not in protein-coding regions may still have 
consequences for gene splicing, transcription factor binding, or the sequence of non-coding RNA. 
 
1.6.2 Mutations of NR genes and the functional consequences 
Like all other genes, the mutations can occur in the any locus of NR genes. Different mutation and 
site the mutation occurred leads to different effect on the function of NR, therefore forms mutant 
phenotype or human disease. For instance, mutation of a nucleotide within the region coding zinc 
fingers of NR DBD may affect the ability NR binding to specific site of DNA; mutation within the 
region of AF-1 domain may impact on NR activating transcription of target gene. 
 
For human PXR gene, mutations in the coding region are rare, although variation in non-coding 
regions may have clinical importance [159]. The results of re-sequencing for 100 individuals from 
different ethnic groups for the PXR gene found nucleotide variety lower than the genome-wide 
average for human genes and no amino acid changing mutations in the LBD [160]. However, 
Huster et al. [161] found two substitutions in the PXR LBD region among 418 Caucasians and 74 
Africans. Sequence differences in the coding region of PXR do not account for well-described 
interindividual differences in metabolism, such as variation in baseline activity or inducibility of 
CYP3A4 in liver or intestine [159]. The nucleotide divergence between the human and 
chimpanzee PXR genes is lower than the average for other genes in the human and chimpanzee 
genomes [162].  
 
Fukuen et al. [163] found the interindividual variability of CYP3A4 expression in human liver 
might resulted from multiple splice variants of PXR. Lim et al. [164] found a Q158K mutation in 
PXR in Chinese subjects decreased rifampin-mediated CYP3A4 induction. Recently, Zhang et al. 
[160] screened systematically for PXR singlenucleotide polymorphisms (SNPs) resulted in the 
identification of 38 SNPs, 6 of which were located within the coding region and 3 that were 
nonsynonymous (P27S, G36R, and R122Q).  
 
HNF4α is a NR involved in glucose homeostasis and is required for normal β cell function. 
Mutations in the HNF4α gene are associated with maturity onset diabetes of the young type 1 
(MODY1). Mutation of V255M in the HNF4α gene could be a predisposing factor for developing 
diabetes [165]. 
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Steroidogenic factor-1 (SF-1) (Ad4BP/NR5A1) is a NR that regulates many aspects of adrenal 
and reproductive development and function. About twenty different mutations have been unveiled 
in humans. The genetic alterations are present as missense mutations, nonsense mutations caused 
by nucleotide deletions and duplications, one nucleotide polymorphism and a 3Mb deletion 
spanning SF-1. The phenotypes of the patients are different, except one, are heterozygous for the 
mutation. Three of the hitherto identified SF-1 mutations cause adrenal failure, while most of the 
mutations cause various levels of gonadal dysgenesis and XY sex reversal [166]. Recently, 
Krylova et al. introduced point mutations blocking phospholipid binding generated SF-1 mutants 
that failed to recruit co-activators and activate transcription and some of these mutants have lost 
the ability to become phosphorylated.  
 
Most recently, Mantovani et al. [167] reported a novel frameshift mutation in the DAX1 gene, 
which established the molecular etiology of the AHC in the siblings. Obtaining a precise genetic 
diagnosis of this adrenal disorder, which, sometimes, cannot be confirmed only by clinical aspects, 
may have important implications for the long-term management of the disease. 
 
1.7 Human ABC transporters  
The ABC transporter superfamily presents in all organisms use the energy of ATP 
binding/hydrolysis to transport substrates across cell membranes [168, 169]. ABC transporters 
contain the ATP-binding cassettes and thus can bind ATP [168, 170, 171].  The ATP-binding site 
in ABC transporters is formed by two conserved sequences, the Walker A (P-loop) and Walker B 
motifs. Eukaryotic ABC transporters function as exporters mediating the efflux of compounds 
from the cytosol to the extracellular space or to the inside of intracellular compartments. ABC 
transporters are vital to any living system and are involved in the translocation of a wide variety of 
substrates ranging from ions, sugars, amino acids, vitamins, lipids, metals, and drugs to larger 
molecules such as oligosaccharides, oligopeptides and proteins [168, 169]. Many ABC 
transporters of are regulated by NRs. 
 
To date, a total of 49 members have been identified in human ABC transporters (see 
http://nutrigene.4t.com/humanabc.htm), which belongs to seven subfamilies designated A 
through G [172]. The human ABC transporters facilitate unidirectional translocation of 
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chemically diverse substrates including amino acids, lipids, inorganic ions, saccharides, metals, 
drugs, and peptides and proteins. Together, they constitute an important component of the defense 
mechanisms used both by normal and tumor cells against cytotoxic compounds. Overexpression 
of these transporters in tumor cells causes resistance to various cytotoxic agents in cancer therapy 
[173]. In addition to their drug efflux function, many of these transporters are now also well 
characterized as mediators of the elimination of a broad range of endogenous substances and 
xenobiotics including therapeutic drugs, metals and chemical toxicants [172]. The transport of 
endogenous compounds is particularly important for maintaining organ and cellular functions. 
Accumulation of these endogenous compounds in organ and cells will result in pathological 
conditions. Genetic variation in ABC transporter genes contributes to a variety of human diseases 
with Mendelian or complex inheritance [174]. 
 
1.7.1 ABCA subfamily 
The human ABCA subfamily contains 12 full transporters and these proteins are the largest by the 
linear sequence within the entire human ABC transporter family [175]. Five of them are located in 
a cluster in the 17q24 chromosome, whereas the other seven genes disperse on six different 
chromosomes. The ABCA subfamily is responsible for transporting cholesterol and lipids. In 
particular, ABCA1 transports cholesterol and the retina-specific ABCA4 transports vitamin A 
derivatives [175].  
 
The ABCA subfamily contains some of the largest ABC transporter genes, with several of them 
being over 2100 amino acids long. Two members of this subfamily, the ABCA1 and ABCA4, 
have been studied extensively. ABCA1 is associated with disorders of cholesterol transport and 
HDL biosynthesis [176, 177], and ABCA4 transports vitamin A derivatives in the outer segments 
of rod photoreceptor cells [175] and therefore performs a crucial step in the vision cycle. The 
ABCA2 gene maps to chromosome 9q34.3 and is most closely related to ABCA1. ABCA2 is 
highly expressed in the brain and it has been proposed that ABCA2 carries out similar cholesterol 
and phospholipid remodeling functions in neurons and glial cells. ABCA7 maps to chromosome 
19p13.3 and is highly expressed in spleen, thymus and lymphoid cells. The function and substrate 
specificity of ABCA5, ABCA6, ABCA7, ABCA8, ABCA9, ABCA10 and ABCA12 are 
unknown. 
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ABCA1/ABC1 has been originally identified as an engulfment receptor on macrophages and play 
a crucial role in the handling of cellular lipids [176, 177]. By promoting the efflux of membrane 
phospholipids and cholesterol to lipid-poor apoprotein acceptors, ABCA1 controls the formation 
of HDLs and thus the whole process of reverse cholesterol transport. Disruption of the mouse 
Abca1 gene resulted in a low level of HDLs and accumulation of cholesterol in tissues [178]. The 
transport of lipids from the Golgi to the plasma membrane was defective these mice, but these 
mice had normal secretion of cholesterol into bile, indicating that Abca1 does not play a role in 
this process [178].   
 
ABCA3 is a 1,704-amino acid protein with a molecular weight of 150 kDa, mapping to human 
chromosome 16p13.3 and has a very similar structure as ABCA1 and ABCA2 [179]. ABCA3 was 
found to be predominantly expressed in alveolar type II cells in the lung, specifically concentrated 
in the membrane of lamellar bodies [180]. Lamellar bodies are densely packed lysosome-like 
structures storing pulmonary surfactant, a mixture of phospholipids and proteins, which reduces 
the surface tension at the air-liquid interface. ABCA3 may play an active role in the excretion of 
the lipid fraction of the pulmonary surfactant [180]. 
 
The ABCA4 gene encodes a 250 kDa photoreceptor-specific protein with 
N-retinylidene-phosphatidylethanolamine (PE) and other vitamin A intermediates as substrates 
[175]. Abca4-deficcient mice have increased all-trans-retinaldehyde after light exposure, 
elevated PE in outer segments, accumulation of the protonated Schiff base complex of 
all-trans-retinaldehyde and PE (N-retinylidene-PE), and remarkable deposition of a major 
lipofuscin fluorophore in retinal pigment epithelium [181]. 
 
The ABCA12 gene is located on chromosome 2q34 and its product is predominantly detected in 
the skin and stomach. A high ABCA12 expression is found in keratinocytes and ABCA12 plays a 
role in skin lipid homeostasis. ABCA12 is localized in the lamellar granules of keratinocytes, 
where it may play a major role in the regulation of lipid trafficking. 
 
1.7.2 ABCB subfamily 
The human ABCB subfamily consists of 4 full and 7 half transporters that can transport peptides 
and bile salts [182, 183]. Half transporters in this subfamily include ABCB2/TAP1 and 
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ABCB3/TAP2, the mitochondrial transporters ABCB6, ABCB7, ABCB8 and ABCB10, as well 
as ABCB9, with a putative lysosomal localization.  
 
ABCB1/MDR is the first human ABC transporter cloned and characterized through its ability to 
confer a multi-drug resistance (MDR) phenotype to cancer cells. ABCB2/TAP1 and 
ABCB3/TAP2 are half transporters that form a heterodimer to transport peptides into the 
endoplasmic reticulum that are presented as antigens by the class I MHC molecules [184-186]. 
Tap1/Abcb2-deficient mice are deficient in antigen presentation and surface class I molecules and 
lack CD8+ cells [187]. A family with recessive inheritance of class I HLA deficiency was 
described that has a nonsense mutation in the ABCB3/TAP2 gene [188]. The closest homolog of 
the TAPs, the ABCB9 half transporter, has been localized to lysosomes [189, 190]. ABCB4 and 
ABCB11 are both located in the liver and are involved in the secretion of bile acids [184]. The 
remaining four half transporters, ABCB6, ABCB7, ABCB8, and ABCB10, localize to the 
mitochondria, where they function in iron metabolism and transport of Fe/S protein precursors 
[184].   
 
ABCB1 (P-gp/MDR1) is a 170-kDa glycoprotein encoded by the human MDR1 gene. The human 
ABCB1 gene extends over more than 100 kb and is located on chromosome 7q21.1 with 28 exons 
[191]. ABCB1 is constitutively expressed in several organs involved in drug absorption and 
elimination such as the intestine, liver, kidney and brain [192]. It is found at high levels on the 
apical surfaces of epithelial cells in the liver (bile canaliculi), kidney (proximal tubule), pancreas 
(pancreatic ductal cell), small intestine and colon (columnar mucosal cell) and adrenal gland. As 
an efflux pump for cell protection against a variety of substances, the substrates of ABCB1 vary 
greatly in size, structure and function, ranging from small molecules such as organic cations, 
carbohydrates, amino acids and some antibiotics to macromolecules such as polysaccharides and 
proteins [193]. More importantly, ABCB1 can transport a number of anticancer drugs, causing the 
MDR phenomenon. Mice homozygous for a disrupted Abcb1a gene are phenotypically normal 
but are sensitive to certain neurotoxins such as ivermectin [194]. 
 
The ABCB4 gene maps to 7q21.1, adjacent to the ABCB1 gene, and encodes a full transporter with 
high homology to ABCB1. ABCB4 is predominantly expressed in the bile cannilicular membrane 
of the liver, but is also found in the heart, muscle and B cells. Disruption of the gene in the mouse 
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resulted in liver pathology due to a deficiency in fatty acid secretion in bile [195]. ABCB4 can 
transport phophatidylcholine from the inner to the outer leaflet of the membrane in vitro [196]. 
Mutations in this gene cause PFIC3 [197, 198] and are associated with intrahepatic cholestasis of 
pregnancy (ICP) [199]. 
 
1.7.3 ABCC subfamily 
The ABCC subfamily consists of 13 transporters and is involved in receptor binding, ion transport, 
xenobiotics and endogenous compound transport, and toxin secretion [200]. The largest ABCCs 
are ABCC1, ABCC2, ABCC3, ABCC6 and CFTR/ABCC7; these contain greater than 1500 
amino acids (except CFTR which contains 1480 amino acid residues) and contain 3 hydrophobic 
transmembrane domains.  Of these proteins, ABCC2 is the largest with 1545 amino acids and a 
molecular weight of 190 kDa [201]. ABCC1, ABCC2 and ABCC3 are lipophilic anion 
transporters with similar substrate ranges and confer resistance to some anticancer drugs [200, 
202, 203]. ABCC4, ABCC5, and ABCC11/MRP8 are cyclic nucleotide transporters [200, 203]. 
The CFTR/ABCC7 protein is a chloride ion channel that plays a role in all exocrine secretions. 
Mutations of this protein cause cystic fibrosis (CF) and congenital bilateral absence of the vas 
deferens (CBAVD) [204]. ABCC8 and ABCC9 proteins bind sulfonylurea and regulate 
potassium channels involved in modulating insulin secretion [205, 206].  
 
The ABCC1 gene maps to 16p13.1 and ABCC1 is expressed on the basolateral membrane of 
epithelial cells in most tissues. ABCC1 has a wide range of substrates and is a significant 
transporter for a diverse range of organic anion conjugates such as glutathione conjugates, 
glucuronides, glutathione disulfide, unconjugated anionic drugs and dyes [207]. ABCC1 is a 
causative factor for the resistance to anticancer drugs including anthracyclines, 
epipodophyllotoxins, vinca alkaloids and camptothecins [207]. Abcc1-deficcient mice have an 
impaired inflammatory response and display hypersensitivity to etoposide [208]. This may be due 
to the fact that ABCC1 can transport leukotriene C4 (LTC4), which is a signaling compound for 
the migration of dendritic cells. 
 
The ABCC2 gene has been mapped to chromosome 10q24 [209]. Its primary function is to export 
organic anions into the bile from the liver. ABCC2 is located in the apical luminal membrane of 
epithelial cells of most excretory organs such as the kidney, liver and intestine. It is also localized 
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in the blood-brain barrier and placenta [210]. Substrate specificity of this protein was 
demonstrated by Abcc2-defficient rats, it was found that these rats were deficient in 
bilirubin-glucuronide secretion and were known to have inactivating mutations in their Abcc2 
gene [211]. This is similar to humans with the same mutations, as these results in patients with 
DJS, an autosomal recessive disorder characterized by jaundice, liver pigmentation and abnormal 
gallbladder function [212]. Abcc2 double knockout mice exhibit biochemical abnormalities that 
are comparable to those of DJS patients [213]. In cells where there was an overexpression of 
ABCC2, resistance to methotrexate, cisplatin, etoposide and epirubicin was evident [214]. 
 
ABCC3 is expressed in the liver, adrenals, pancreas, kidney and gut. Like ABCC1 and ABCC2, it 
is also an organic anion transporter, but it prefers glucuronate conjugates over glutathione 
conjugates which is in contrast to ABCC1 and ABCC2 [215]. ABCC3 does not confer resistance 
to most drugs that are transported as a glutathione conjugate via ABCC1 and ABCC2. 
ABCC3-transfected cells can confer resistance to etoposide, vincristine and methotrexate, which 
is less than the resistance profile of ABCC1 and ABCC2. The high expression levels of ABCC3 in 
the basolateral membrane of hepatocytes implicate that this transporter may be the efflux pump 
for organic anions transported from the liver into the blood when secretion into the bile is being 
impeded.  Abcc3-deficcient mice had normal bile salt transport; however, they had reduced 
blood bilirubin glucuronide levels [216]. 
 
The ABCC6 gene has been mapped to 16p13.1 consists of 31 exons, encoding a protein of 1503 
amino acids [217]. ABCC6 transports the glutathione S-conjugates, LTC4 and S-(2, 
4-dinitrophenyl) glutathione, and the cyclopentapeptide BQ123 [218]. However, ABCC6 only 
conferred a low-level resistance to etoposide, teniposide, doxorubicin, and daunorubicin [218]. 
ABCC6 is highly expressed in the liver and kidney. Abcc-deficient mice showed remarkable 
mineralization of the connective tissues, including skin, arterial blood vessels, and retina [219, 
220]. 
 
ABCB11 has been mapped to chromosome 2q24 and its 28 exons encode a protein of 1321 amino 
acids [221]. ABCB11 is the major canalicular bile salt export pump (BSEP) in humans [222]. 
Mutations in this gene cause two different clinical entities of the ABCB11-deficiency syndrome: a 
mild form called benign recurrent intrahepatic cholestasis type 2 (BRIC2), and a severe form 
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called PFIC2. These two diseases represent a heterogeneous group of cholestatic conditions, and 
BRIC2 may develop into PFIC2. 
 
1.7.4 ABCD subfamily 
The ABCD subfamily contains 4 half transporters and two each in the Drosophila melanogaster 
and yeast genomes. The yeast PXA1 and PXA2 products dimerize to form a functional transporter 
involved in very long chain fatty acid oxidation in the peroxisome [223]. All of the genes encode 
half transporters that are located in the peroxisome, where they function as homo- and/or 
heterodimers in the regulation of very long chain fatty acid transport [224]. 
 
ABCD1 contains 10 exons and spans 20 kb of genomic DNA. As a half transporter, ABCD1 is 
involved in peroxisomal import of fatty acids and/or fatty acyl-CoAs in the organelle [225]. 
Defects in this gene can cause ALD/X-ALD, an X-chromosome recessively inherited 
demyelinating disorder of the nervous system [226]. ALD is a serious progressive, genetic 
disorder that affects the adrenal glands, spinal cord and white matter of the nervous system [227, 
228]. ALD can present itself in many different forms, and common forms in males include 
childhood cerebral forms, adrenomyeloneuropathy (AMN), and Addison disease only [227]. The 
principal biochemical abnormality of ALD is the accumulation of saturated, very long chain fatty 
acids, particularly hexacosanoic (C26:0) and tetracosanoic (C24:0) fatty acids, as a result of the 
impaired capacity to degrade these substances, a function that normally takes place in the 
peroxisome [227]. 
 
1.7.5 ABCG subfamily 
There are 5 half-transporters in the ABCG subfamily, which are able to transport drugs, lipids, 
bile and cholesterol [229, 230]. The best characterized transporter is ABCG2, whose 
overexpression confers multidrug resistance [231]. ABCG2 is also a  potential marker of stem 
cells [232].  
 
With high expression in the brain endothelium, gastrointestinal tract, and placenta, ABCG2 is 
important in the protection from xenobiotics, limiting oral bioavailability of drugs, forming part 
of the blood-brain barrier, blood-testis barrier, and maternal-fetal barrier [171]. Notably, ABCG2 
is often expressed in stem cell populations, where it may play a role in xenobiotic protection [232]. 
  30
The ABCG2/BCRP gene contains 16 exons spanning over 66 kb located on chromosome 4q22 
[233]. ABCG2 is a half-transporter only consisting of one nucleotide-binding domain and one 
membrane-spanning domain [234]. The overexpression of ABCG2 confers resistance to a wide 
range of anticancer agents, including camptothecins, anthracylines, and mitoxantrone [235]. 
 
Like other members of the ABCG subfamily, ABCG5 and ABCG8 are half-transporters [229]. 
The ABCG5 and ABCG8 genes are closely arranged with an insertion of 85-140 bases in opposing 
orientation. Both ABCG5 and 8 are expressed mainly in liver and intestine. Mutations in ABCG5 
and ABCG8 are associated with sitosterolemia [236-238], a rare inherited disease characterized by 
elevated concentration of plant or fish sterols in plasma, most importantly sitosterol (24-ethyl 
cholesterol). ABCG5 and ABCG8 may form a functional (and obligatory) heterodimer. The 
absorption of plant sterols in the intestine is strongly increased in sitosterolemic patients who also 
suffer from hypercholesterolemia and decreased biliary cholesterol secretion. Asian 
sitosterolemia patients have almost exclusive mutations in ABCG5, and Caucasian patients have 
mutations in ABCG8. This suggests that there are independent functions of the two genes, and that 
they may also form heterodimers to transport non-cholesterol sterols in plants and shellfish. 
 
1.7.6 ABCE and ABCF subfamilies 
ABCE1 and ABCFs only contain ATP-binding domains without the function of a typical ABC 
transporter. Members in these two subfamilies mainly regulate protein synthesis or expression. 
The ABCE subfamily is solely composed of the oligo-adenylate-binding protein, a molecule that 
recognizes oligo-adenylate and is generated in response to infection by certain viruses [239]. 
ABCF1 appears to mediate the activation of the eIF-2α kinase in the ribosome [240]. 
 
1.8 Herbal medicines and herb-drug interactions  
Herbal medicines are commonly used worldwide, although their mechanisms of action are 
generally unknown and there is a lack of evidence of efficacy and safety data [241]. An estimated 
one third of adults in developed nations and more than 80% of the population in many developing 
countries apply herbal medicines in the hope of promoting health and managing common 
maladies such as cold, inflammation, heart diseases, and diabetes. To date, there are more than 
11,000 species of herbal plants that are in use medicinally and, of these, about 500 species are 
commonly used in Asian and other countries. These herbs are often co-administered with 
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therapeutic drugs, raising the potential of drug-herb interactions, which may have important 
clinical significance based on an increasing number of clinical reports of such interactions.   
 
The interaction of herbal medicines with prescribed drugs is a significant safety concern, 
especially for drugs with narrow therapeutic indices (e.g. warfarin and digoxin). Because the 
pharmacokinetics and/or pharmacodynamics of the drug may be altered by combination with 
herbal remedies, potentially severe and perhaps even life-threatening adverse reactions may occur. 
Due to the clinical significance of herbal interactions with drugs, it is important to identify drugs 
in drug development that may interact with herbal medicines. 
 
1.8.1 Reported clinical herb-drug interactions 
A number of clinical herb-drug interactions have been reported in the literature. Common herbal 
medicines that interact with drugs include St John’s wort, ginkgo, danshen, ginger, ginseng, kava, 
and garlic. However, documented herb-drug interactions are sparse and many of the observed 
herb-drug interactions are based on case and case series reports. In many cases, the herb-drug 
interactions may cause drug clearance and/or cause drug toxicity, or even be fatal. 
 
Garlic, a widely used medicinal herb, is reported to have antimicrobial and immune-enhancing 
effects [242]. It is one of the herbal supplements most commonly used by HIV-infected patients to 
improve health and to treat some opportunistic infections [242].  Treatment with Kwar garlic 
extract (with an allicin potential of 600 μg, 1.5 mg alliin and 0.03 S-allyl-L-cysteine in each 
600-mg tablet, 3 × 600 mg twice daily, Lichtwer Pharma, Eatontown, NJ) for 14 days did not 
significantly alter the ratio of dextromethorphan to its metabolite (P > 0.05). In healthy volunteers 
(n = 10, 4 men and 6 women), a 3-week administration of garlic caplets (GarliPure, Maximum 
Allicin Formula; Natrol, each caplet contains 3.6 mg garlic powdered extract) 2 times daily 
significantly decreased the plasma AUC by 51%, trough concentration (C8h) by 49% and Cmax by 
54% of the protease inhibitor saquinavir [243].  Two case reports suggested the combination of 
warfarin and garlic extract caused an increase of clotting time and internationally normalized ratio 
(INR) [244]. There were case reports that garlic could cause postoperative bleeding and 
spontaneous spinal epidural hematoma [244]. The additive effect is considered to be due to that 
some garlic components have anticoagulant effect, and thus enhanced the effect of warfarin. 
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Ginkgo is one of the most popular herbal medicines in the world, due to its purported and 
unproven beneficial effects including memory-enhancing, cognition-improving, and antiplatelet 
effects [245, 246]. Ginkgo may interact with warfarin, as a few case reports associated 
concomitant use of ginkgo extract with warfarin with the development of intracerebral 
haemorrhage [244]. There is case report on spontaneous hyphema when ginkgo extract is 
combined with aspirin. Additionally, there is a case report on fatal intracerebral mass bleeding 
associated with the combined use of ginkgo extract and ibuprofen [244]. However, a recently 
published randomised, double blind, placebo-controlled crossover study indicated that oral 
ingestion of G. biloba extract (100 mg daily for 4 weeks) did not alter the INR in 24 Danish 
outpatients (14 women and 10 men) on stable, long-term warfarin treatment, and the geometric 
mean dosage of warfarin did not change during the treatment periods [247]. It appears that many 
factors associated with the source of G. biloba extract, dosing regimen and patients influence the 
clinical outcomes when combined with warfarin. 
 
In a recent clinical study involving 18 healthy Chinese subjects, treatment of G. biloba (140 mg, 
bid) for 12 days significantly decreased the plasma concentrations of omeprazole and its sulfone 
conjugate, while 5-hydroxyomeprazole level was significantly increased [248]. A significant 
decrease in the ratio of omeprazole AUC to 5-hydroxyomeprazole was observed in poor and 
extensive metabolizers with regard to CYP2C19 genotype, with the decrease be greater in poor 
metabolizers than extensive metabolizers [248]. No significant changes in the AUC ratios of 
omeprazole to its sulfone were observed. These results indicate that ginkgo is able to induce 
CYP2C19 and thus enhance omeprazole hydroxylation in a CYP2C19 genotype-dependent 
manner. Cautions should be taken when patients concomitantly take ginkgo and CYP2C19 
substrates. 
 
Ginseng is a widely used herbal medicine due to its purported anti-hypertensive, anti-fatigue, 
neuroprotective, antioxidative, chemopreventive, hypolipidemic, cognition-enhancing, 
immuno-enhancing, ulcer-healing, and anticancer effects [249]. An open non-randomized clinical 
study in healthy volunteers (n = 14) indicated that ginseng extract increased blood alcohol 
clearance by 30% [250]. This could be due to delayed gastric emptying by ginsenosides, and 
induction of alcohol oxidizing systems and CYP2E1. Several case reports have documented 
suspected interactions of ginseng with the monoamine oxidase inhibitor phenelzine [244]. 
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Ginseng has the potential to cause drug interaction with warfarin and concomitant use of ginseng 
with warfarin should be avoided. 
 
St John's wort is one of the most commonly used herbal medicines for the therapy of depression 
[251]. The herbal medicine can reduce the clearance of a number of drugs including cyclosporine, 
midazolam, tacrolimus, amitriptyline, digoxin, indinavir, warfarin, phenprocoumon and 
theophylline [149]. For example, long-term administration of St John's wort (900 mg/day for 2 
weeks) significantly increased the oral clearance of midazolam by 108.9% and decreased its oral 
bioavailability by 39.3% [252]. Similarly, a randomized, placebo-controlled and cross-over study 
in 13 healthy subjects revealed that treatment with St John’s wort at 900 mg/day significantly 
decreased the Cmax and AUC of quazepam [253]. Bauer et al. [254] reported that treatment of St 
John’s wort extract (600 mg/day) for 2 weeks decreased the AUC, Cmax and Ctrough of cyclosporine 
by 41-46% in renal transplant patients. In an open-label, crossover, and fixed-sequence study with 
10 healthy subjects, treatment with St John's wort at 900 mg/day for 2 weeks significantly 
decreased the AUC of imatinib by 32%,  Cmax by 29%, and elimination half-life by 21% [255]. In 
an unblinded, randomized crossover study involving 5 cancer patients, it was found that treatment 
of St John’s wort (900 mg/day, oral) for 18 days decreased the plasma levels of SN-38 (the active 
metabolite of irinotecan) by 42% [256]. 
 
Long-term treatment of St. John's wort (900 mg/day) for median period of 31 days (14-47 days) 
lowered the trough plasma levels of methadone by 47% in patients [257]. Intake of St John’s wort 
at 900 mg/day for 2 weeks led to a decrease in the plasma AUC of indinavir by 57% and 
extrapolated 8-hr indinavir trough concentration by 81% in healthy volunteers [258]. The 
ingestion of St John’s wort elevated the oral clearance of nevirapine [154]. Treatment o 
 
1.8.2 Potential Mechanisms for herb-drug interactions 
The underlying mechanisms for most reported drug interactions with herbal medicines have not 
been fully elucidated. As with drug-drug interactions, both pharmacokinetic and 
pharmacodynamic mechanisms are implicated in these interactions. 
 
Alterations in absorption, metabolism, distribution or excretion of drugs are the cause for 
pharmacokinetic interactions. Altered drug metabolism by herbal medicines is often a result of 
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CYP induction and/or inhibition [259]. The most well-studied and understood example of this is 
the induction of CYP3A4 and 2B6 by St John's wort in humans [260, 261].  Of the components 
of St. John’s wort, hyperforin is purported to be the active constituent and it is the most potent 
agonist for PXR with a Ki of 27 nM [260]. Recently, the level of ABC and other transporters is 
increasingly being identified as a mechanism of clinically important drug–drug interactions. For 
example, the importance of the level of ABCB1 (P-gp/MDR1) in drug-drug interactions is 
increasingly being identified [262, 263]. Many studies have shown that P-gp can affect the 
pharmacokinetics of numerous structurally diverse drugs. Moreover, ABCB1 gene variability 
influences absorption and distribution of drugs transported. Inhibition or induction of P-gp by 
coadministered drugs and herbal medicine may lead to pharmacokinetic interactions, and 
therefore result in unexpected toxicities or undertreatment [262, 263]. Due to the important role 
of P-gp in drug transport and excretion, modulation of P-gp by herbal medicines may have 
significant pharmacokinetic consequences [262]. St John’s wort induces intestinal Pgp in vitro 
and in vivo [264, 265]. Oral administration of St John’s wort for 14 days in healthy volunteers 
resulted in a 1.4-fold increase in P-gp expression [264]. The substrates of P-gp, fexofenadine and 
digoxin which are often used as probes for examining P-gp activity in vivo, were found to have 
increased clearance in healthy subjects treated with St John’s wort [266]. However, there is rare 
clinical evidence for altered protein binding of drugs by herbal medicines. Given that many herbal 
components are highly bound by plasma proteins, they may displace drugs from the binding sites. 
 
Herbal medicines are often administered orally and they can attain moderate to high 
concentrations in the gut lumen (the primary site of absorption for most orally-administered drugs) 
and liver, and may exert a significant effect on enterocytes and hepatocytes. Both P-gp and 
CYP3A4 are abundantly expressed in the villus tip of enterocytes and hepatocytes [267, 268]. The 
interplay of both intestinal P-gp and CYP3A4 has a strong effect on the bioavailability of many 
orally-administered drugs including cyclosporine, midazolam, talinolol, statins, HIV protease 
inhibitors and verapamil [269]. Thus, the modulation of intestinal and hepatic P-gp and CYP3A4 
by herbal medicines represents a potentially important mechanism by which the bioavailability of 
coadministered drugs can be modulated. 
 
Altered pharmacokinetics almost inevitably leads to a significant change in response to drugs that 
have narrow therapeutic indices. However, given that a single herbal preparation may contain 
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more than 100 components, all of which may have unknown biological activities, a herb can 
potentially mimic, increase, or reduce the effects of co-administered drugs through simultaneous 
effects on the same drug targets [270]. If the effect of the drug in combination with the herbal 
medicine is enhanced (e.g. synergistic or additive effect), unfavorable on target toxicity may 
occur. In contrast, some herbal remedies may contain compounds with antagonistic properties, 
which are likely to reduce drug efficacy and produce therapeutic failure. The synergistic or 
antagonistic effects between herbs and drugs often result from the competitive or complementary 
effect of the drug and the coadministered herbal constituents at the same drug targets.  
 
Combined use of herbs with drugs may mimic, increase, or reduce the effects of either component, 
resulting in clinically important herb-drug interactions [270]. Synergistic or additive therapeutic 
effects may lead to unfavorable toxicities and complicate the dosing regimen of long-term 
medications, while antagonistic interactions will result in decreased efficacy and therapeutic 
failure. The synergistic or antagonistic effects often result from the competitive or complementary 
effect of the drug and the combined herbal constituents on the same drug target.  
 
Herbal medicines such as danshen, ginkgo, ginseng, ginger and garlic may enhance the 
anticoagulant activity of warfarin by acting on the same drug target vitamin K epoxide reductase 
[271].  All these herbal products may increase bleeding in people taking warfarin. Cases have 
been reported where the combination of St John’s wort and selective serotonin re-uptake 
inhibitors (e.g. sertraline and nefazodone) caused symptoms characteristic of central serotonergic 
syndrome, in particular in the elderly [149]. This syndrome is characterized by confusion, 
agitation, hyperreflexia, shivering or tremor, diaphoresis, nausea, diarrhea, lack of co-ordination, 
fever, coma, flushing or rhabdomyolysis. This may be due to that St John’s wort inhibited rat 
vesicular uptake of monamines including serotonin, dopamine and norepinephrine. 
 
1.9 Objectives of my PhD thesis 
In this project, we hypothesized that the phenotype of nsSNPs of NRs and their target genes could 
be predicted using computational approaches and that herbal compounds regulated CYP3A4 via 
PXR-mediated pathway. To test our hypothesis, we have: a) predicted the potential functional 
impact of nsSNPs of human NR genes using a bioinformatic approach; b) predicted the phenotype 
of nsSNPs in human ABC transporters using an identical bioinformatic approach; and c) 
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investigated the effects of a panel of herbal compounds on the activity of PXR and the expression 
of its target gene CYP3A4 in cell lines derived from human colon and liver tumors. 
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CHAPTER 2 PREDICTION OF DELETERIOUS FUNCTIONAL EFFECTS OF 
NON-SYNONYMOUS SNPS IN HUMAN NR GENES USING A 
BIOINFORMATICS APPROACH 
 
2.1 Introduction 
NRs are a group of important proteins that are found in the interior of cells [272]. Different from 
other classes of receptors, NRs can directly interact with genomic DNA and act as a class of 
transcriptional regulators. The primary function of NRs is to sense and bind small molecules such 
as hormones and certain exogenous molecules and control the transcription of crucial target genes 
which regulate a variety of important biological functions such as cell growth, metabolism, 
development and homeostasis [272]. To date, forty-eight NR members have been found in human 
beings [6]. All NRs form a superfamily and are classified according to their conserved structural 
domains. NRs have a similar modular structure which contains several functional domains from 
the N- to C-terminus [272], including the variable modulatory A/B domain that is near the 
N-terminal regulatory domain; the highly conserved DBD containing two zinc fingers which 
encompass ∼80 amino acid residues; the flexible hinge D region which connects the DBD with the 
LBD; the LBD which is moderately conserved in sequence and highly conserved in structure 
between the various NRs; and an F-domain that is not found in all NRs. The DBD binds specific 
sequences of DNA called hormone response elements, while the LBD embraces a hydrophobic 
ligand-binding pocket that is specific to different receptors. Of the six main structural domains, 
the DBD and LBD are the two most conserved domains and are regarded as dual signatures of NR 
superfamily [272].  
 
SNPs, i.e. variations of genomic DNA sequence at a single nucleotide between the different 
members of a species or paired chromosomes in an individual, are the most common type of point 
mutations and most frequent type of gene variations [273]. The position where the SNP occurs 
may fall within any fragment of the genome, e.g. exons’ or introns’ or outside of a gene region. 
When an SNP does not affect the product of a gene, it is termed ‘synonymous SNP’ (sometimes it 
is also called  ‘silent’ mutation) since it does not result in a change of the amino acid sequence of 
the encoded protein [273]. Nearly all of the SNPs which occur in non-coding regions of DNA are 
silent mutations. However, when an SNP occurs in a coding region of a gene, for the reason of 
genetic codon degeneracy, it is not necessary to change the amino acid sequence of the 
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corresponding protein. Only when a SNP falls within an exon of a gene and results in a change in 
the amino acid sequence, it is termed ‘non-synonymous SNP’ (‘nsSNP’). All nsSNPs may 
potentially affect functions and interactions of expressed proteins and could have an impact on 
certain human diseases [274]. SNPs that are not in protein-coding regions may still have 
consequences for gene splicing, transcription factor binding, or the sequence of non-coding RNA 
[274]. To understand the relationship between genetic mutations such as nsSNPs and phenotypic 
variation, it is essential to assess the structural consequences of the respective non-synonymous 
mutations in proteins [275]. 
 
The largest primary database for SNPs is the public database of SNPs at the National Center for 
Biotechnology Information (NCBI dbSNP database, USA) which was developed to facilitate the 
management of SNP data, to integrate these data with other NCBI resources, and to widely 
distribute the information to the global scientific community. Up to 25 March 2010, a total of 
64,352,606 (24,760,881 validated) SNPs for 56 organisms and 23,653,737 (14,653,228 validated, 
with 10,375,413 in genes) SNPs in humans have been identified and deposited to the NCBI SNP 
database (http//www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi, Build 131). However, 
there is a much smaller number of missense SNPs (n = 110,927) distributed in 20,411 human 
genes according to the dbSNP Build 130. Human data in dbSNP Build 130 has been mapped to 
the NCBI human Genome Build 36.3. The dbSNP database also provides supplementary 
information about the validation status, population-specific allele frequencies, and individual 
genotypes for dbSNP submission. Haplotype and linkage disequilibrium data are being 
incorporated in dbSNP as data are released from the International HapMap project 
(http://www.hapmap.org/). Functional variants are identified when a dbSNP submission can be 
matched to the Online Mendelian Inheritance in Man (OMIM; 
http://www.ncbi.nlm.nih.gov/omim/).  
 
Using an experimental approach to explore the potential impact of nsSNPs on protein function 
and the association between these nsSNPs and disease susceptibility would be extremely 
time-consuming and almost unlikely and probably suffer from low statistical power to distinguish 
disease-causing nsSNPs from non-disease-causing nsSNPs [276]. However, to prioritize 
candidate nsSNPs for their likely impact on protein function and disease susceptibility, 
bioinformatics methods can provide a solution to this problem. Bioinformatics approaches that 
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are based on the biochemical severity of the amino acid substitution, and the protein sequence 
and/or structural information, can offer a more feasible means for phenotype prediction. The 
algorithm “Sorting intolerant from tolerant” (SIFT, http://blocks.fhcrc.org/sift/SIFT.html) [277] 
is used to predict the functional effect of an amino acid substitution according to sequence 
homology and the physical properties of amino acids. This can be applied to naturally-occurring 
nsSNPs and laboratory-induced missense mutations. Another important algorithm is 
Polymorphism Phenotyping (PolyPhen, http://genetics.bwh.harvard.edu/pph/) [278], which 
predicts the possible impact of an amino acid substitution on the structure and function of a human 
protein based on straightforward physical and comparative considerations. Additionally, other 
algorithms also employ sequence and/or structural information, such as SNPs3D (a web resource 
and database that provides and integrates as much information as possible on disease/gene 
relationships at the molecular level; http://www.snps3d.org/) [279], PMUT (a web-based tool for 
prediction of the pathological character of single point amino acid mutations based on the use of 
neural networks; http://mmb2.pcb.ub.es: 8080/PMut/) [280], and topoSNP (a topographic 
database of nsSNPs with and without known disease association; 
http://gila.bioengr.uic.edu/snp/toposnp/) [281]. Generally, these computational methods provide 
a feasible, high-throughput way to determine the impact of large numbers of nsSNPs on protein 
function. 
 
Although extensive research on the relationship between the genotype and phenotype of nsSNPs 
in human NR genes has been undertaken, this is still limited to a small fraction of nsSNP identified. 
Although deleterious nsSNPs of human NR genes have received great interest from experimental 
scientists, the functional impact of most nsSNPs in human NR genes is unknown. The aim of this 
study was to predict the phenotypic effect of all coding-region nsSNPs in human NR genes using 
in silico approaches and the predicted results were compared with published phenotypic studies. 
 
2.2 Materials and methods 
2.2.1 Collection of human NR genes 
The data on human NR genes were all collected from Entrez Gene on the NCBI Website 
(http://www.ncbi.nlm.nih.gov/sites/entrez) and HUGO gene database (http://www.genenames. 
org/). All of the human NR genes investigated in this study were named in accordance with the 
NRs Nomenclature Committee (1999) [282] and NucleaRDB (http://www.receptors.org/NR/) 
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[283]. With improved knowledge of molecular biology, we have excluded some previously used 
gene names that have expired and some genes from Entrez Gene that are not real NR genes. 
Finally, we collected 48 human NR genes which could be grouped into 7 subfamilies (Table 2-1). 
 
Table 2-1. List of human NR genes and their nsSNPs. 
Group Gene 
name 
Chromosomal 
location 
Receptor name Number 
of amino 
acids 
Number 
of exons 
Number 
of 
nsSNPs
Subfamily 1: Thyroid hormone receptor-like  
THRA 17q11.2 Thyroid hormone receptor-α 
(NR1A1)  
690 10 3 Group A 
THRB 3p24.2 Thyroid hormone receptor-β 
(NR1A2)  
461 12 26 
RARA 17q21 Retinoic acid receptor-α (RARα; 
NR1B1)  
462 10 0 
RARB 3p24 Retinoic acid receptor-β (RARβ; 
NR1B2)  
448 8 0 
Group B 
RARG 12q13 Retinoic acid receptor-γ (RARγ; 
NR1B3)  
454 11 2 
PPARA 22q13.31 Peroxisome proliferator-activated 
receptor-α (PPARα; NR1C1)  
468 9 8 
PPARD 6p21.2-p21.1 Peroxisome proliferator-activated 
receptor-β/δ (PPARβ/δ; NR1C2)  
441 8 0 
Group C 
PPARG 3p25 Peroxisome proliferator-activated 
receptor-γ (PPARγ; NR1C3)  
505 7 9 
NR1D1 17q11.2 Rev-ErbAα (Rev-ErbAα)  614 8 1 Group D 
NR1D2 3p24.2 Rev-ErbAβ (Rev-ErbAβ)  579 8 4 
RORA 15q21-q22 RAR-related orphan receptor-α 
(RORα; NR1F1)  
556 14 0 
RORB 9q22 RAR-related orphan receptor-β 
(RORβ; NR1F2)  
459 10 0 
Group F 
RORC 1q21 RAR-related orphan receptor-γ 
(RORγ; NR1F3)  
518 12 2 
NR1H2 19q13.3-q13.3 Liver X receptor-β (LXRα)  461 10 1 
NR1H3 11p11.2 Liver X receptor-α (LXRβ)  447 10 2 
Group H 
NR1H4 12q23.1 Farnesoid X receptor (FXR)  472 11 1 
VDR 12q13.11 Vitamin D receptor (VDR; NR1I1) 427 11 15 
NR1I2 3q12-q13.3 Pregnane X receptor (PXR) 473 9 12 
Group I 
NR1I3 1q23.3 Constitutive androstane receptor 
(CAR)  
348 9 8 
Subfamily 2: Retinoid X receptor-like 
HNF4A 20q12-q13.1 Hepatocyte nuclear factor-4α 
(HNF-4α; NR2A1)  
474 10 8 Group A 
HNF4G 8q21.11 Hepatocyte nuclear factor-4-γ 
(HNF4γ; NR2A2)  
445 10 3 
RXRA 9q34.3 Retinoid X receptor-α (RXRα; 
NR2B1)  
462 10 4 
RXRB 6p21.3 Retinoid X receptor-β (RXRβ; 
NR2B2)  
533 10 2 
Group B 
RXRG 1q22-q23 Retinoid X receptor-γ (RXRγ; 463 11 0 
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NR2B3)  
NR2C1 12q22 Testicular receptor 2 (TR2)  603 15 1 Group C 
NR2C2 3p25 Testicular receptor 4 (TR4)  615 15 2 
NR2E1 6q21 Human homologue of the 
Drosophila tailless gene (TLX)  
385 9 0 Group E 
NR2E3 15q22.32 Photoreceptor cell-specific NR 
(PNR)  
367 4 8 
NR2F1  5q14 Chicken ovalbumin upstream 
promoter-transcription factor I 
(COUP-TFI)  
423 3 0 
NR2F2 15q26 Chicken ovalbumin upstream 
promoter-transcription factor II 
(COUP-TFII)  
414 3 0 
Group F 
NR2F6 19p13.1 V-erbA-related gene (EAR-2; 
NR2F6)  
404 4 4 
Subfamily 3: Estrogen receptor-like 
ESR1 6q25.1 Estrogen receptor-α (ERα; NR3A1) 595 8 6 Group A 
ESR2 14q23.2 Estrogen receptor-β (ERβ; NR3A2 530 9 0 
ESRRA 11q13 Estrogen-related receptor-α (ERRα; 
NR3B1)  
423 7 3 
ESRRB 14q24.3 Estrogen-related receptor-β (ERRβ; 
NR3B2)  
500 12 5 
Group B 
ESRRG 1q41 Estrogen-related receptor-γ (ERRγ; 
NR3B3)  
458 7 2 
NR3C1 19p13.1 Glucocorticoid receptor (GR)  777 11 24 
NR3C2 4q31.3 Mineralocorticoid receptor (MR)  984 9 10 
PGR 11q22-q23 Progesterone receptor (PR; NR3C3) 933 8 17 
Group C 
AR Xq11.2-q12 Androgen receptor (AR; NR3C4) 920 8 216 
Subfamily 4: Nerve growth factor IB-like 
NR4A1 12q13 Nerve growth factor IB (NGFIB) 598 8 3 
NR4A2 2q22-q23 NR related 1 (NURR1)  598 8 0 
Group A 
NR4A3 9q22 Neuron-derived orphan receptor 1 
(NOR1)  
626 9 2 
Subfamily 5: Steroidogenic factor-like 
NR5A1 9q33 Steroidogenic factor 1 (SF1) 
(phospholipids)  
461 7 4 Group A 
NR5A2 1q32.1 Liver receptor homolog-1 (LRH-1) 495 8 1 
Subfamily 6: Germ cell nuclear factor-like 
Group A NR6A1 9q33-q34.1 Germ cell nuclear factor (GCNF)  480 10 0 
Subfamily 0: Miscellaneous 
NR0B1 Xp21.3-p21.2 Dosage-sensitive sex reversal, 
adrenal hypoplasia critical region, 
on chromosome X, gene 1 (DAX1) 
470 2 17 Group B 
NR0B2 1p36.1 Small heterodimer partner (SHP)  257 2 6 
Group C       
 
 
2.2.2 Dataset of nsSNPs of human NR genes 
All datasets of the nsSNPs in human NR genes were collected from the NCBI dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) and SWISS-Prot databases (http://ca.expasy. 
org/sprot/). Fields used included gene symbol, gene name, mRNA accession number, protein 
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accession number, SNP ID, amino acid residue 1 (wild-type), SWISS source ID, amino acid 
position, amino acid residue 2 (mutated), and phenotype were captured (Figure 2-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1. Flow chart of the processes for collecting and selecting nsSNPs in human NR genes. 
 
2.2.3 Data compiling for phenotype of nsSNPs of human NR genes 
The phenotype data of nsSNPs of human NR genes available were compiled from the PubMed 
(http://www.ncbi.nlm.nih.gov/PubMed/), OMIM (http://www.ncbi.nlm.nih.gov/sites/entrez?db 
=omim) and UniProtKB/Swiss-Prot databases (http://ca.expasy.org/sprot/). All relevant data on 
the effect of the nsSNP on human NR activity and the correlation between the nsSNP and disease 
obtained from in vitro (e.g. SDM and clinical association studies) were collected. 
 
2.2.4 Prediction of the phenotype of nsSNPs in human NR genes 
We used SIFT (http://blocks.fhcrc.org/sift/SIFT.html) [277] and PolyPhen 
(http://genetics.bwh.harvard.edu/pph/) [278] to predict the presumed effects of nsSNPs on protein 
structures and functions. These two bioinformatic tools enable high-throughput prediction of the 
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potential impact of nsSNPs and large-scale polymorphism analyses. Both SIFT and PolyPhen 
algorithms provide a series of prediction score categories based on the probability that an nsSNP 
will be tolerant or deleterious. SIFT uses position-specific information derived from sequence 
alignment to predict tolerated and deleterious substitutions for every position of the query 
sequence, and requires only sequence and homologue information derived from a phylogeny or 
sequence alignment. SIFT is based on a position-specific scoring matrix (PSSM), and estimates 
positions that will be unfavourable to mutation, based on tolerated mutations in homologues. 
SIFT can be applied not only to naturally-occurring nsSNPs but also to artificial missense 
mutations [277, 284]. Using the NCBI position specific iterative (PSI)-BLAST program [285], 
SIFT performs as following: a) searching for similar sequences; b) choosing closely related 
sequences that may share similar function to the query sequence; c) obtaining the alignment of 
these chosen sequences; and d) calculating normalized probabilities for all possible substitutions 
from the alignment. SIFT scores are designated as tolerant (0.201-1.00), borderline (0.101-0.20), 
potentially intolerant (0.051-0.10), or intolerant (0.00-0.05) [286, 287]. Likewise, the PolyPhen 
algorithm applies a wide variety of features that are sequence-, evolutionary-, and structurally 
based to predict whether an nsSNP is likely to affect protein function, and performs optimally if 
structural information is available. It performs sequence-based characterization of substation sites 
and profile analysis of homologous sequences and maps of the substitution sites to known protein 
three dimensional structure. PolyPhen combines a conservation score with additional properties 
(physico-chemical differences and structural features of the polymorphic variants) in order to 
predict the functional importance of an amino acid alteration. Currently, more than 11,000 
nsSNPs have been annotated [284]. PolyPhen performs the prediction through sequence-based 
characterization of the substitution site, calculation of position-specific independent count (PSIC) 
profile scores for two amino acid variants, and calculation of structural parameters and contacts. 
PolyPhen scores are classified as probably benign (0.000-0.999), borderline (1.000-1.249), 
potentially damaging (1.250- 1.499), possibly damaging (1.500-1.999), or damaging (≥ 2.000) 
[287].  
 
2.2.5 Validation of the phenotype prediction of nsSNPs of human NR genes 
nsSNPs of human NR genes with experimental evidence of altered activity or disease association 
were considered “really” deleterious. The phenotypic data are from both in vitro and in vivo 
studies, in which the SDM analyses often provide direct evidence indicating the functional impact 
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of nsSNPs. Prediction accuracy was analyzed according to positive findings from these 
benchmarking experiments. 
 
2.2.6 Statistical Analyses 
Concordance analysis between the functional consequences of each nsSNP of NR genes predicted 
by the two in silico methods was assessed using Spearman’s rank correlation coefficient ρ. 
Correlation analysis between prediction score for deleterious nsSNPs and number of functional 
nsSNPs confirmed by in vivo/in vitro experiments was conducted using the Pearson’s χ2 test [288]. 
P values below 0.05 were considered statistically significant. 
 
2.3 Results 
2.3.1 Selection of human nsSNPs of NR genes  
Figure 2-1 illustrates the process of collecting the nsSNP data for human NR genes, and seven 
steps were followed to mine the data on human NR genes and the nsSNPs. From step 1 to step 2, a 
total of 48 validated human NR genes which were compiled (Table 2-1). Meanwhile, 65 genes 
which identified encoding NR interacting proteins, binding factors and so on, were excluded for 
further nsSNP search. From steps 3 to 5, a total of 442 nsSNPs were collected from 48 human NR 
genes, with a mean value of 9.21 nsSNP per gene (Table 2-1).  
 
In our data search, some previously reported SNPs in the dbSNP have been identified as invalid 
by later studies due to wrong sequencing and alignment. These erroneous SNPs have expired or 
have merged with other SNPs and some NR genes have been renamed. We have carefully 
cross-examined the databases and removed those old NR genes and invalid SNPs. Finally, a total 
of 442 nsSNPs including 144 RefSNPs and 298 SWISS SNPs were included in our dataset of 
nsSNPs of human NR genes (see Table 2-2). 
  
The nsSNPs mainly occurred in the following human NR genes: androgen receptor gene 
(AR/NR3C4), dosage-sensitive sex reversal gene (NR0B1/DAX1), thyroid hormone receptor-β 
gene (THRB/NR1A2), vitamin D receptor gene (VDR/NR1I1), glucocorticoid receptor gene 
(NR3C1/GR), peroxisome proliferator-activated receptor-γ gene (PPARG/NR1C3), progesterone 
receptor gene (PGR/NR3C3), hepatocyte nuclear factor-4α gene (HNF4A/NR2A1), and 
mineralocorticoid receptor gene (NR3C2/MR). The AR/NR3C4 gene contained the largest number 
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Table 2-2. Collected nsSNPs of human NR genes and the predicted phenotype by the SIFT and PolyPhen algorithms. 
Gene symbol Source ID AA 
change 
SIFT 
score 
SIFT 
prediction 
SIFT 
net 
score 
PolyPhe
n score 
PolyPhen 
prediction
Polyphen 
score 
Phenotype 
(Data from Mutdb and 
OMIM) 
Reference 
AR/NR3C4 VAR_004679 E2K 0.00* Deleterious 0 3.57 Benign 1.267 PAIS [307] 
AR/NR3C4 VAR_004680 L54S 0.00* Deleterious 0.01 3.7 Benign 1.338 Prostate cancer [308] 
AR/NR3C4 VAR_004681 L57Q 1.00* Tolerated 0.61 3.61 Probably 
damaging
2.263 Prostate cancer [309] 
AR/NR3C4 VAR_009711 Q64R 0.02* Deleterious 0.03 3.59 Benign 0.634 Prostate cancer [308] 
AR/NR3C4 VAR_009712 Q112H 0.00* Deleterious 0.02 3.55 Possibly 
damaging
1.829 Prostate cancer [308] 
AR/NR3C4 VAR_009713 K180R 0.00* Tolerated 0.09 3.15 Benign 1.393 Prostate cancer [308] 
AR/NR3C4 VAR_009224 Q194R 0.12* Tolerated 0.67 3.24 Benign 0.617 CAIS [310] 
AR/NR3C4 VAR_009714 S205R 0.00* Tolerated 0.08 3.16 Benign 1.345   [311] 
AR/NR3C4 VAR_009715 G214R 0.00* Deleterious 0.01 3.29 Possibly 
damaging
1.58 MAIS; 20% lower 
transactivation capacity 
[312] 
AR/NR3C4 VAR_009225 L255P 0.00* Tolerated 0.11 3.06 Probably 
damaging
2.122 CAIS [313] 
AR/NR3C4 VAR_009716 M266T 0.00* Deleterious 0 3.03 Probably 
damaging
2.716 Prostate cancer [308] 
AR/NR3C4 VAR_009717 P269S 0.22* Tolerated 0.42 3.32 Benign 0.841 Prostate cancer [311] 
AR/NR3C4 VAR_009718 P340L 0.01* Tolerated 0.07 3.05 Probably 
damaging
2.431 Prostate cancer [314] 
AR/NR3C4 VAR_009226 P390R 0.00* Deleterious 0.03 3.06 Probably 
damaging
2.621 CAIS [315] 
AR/NR3C4 VAR_009227 P390S 0.00* Tolerated 0.22 3.06 Probably 
damaging
2.396 MAIS [316] 
AR/NR3C4 VAR_009228 Q443R 0.02 Deleterious 0.05 3.08 Possibly 
damaging
1.868 CAIS; might be a 
polymorphism 
[315] 
AR/NR3C4 VAR_009719 G491S 0.22 Tolerated 0.53 3.08 Benign 0.277 CAIS [317] 
AR/NR3C4 VAR_009720 D528G 0.11 Deleterious 0 3.01 Possibly 
damaging
1.815 Prostate cancer [308] 
AR/NR3C4 VAR_009721 L547F 0.16 Tolerated 1 3.02 Benign 0.58 PAIS [318, 319] 
AR/NR3C4 VAR_009722 P548S 0.17 Deleterious 0 3.02 Probably 
damaging
2.189 MAIS [320] 
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AR/NR3C4 VAR_009723 C559Y 0 Deleterious 0 3.02 Probably 
damaging
3.346 CAIS [290] 
AR/NR3C4 VAR_009725 G568V 0 Deleterious 0 3.02 Probably 
damaging
2.499 PAIS [321, 322] 
AR/NR3C4 VAR_009726 G568W 0 Deleterious 0 3.02 Probably 
damaging
2.274 PAIS [318, 323] 
AR/NR3C4 VAR_009727 Y571C 0 Deleterious 0 3.02 Probably 
damaging
2.758 CAIS [324] 
AR/NR3C4 VAR_009728 A573D 0 Deleterious 0 3.02 Possibly 
damaging
1.96 CAIS; defective DNA 
binding and transactivation 
[325] 
AR/NR3C4 VAR_009729 L574P 0.03 Deleterious 0 3.02 Probably 
damaging
2.192 Prostate cancer [289] 
AR/NR3C4 VAR_009730 T575A 0.14 Deleterious 0 3.02 Possibly 
damaging
1.825 Prostate cancer [289, 326] 
AR/NR3C4 VAR_009731 C576F 0 Deleterious 0 3.02 Probably 
damaging
3.346 CAIS; lack of DNA binding [327] 
AR/NR3C4 VAR_009732 C576R 0 Deleterious 0 3.02 Probably 
damaging
3.571 CAIS [290] 
AR/NR3C4 VAR_009733 C579F 0 Deleterious 0 3.02 Probably 
damaging
3.346 CAIS; reduced transcription 
and DNA binding 
[328] 
AR/NR3C4 VAR_009734 C579Y 0 Deleterious 0 3.02 Probably 
damaging
3.346 CAIS [329] 
AR/NR3C4 VAR_009735 K580R 0 Deleterious 0 3.02 Benign 1.393 Prostate cancer [289, 326] 
AR/NR3C4 VAR_009736 V581F 0.03 Deleterious 0 3.02 Possibly 
damaging
1.88 CAIS [330] 
AR/NR3C4 VAR_009737 F582S 0 Deleterious 0 3.02 Probably 
damaging
2.603 PAIS [331] 
AR/NR3C4 VAR_009738 F582Y 0 Deleterious 0 3.02 Benign 1.478 PAIS,  CAIS [328, 332] 
AR/NR3C4 VAR_009740 R585K 0 Deleterious 0 30.2 Possibly 
damaging
1.529 CAIS [329] 
AR/NR3C4 VAR_009741 A586V 0.01 Deleterious 0 3.02 Possibly 
damaging
1.542 Prostate cancer; somatic 
mutation 
[289, 326] 
AR/NR3C4 VAR_009742 A587S 0.06 Deleterious 0 3.02 Benign 0.435 Prostate cancer; somatic 
mutation 
[326] 
AR/NR3C4 VAR_009743 A596T 0.08 Deleterious 0 3.02 Possibly 
damaging
1.542 PAIS; abolished 
dimerization 
[333, 334] 
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AR/NR3C4 VAR_009744 S597G 0.33 Deleterious 0 3.02 Benign 0.61 PAIS; high dissociation rate; 
partially restored 
DNA-binding activity of 
P-617 mutant receptors 
[290] 
AR/NR3C4 VAR_009745 S597T 0.08 Deleterious 0 3.02 Possibly 
damaging
1.55 PAIS [335] 
AR/NR3C4 VAR_009746 C601F 0 Deleterious 0 3.02 Probably 
damaging
3.346 CAIS [336] 
AR/NR3C4 VAR_009747 D604Y 0 Deleterious 0 3.02 Probably 
damaging
2.639 PAIS [331] 
AR/NR3C4 VAR_004684 R607Q 0.11 Deleterious 0 3.02 Possibly 
damaging
1.754 PAIS and breast cancer; male 
breast cancer with 
Reifenstein syndrome 
[322, 337] 
AR/NR3C4 VAR_004685 R608K 0.01 Deleterious 0 3.02 Possibly 
damaging
1.529 PAIS and breast cancer; 
defective nuclear 
localization; male breast 
cancer with Reifenstein 
syndrome 
[338] 
AR/NR3C4 VAR_009748 N610T 0.03 Deleterious 0 3.02 Probably 
damaging
2.063 PAIS [337] 
AR/NR3C4 VAR_009749 C611Y 0 Deleterious 0 3.02 Probably 
damaging
3.346 CAIS [339] 
AR/NR3C4 VAR_009751 R615H 0 Deleterious 0 3.02 Possibly 
damaging
1.979 CAIS and PAIS [340] 
AR/NR3C4 VAR_009752 R615P 0 Deleterious 0 3.02 Probably 
damaging
2.429 CAIS [341] 
AR/NR3C4 VAR_009753 L616P 0 Deleterious 0 3.02 Probably 
damaging
2.243 CAIS [342] 
AR/NR3C4 VAR_009754 L616R 0 Deleterious 0 3.02 Probably 
damaging
2.018 PAIS [343] 
AR/NR3C4 VAR_009755 R617P 0 Deleterious 0 3.02 Probably 
damaging
2.204 CAIS and PAIS; loss of 
DNA-binding activity; 
associated with G-597 PAIS 
patient 
[290] 
AR/NR3C4 VAR_009756 C619Y 0 Deleterious 0 3.02 Probably 
damaging
3.346 Prostate cancer; loss of DNA 
binding; somatic mutation 
[289, 326] 
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AR/NR3C4 VAR_009757 R629Q 0.29 Deleterious 0 3.02 Possibly 
damaging
1.731 Prostate cancer [289, 344] 
AR/NR3C4 VAR_009758 K630T 0 Deleterious 0 3.02 Possibly 
damaging
2 Prostate cancer [308] 
AR/NR3C4 rs1800053 A645D 0.23 Tolerated 0.25 3.12 Benign 0.29   [341, 345] 
AR/NR3C4 VAR_009760 S647N 0.24 Tolerated 0.22 3.03 Benign 0.038 Prostate cancer [346] 
AR/NR3C4 VAR_004687 I664N 0.07 Tolerated 0.13 3.02 Benign 0.231 CAIS and PAIS [347] 
AR/NR3C4 rs9332968 I664T 0.13 Tolerated 0.2 3.02 Benign 1.162   [348] 
AR/NR3C4 VAR_009761 Q670R 0.16 Deleterious 0.01 3.02 Possibly 
damaging
1.906 Prostate cancer [308] 
AR/NR3C4 VAR_009762 P671H 0 Deleterious 0.03 3.02 Possibly 
damaging
1.92 PAIS [341] 
AR/NR3C4 VAR_009763 I672T 0.24 Deleterious 0 3.02 Benign 1.452 Prostate cancer [289] 
AR/NR3C4 VAR_004688 L677P 0.03 Deleterious 0 3.02 Probably 
damaging
2.243 CAIS [349] 
AR/NR3C4 VAR_009764 E681K 0.04 Deleterious 0 3.02 Possibly 
damaging
1.609 CAIS [350] 
AR/NR3C4 VAR_013474 P682T 0.02 Deleterious 0 3.02 Probably 
damaging
2.396 PAIS [351] 
AR/NR3C4 VAR_009765 G683A 0.3 Tolerated 0.3 3.02 Benign 0.312 Prostate cancer [289] 
AR/NR3C4 VAR_009766 V684I 0.09 Deleterious 0.01 3.02 Benign 1.024 CAIS [339] 
AR/NR3C4 VAR_009767 C686R 0.08 Tolerated 0.14 3.02 Probably 
damaging
2.577 PAIS [341] 
AR/NR3C4 VAR_009768 A687V 0.05 Deleterious 0 3.02 Possibly 
damaging
1.577 PAIS [341] 
AR/NR3C4 VAR_009769 G688E 0.11 Deleterious 0 3.02 Probably 
damaging
2.274 CAIS [352] 
AR/NR3C4 VAR_004690 D695H 0.03 Deleterious 0 3.02 Probably 
damaging
2.157 CAIS [353] 
AR/NR3C4 VAR_004691 D695N 0.1 Deleterious 0 3.02 Possibly 
damaging
1.784 CAIS [353] 
AR/NR3C4 VAR_004692 D695V 0.02 Deleterious 0 3.02 Benign 1.043 CAIS [354] 
AR/NR3C4 VAR_009771 L700M 0.15 Deleterious 0 3.02 Possibly 
damaging
1.966 CAIS [355] 
AR/NR3C4 VAR_009772 L701F 0.11 Deleterious 0 3.02 Possibly 
damaging
1.568 CAIS [317] 
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AR/NR3C4 VAR_009773 L701H 0.01 Deleterious 0 3.02 Probably 
damaging
2.243 CAIS and prostate cancer [289] 
AR/NR3C4 VAR_009774 S702A 0.08 Deleterious 0.01 3.02 Benign 1.308 CAIS [348] 
AR/NR3C4 VAR_009775 S703C 0 Deleterious 0 3.02 Possibly 
damaging
1.924 CAIS [339] 
AR/NR3C4 VAR_004693 S703G 0.05 Deleterious 0 3.02 Possibly 
damaging
1.699 PAIS and CAIS [356] 
AR/NR3C4 VAR_009776 N705S 0.1 Deleterious 0 3.02 Probably 
damaging
1.838 CAIS [343] 
AR/NR3C4 VAR_013475 N705Y 0.07 Deleterious 0 3.02 Probably 
damaging
2.513 CAIS [357] 
AR/NR3C4 VAR_004694 L707R 0.01 Deleterious 0 3.02 Probably 
damaging
2.018 CAIS [358] 
AR/NR3C4 VAR_009777 G708A 0.47 Deleterious 0 3.02 Possibly 
damaging
1.659 PAIS [359] 
AR/NR3C4 VAR_009778 G708V 0.05 Deleterious 0 3.02 Probably 
damaging
2.183 CAIS [339] 
AR/NR3C4 VAR_009779 R710T 0.02 Deleterious 0 3.02 Probably 
damaging
2.114 CAIS [355] 
AR/NR3C4 VAR_013476 Q711E 0.21 Deleterious 0 3.02 Probably 
damaging
1.643 PAIS  [351] 
AR/NR3C4 VAR_009780 L712F 0.06 Deleterious 0 3.02 Possibly 
damaging
1.568 PAIS [333] 
AR/NR3C4 VAR_009781 V715M 0.17 Deleterious 0 3.02 Benign 1.43 Prostate cancer [289, 360] 
AR/NR3C4 VAR_009782 K717E 0.34 Deleterious 0 3.02 Possibly 
damaging
1.618 Prostate cancer [289] 
AR/NR3C4 VAR_009783 K720E 0.05 Deleterious 0 3.02 Probably 
damaging
1.618 Prostate cancer with bone 
metastases 
[289] 
AR/NR3C4 VAR_009784 A721T 0.1 Deleterious 0.02 3.02 Benign 1.291 Prostate cancer; somatic 
mutation 
[289] 
AR/NR3C4 VAR_009785 L722F 0.11 Deleterious 0 3.02 Possibly 
damaging
1.517 CAIS [341] 
AR/NR3C4 VAR_009786 P723S 0.03 Deleterious 0 3.02 Probably 
damaging
2.396 CAIS [355] 
AR/NR3C4 VAR_009787 G724D 0.04 Deleterious 0 3.02 Probably 
damaging
2.049 CAIS and prostate cancer [289] 
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AR/NR3C4 VAR_009788 F725L 0.01 Deleterious 0 3.02 Probably 
damaging
2.153 PAIS [335, 361] 
AR/NR3C4 VAR_009789 R726L 0.08 Deleterious 0 3.02 Probably 
damaging
2.218 Prostate cancer [289, 362] 
AR/NR3C4 VAR_009790 N727K 0.06 Deleterious 0 3.02 Probably 
damaging
1.821 MAIS [361, 363] 
AR/NR3C4 VAR_009791 L728S 0 Deleterious 0 3.02 Possibly 
damaging
1.897 PAIS [364] 
AR/NR3C4 VAR_004695 V730M 0.04 Deleterious 0.03 3.02 Benign 0.075 Prostate cancer [289] 
AR/NR3C4 VAR_004696 D732N 0 Deleterious 0 3.02 Possibly 
damaging
1.739 CAIS [365] 
AR/NR3C4 VAR_004697 D732Y 0 Deleterious 0 3.02 Probably 
damaging
2.639 CAIS [348] 
AR/NR3C4 VAR_009792 Q733H 0.01 Deleterious 0 3.02 Probably 
damaging
2.123 PAIS [352] 
AR/NR3C4 VAR_009793 I737T 0 Deleterious 0 3.02 Probably 
damaging
2.024 PAIS [296] 
AR/NR3C4 VAR_009794 W741R 0.01 Deleterious 0 3.02 Probably 
damaging
3.902 CAIS [366] 
AR/NR3C4 VAR_004698 M742I 0.08 Deleterious 0 3.02 Probably 
damaging
2.266 PAIS [367] 
AR/NR3C4 VAR_009795 M742V 0.06 Deleterious 0 3.02 Probably 
damaging
2.266 PAIS [340, 361] 
AR/NR3C4 VAR_013477 G743E 0.89 Deleterious 0 3.02 Possibly 
damaging
1.849 CAIS [351] 
AR/NR3C4 VAR_004699 G743V 0.14 Deleterious 0 3.02 Probably 
damaging
1.799 PAIS and CAIS [368] 
AR/NR3C4 VAR_009796 L744F 0.06 Deleterious 0.01 3.02 Benign 1.399 CAIS and prostate cancer [369] 
AR/NR3C4 VAR_009797 M745T 0.02 Deleterious 0 3.02 Probably 
damaging
2.716 PAIS [340] 
AR/NR3C4 VAR_009798 V746M 0.26 Deleterious 0 3.02 Benign 1.273 PAIS [341] 
AR/NR3C4 VAR_009799 A748D 0.03 Deleterious 0 3.02 Possibly 
damaging
1.812 PAIS [370] 
AR/NR3C4 VAR_009800 A748T 0.04 Deleterious 0 3.02 Benign 1.457 Prostate cancer [289] 
AR/NR3C4 VAR_009801 A748V 0.02 Deleterious 0.05 3.02 Benign 0.546 Prostate cancer [289] 
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AR/NR3C4 VAR_009802 M749I 0.08 Deleterious 0.02 3.02 Probably 
damaging
1.901 Prostate cancer [289] 
AR/NR3C4 VAR_004700 M749V 0.06 Deleterious 0.01 3.02 Probably 
damaging
2.019 PAIS and CAIS [343] 
AR/NR3C4 VAR_004701 G750D 0.03 Deleterious 0 3.02 Possibly 
damaging
1.928 CAIS; loss of androgen 
binding 
[371] 
AR/NR3C4 VAR_009803 G750S 0.16 Deleterious 0.01 3.02 Possibly 
damaging
1.703 Prostate cancer [372] 
AR/NR3C4 VAR_009804 W751R 0.06 Deleterious 0 3.02 Probably 
damaging
3.902 CAIS [369] 
AR/NR3C4 VAR_004702 R752Q 0.01 Deleterious 0 3.02 Probably 
damaging
1.696 CAIS [373] 
AR/NR3C4 VAR_009805 F754L 0.13 Deleterious 0.01 3.02 Probably 
damaging
2.001 PAIS and prostate cancer [289, 337] 
AR/NR3C4 VAR_004703 F754V 0.15 Deleterious 0 3.02 Probably 
damaging
2.104 CAIS [374] 
AR/NR3C4 VAR_009806 T755A 0.28 Deleterious 0 3.02 Benign 1.358 Prostate cancer [289] 
AR/NR3C4 VAR_009807 N756S 0.08 Deleterious 0.01 3.02 Possibly 
damaging
1.853 PAIS [341] 
AR/NR3C4 VAR_009808 V757A 0.25 Tolerated 0.28 3.02 Benign 0.487 Prostate cancer [289, 326] 
AR/NR3C4 VAR_009809 N758T 0.02 Deleterious 0 3.02 Possibly 
damaging
1.864 PAIS; 50% reduction 
transactivation 
[375] 
AR/NR3C4 VAR_009810 S759F 0 Deleterious 0.01 3.02 Possibly 
damaging
1.79 CAIS [289, 343] 
AR/NR3C4 VAR_009811 S759P 0.03 Tolerated 0.06 3.02 Possibly 
damaging
1.626 Prostate cancer [289] 
AR/NR3C4 VAR_004704 L762F 0.03 Deleterious 0 3.02 Possibly 
damaging
1.568 CAIS; loss of androgen 
binding 
[371] 
AR/NR3C4 VAR_004705 Y763C 0.17 Deleterious 0 3.02 Probably 
damaging
2.758 PAIS and prostate cancer; 
partial loss of androgen 
binding 
[289] 
AR/NR3C4 VAR_009812 Y763H 0.09 Deleterious 0 3.02 Possibly 
damaging
1.858 CAIS [296, 373] 
AR/NR3C4 VAR_009813 F764L 0.08 Deleterious 0 3.02 Probably 
damaging
2.153 CAIS [340] 
AR/NR3C4 VAR_004707 A765T 0.03 Deleterious 0 3.02 Possibly 
damaging
1.542 CAIS; loss of androgen 
binding 
[365, 371, 
376] 
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AR/NR3C4 VAR_009814 A765V 0.03 Deleterious 0 3.02 Possibly 
damaging
1.542 CAIS [348] 
AR/NR3C4 VAR_009815 P766S 0.08 Deleterious 0 3.02 Probably 
damaging
2.396 CAIS [370] 
AR/NR3C4 VAR_009816 D767E 0.07 Deleterious 0 3.02 Possibly 
damaging
1.514 CAIS [338] 
AR/NR3C4 VAR_009817 L768P 0.01 Deleterious 0 3.02 Probably 
damaging
2.243 CAIS [317] 
AR/NR3C4 VAR_009818 N771H 0.11 Deleterious 0 3.02 Possibly 
damaging
1.838 PAIS [377] 
AR/NR3C4 VAR_009819 E772A 0.03 Deleterious 0.01 3.02 Probably 
damaging
2.036 PAIS [361, 378] 
AR/NR3C4 VAR_009820 E772G 0.03 Deleterious 0 3.02 Probably 
damaging
2.092 PAIS [379] 
AR/NR3C4 VAR_004709 R774C 0.03 Deleterious 0 3.02 Probably 
damaging
2.654 CAIS; loss of androgen 
binding; frequent mutation 
[361] 
AR/NR3C4 VAR_004708 R774H 0.01 Deleterious 0 3.02 Possibly 
damaging
1.979 CAIS and PAIS; almost 
complete loss of androgen 
binding 
[343] 
AR/NR3C4 VAR_004710 R779W 0.17 Deleterious 0.01 3.02 Probably 
damaging
2.084 CAIS [292] 
AR/NR3C4 VAR_004711 M780I 0.11 Deleterious 0 3.02 Probably 
damaging
2.266 PAIS and CAIS [367, 380] 
AR/NR3C4 VAR_009821 S782N 0.07 Tolerated 0.28 3.02 Benign 0.194 Prostate cancer; somatic 
mutation 
[308] 
AR/NR3C4 VAR_004712 C784Y 0.1 Deleterious 0 3.02 Probably 
damaging
3.346 CAIS; loss of androgen 
binding and of 
transactivation 
[376] 
AR/NR3C4 VAR_004713 M787V 0.05 Deleterious 0 3.02 Probably 
damaging
2.234 CAIS [381] 
AR/NR3C4 VAR_009822 R788S 0.35 Deleterious 0 3.02 Possibly 
damaging
1.735 MAIS [382] 
AR/NR3C4 VAR_009823 L790F 0.23 Deleterious 0 3.02 Benign 0.215 MAIS [383] 
AR/NR3C4 VAR_009824 S791P 0.05 Deleterious 0 3.02 Possibly 
damaging
1.924 Prostate cancer [289] 
AR/NR3C4 VAR_009825 E793D 0.01 Deleterious 0.01 3.02 Benign 1.425   [348] 
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AR/NR3C4 VAR_004714 F794S 0 Deleterious 0 3.02 Probably 
damaging
2.603 CAIS [384] 
AR/NR3C4 VAR_004715 Q798E 0.11 Deleterious 0 3.02 Possibly 
damaging
1.643 PAIS, MAIS and prostate 
cancer 
[289] 
AR/NR3C4 VAR_009826 C806Y 0.02 Deleterious 0 3.02 Probably 
damaging
3.346 PAIS [385] 
AR/NR3C4 VAR_004716 M807R 0 Deleterious 0 3.02 Probably 
damaging
2.717 CAIS; loss of transactivation [386, 387]  
AR/NR3C4 VAR_009827 M807T 0 Deleterious 0.01 3.02 Probably 
damaging
2.658 PAIS [387, 388] 
AR/NR3C4 VAR_004717 M807V 0.06 Deleterious 0.01 3.02 Probably 
damaging
2.394 CAIS; 25% androgen 
binding 
[292, 387] 
AR/NR3C4 VAR_009828 L812F 0.06 Tolerated 0.07 3.02 Benign 0.171 PAIS [389] 
AR/NR3C4 VAR_004718 S814N 0.33 Deleterious 0 3.02 Benign 1.474 MAIS, CAIS and PAIS [361] 
AR/NR3C4 VAR_009829 G820A 0 Deleterious 0 3.02 Possibly 
damaging
1.824 CAIS [313] 
AR/NR3C4 VAR_009830 L821V 0.05 Deleterious 0 3.02 Benign 1.343 PAIS [348] 
AR/NR3C4 VAR_013478 F827V 0.42 Deleterious 0 3.02 Probably 
damaging
2.378 PAIS [351] 
AR/NR3C4 VAR_009831 L830P 0 Deleterious 0 3.02 Probably 
damaging
2.122 Prostate cancer [289] 
AR/NR3C4 VAR_004719 R831L 0.08 Deleterious 0 3.02 Probably 
damaging
2.429 CAIS [390, 391]  
AR/NR3C4 VAR_004720 R831Q 0.35 Deleterious 0 3.02 Possibly 
damaging
1.754 CAIS; loss of androgen 
binding 
[390] 
AR/NR3C4 VAR_009832 Y834C 0 Deleterious 0 3.02 Probably 
damaging
2.758 CAIS; loss of androgen 
binding 
[366] 
AR/NR3C4 VAR_004721 R840C 0.01 Deleterious 0 3.02 Probably 
damaging
2.596 PAIS [392] 
AR/NR3C4 VAR_004722 R840G 0.04 Deleterious 0 3.02 Probably 
damaging
2.371 PAIS [376] 
AR/NR3C4 VAR_009229 R840S 0.12 Deleterious 0 3.02 Probably 
damaging
2.076 PAIS [393] 
AR/NR3C4 rs9332969 R840H 0.15 Deleterious 0 3.02 Probably 
damaging
1.98   [318] 
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AR/NR3C4 VAR_009833 I841S 0.08 Deleterious 0 3.02 Possibly 
damaging
1.819 PAIS [341] 
AR/NR3C4 rs9332970 I842T 0.07 Deleterious 0 3.02 Possibly 
damaging
1.895 CAIS [343] 
AR/NR3C4 VAR_009834 R846G 0.15 Tolerated 0.14 3.06 Benign 0.809 Prostate cancer;  PAIS [289, 326] 
AR/NR3C4 VAR_009835 R854K 0.08 Tolerated 0.3 3.02 Benign 1.102 PAIS [364] 
AR/NR3C4 VAR_004725 R855C 0 Deleterious 0 3.02 Probably 
damaging
2.654 CAIS [343] 
AR/NR3C4 rs9332971 R855H 0.02 Deleterious 0 3.02 Possibly 
damaging
1.979 PAIS [343, 394] 
AR/NR3C4 VAR_009836 F856L 0.15 Deleterious 0 3.02 Benign 1.199 CAIS and PAIS [395] 
AR/NR3C4 VAR_009837 L863R 0 Deleterious 0 3.02 Probably 
damaging
1.849 CAIS [385] 
AR/NR3C4 VAR_009838 D864G 0.18 Tolerated 0.07 3.02 Benign 0.875 CAIS [396] 
AR/NR3C4 VAR_004727 D864N 0.07 Deleterious 0.01 3.02 Possibly 
damaging
1.67 CAIS; loss of androgen 
binding 
[371] 
AR/NR3C4 VAR_009839 S865P 0.02 Deleterious 0 3.02 Possibly 
damaging
1.924 CAIS and AIS [395] 
AR/NR3C4 VAR_004728 V866E 0 Deleterious 0 3.02 Probably 
damaging
1.863 CAIS [317] 
AR/NR3C4 VAR_004729 V866L 0.7 Tolerated 1 3.02 Benign 0.071 PAIS [397] 
AR/NR3C4 VAR_004730 V866M 0.13 Deleterious 0.02 3.02 Benign 0.299 CAIS, PAIS and prostate 
cancer 
[289, 337, 
361] 
AR/NR3C4 VAR_004731 I869M 0.09 Deleterious 0.01 3.02 Benign 1.286 PAIS; perineal hypospadias [367] 
AR/NR3C4 VAR_009840 A870G 0.19 Deleterious 0.05 3.02 Benign 1.217 PAIS [359] 
AR/NR3C4 VAR_009841 A870V 0.38 Tolerated 1 3.02 Benign 0.46 PAIS [331] 
AR/NR3C4 VAR_009842 R871G 0.28 Deleterious 0.01 3.02 Benign 0.876 MAIS [361, 378] 
AR/NR3C4 VAR_013479 H874R 0.67 Deleterious 0.02 3.02 Probably 
damaging
2.373 CAIS [289, 351]  
AR/NR3C4 VAR_009843 H874Y 0.8 Deleterious 0 3.02 Probably 
damaging
2.144 Prostate cancer [289] 
AR/NR3C4 VAR_004732 T877A 0.25 Deleterious 0 3.02 Probably 
damaging
1.591 Prostate cancer; altered 
steroid binding 
characteristics and response 
to antiandrogens; bone 
[289] 
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metastases 
AR/NR3C4 VAR_009844 T877S 0.2 Deleterious 0 3.02 Benign 0.696 Prostate cancer [398] 
AR/NR3C4 VAR_013480 D879Y 0.16 Deleterious 0 3.02 Probably 
damaging
2.028 MAIS [351] 
AR/NR3C4 VAR_009845 L880Q 0.01 Deleterious 0 3.02 Probably 
damaging
1.847 Prostate cancer [289] 
AR/NR3C4 VAR_009846 L881V 0.17 Deleterious 0.01 3.02 Benign 1.108 CAIS [399] 
AR/NR3C4 VAR_009847 M886V 0.01 Tolerated 0.2 3.02 Probably 
damaging
2.202 MAIS [309] 
AR/NR3C4 VAR_009848 V889M 0.06 Deleterious 0 3.02 Benign 1.43 CAIS and PAIS [296, 373] 
AR/NR3C4 VAR_009849 D890N 0.05 Tolerated 0.43 3.02 Benign 0.342 Prostate cancer [289, 335] 
AR/NR3C4 VAR_009850 F891L 0.2 Deleterious 0 3.02 Probably 
damaging
2.15 Prostate cancer [289] 
AR/NR3C4 VAR_004733 P892L 0 Deleterious 0 3.02 Probably 
damaging
2.846 CAIS [400] 
AR/NR3C4 VAR_004734 M895T 0 Deleterious 0.01 3.02 Probably 
damaging
2.452 CAIS; low androgen binding 
and transactivation 
[376, 400]  
AR/NR3C4 VAR_009851 A896T 0.06 Deleterious 0.01 3.02 Benign 0.252 Prostate cancer [339] 
AR/NR3C4 VAR_009852 I898T 0 Deleterious 0 3.02 Probably 
damaging
1.969 CAIS [352] 
AR/NR3C4 VAR_009853 Q902R 0.01 Tolerated 0.12 3.02 Benign 0.61 Prostate cancer [398] 
AR/NR3C4 VAR_009854 V903M 0.01 Deleterious 0 3.02 Benign 1.242 PAIS [364] 
AR/NR3C4 VAR_009855 P904H 0 Deleterious 0 3.02 Probably 
damaging
2.621 CAIS [364] 
AR/NR3C4 VAR_009856 P904S 0 Deleterious 0 3.02 Probably 
damaging
2.396 CAIS [348] 
AR/NR3C4 VAR_004735 L907F 0.01* Deleterious 0 3.02 Possibly 
damaging
1.568 CAIS [371, 401]  
AR/NR3C4 VAR_009857 G909E 0.00* Deleterious 0 3.02 Probably 
damaging
2.274 Prostate cancer [289] 
AR/NR3C4 VAR_009858 G909R 0.00* Deleterious 0 3.02 Probably 
damaging
2.274 PAIS [400] 
AR/NR3C4 VAR_009859 K910R 0.2* Tolerated 0.76 3.02 Benign 0.144 Prostate cancer [289, 402] 
AR/NR3C4 VAR_009860 V911L 0.00* Deleterious 0.02 3.02 Benign 1.322 PAIS [380] 
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AR/NR3C4 VAR_004736 P913S 0.00* Deleterious 0 3.02 Probably 
damaging
2.396 PAIS [339] 
AR/NR3C4 VAR_009861 F916L 0.00* Deleterious 0 3.02 Probably 
damaging
2.153 CAIS [356] 
AR/NR3C4 VAR_009862 H917R 0.00* Deleterious 0 3.02 Probably 
damaging
2.696 CAIS [317] 
AR/NR3C4 VAR_009863 Q919R 0.00* Deleterious 0 3.76 Benign 1.402 Prostate cancer [289] 
ESR1/NR3A1 rs9340773 G76S 0.78 Tolerated 0.86 2.93 Benign 0.089    
ESR1/NR3A1 rs17847065 P145Q Not 
scored
Tolerated 0.86 3.5 Probably 
damaging
2.011    
ESR1/NR3A1 VAR_004671 G160C 0.05 Deleterious 0.05 2.89 Benign 1.451    
ESR1/NR3A1 rs17847076 T167S Not 
scored
Tolerated 0.88 2.86 Benign 0.27    
ESR1/NR3A1 VAR_004672 V364E 0 Deleterious 0 2.86 Probably 
damaging
2.214 Estrogen resistance; 
dominant-negative inhibitor 
of the wild-type ESR 
[403] 
ESR1/NR3A1 VAR_004673 G400V 0 Deleterious 0 2.86 Possibly 
damaging
1.599 Destabilized receptors and 
decreased affinity for 
estradiol at 25oC, but not at 
4oC 
[291] 
ESRRA/NR3B1 rs7996600 L385P   Deleterious 0 2.66 Probably 
damaging
2.121    
ESRRA/NR3B1 rs45585533  P173Q   Tolerated 0.6 2.64 Benign 0.155    
ESRRA/NR3B1 rs45588331  A378V   Tolerated 1 2.63 Benign 1.069    
ESRRB/NR3B2 rs1141580 D3E Not 
scored
Tolerated 0.77 3.32 Benign 0.057    
ESRRB/NR3B2 rs1141582 L46M Not 
scored
Tolerated 0.23 2.73 Benign 0.719    
ESRRB/NR3B2 rs1064445 S192N 0.5 Tolerated 0.58 2.66 Benign 0.189    
ESRRB/NR3B2 rs4277274 D221Y 0 Damaging 0.01 2.64 Probably 
damaging
2.087    
ESRRB/NR3B2 rs61742642  P386S   Tolerated 1 2.67 Benign 0.587    
ESRRG/NR3B3 rs11572693 T49M 0.23 Damaging 0.05 2.89 Benign 1.106    
ESRRG/NR3B3 rs1064199 V312F 0.4 Deleterious 0 2.63 Benign 1.299    
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HNF4A/NR2A1 VAR_004668 R127W 0 Deleterious 0 2.63 Probably 
damaging
2.88 MODY1  [404, 405] 
HNF4A/NR2A1 rs1800961 T138I 0.18 Tolerated 0.18 2.74 Benign 0.633    
HNF4A/NR2A1 VAR_010600 V255M 0.09 Deleterious 0.01 2.63 Benign 1.304 Late-onset NIDDM [406] 
HNF4A/NR2A1 VAR_010601 E276Q 0 Deleterious 0 2.63 Possibly 
damaging
1.755 MODY1 [407] 
HNF4A/NR2A1 rs6093980 L288F 0.01 Damaging 0.01 2.73 Possibly 
damaging
1.823   
HNF4A/NR2A1 VAR_004670 V393I 0.16* Tolerated 0.41 3.3 Benign 0.937 MODY1; reduced 
transactivation activity; 
NIDDM 
[294] 
HNF4A/NR2A1 rs6031602 P429L 0.01* Damaging 0.05 3.29 Probably 
damaging
2.25    
HNF4A/NR2A1 rs1063239 P444S 0.79* Tolerated 0.79 3.29 Benign 1.449    
HNF4G/NR2A2 rs294354  S29N   Tolerated 0.28 3.42 Benign 0.058    
HNF4G/NR2A2 rs3765201 M142R 0.06 Tolerated 0.07 2.91 Probably 
damaging
2.721    
HNF4G/NR2A2 rs1805098 M189I 0.27 Tolerated 0.19 2.91 Possibly 
damaging
1.837    
NR0B1/DAX1 VAR_004738 R267P 0.02 Deleterious 0.01 2.75 Probably 
damaging
2.27 CAH [408] 
NR0B1/DAX1 VAR_004740 W291C 0.05 Deleterious 0 2.75 Probably 
damaging
3.757 CAH [409] 
NR0B1/DAX1 VAR_018303 L295P 0 Deleterious 0 2.75 Probably 
damaging
2.11 CAH [410] 
NR0B1/DAX1 VAR_018304 A300P 0 Deleterious 0 2.75 Possibly 
damaging
1.638 CAH [411] 
NR0B1/DAX1 VAR_004741 A300V 0.07 Deleterious 0.04 2.75 Benign 1.413 CAH [412] 
NR0B1/DAX1 rs41402346  Q359T   Deleterious 0.03 2.79 Probably 
damaging
2.105    
NR0B1/DAX1 VAR_004742 E377K 0 Deleterious 0 2.75 Benign 1.47 CAH [375] 
NR0B1/DAX1 VAR_018300 Y380D 0.03 Deleterious 0.05 2.75 Probably 
damaging
2.841 CAH [413] 
NR0B1/DAX1 VAR_018301 L381H 0 Deleterious 0 2.75 Probably 
damaging
2.11 CAH [413, 414] 
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NR0B1/DAX1 rs28935180 K382N 0 Deleterious 0 2.75 Possibly 
damaging
1.702 CAH [409] 
NR0B1/DAX1 VAR_004744 V385G 0 Deleterious 0 2.75 Probably 
damaging
2.185 CAH [375] 
NR0B1/DAX1 rs11550590 Q400L Not 
scored
Deleterious 0.01 2.76 Probably 
damaging
2.409    
NR0B1/DAX1 VAR_004745 R425G 0 Deleterious 0 2.76 Probably 
damaging
2.189 CAH [375] 
NR0B1/DAX1 VAR_018305 R425T 0 Deleterious 0 2.76 Benign 0.7 CAH [411] 
NR0B1/DAX1 VAR_018302 I439S 0 Deleterious 0 2.76 Probably 
damaging
2.099 CAH (mild phenotype) [415] 
NR0B1/DAX1 rs28935481 N440I Not 
scored
Deleterious 0.01 2.76 Probably 
damaging
2.359 CAH [416, 417] 
NR0B1/DAX1 VAR_018306 L466R 0 Deleterious 0 2.83 Possibly 
damaging
1.885 CAH [411] 
NR0B2/SHP VAR_026015 R57W 0 Deleterious 0 2.13 Possibly 
damaging
1.963 Early-onset obesity; 
Japanese population; loss of 
repressor activity 
 
NR0B2/SHP rs6659176 G170A Not 
scored
Tolerated 1 2.21 Benign 1.154    
NR0B2/SHP VAR_026016 G189E 1 Tolerated 1 2.13 Benign 1.004 Early-onset obesity; 
Japanese population; strong 
decrease of repressor activity
 
NR0B2/SHP VAR_026017 A195S 0.48 Tolerated 0.33 2.13 Benign 0.96 Early-onset obesity; 
Japanese population; slight 
decrease of repressor 
activity; obesity, mild, 
early-onset 
[418] 
NR0B2/SHP VAR_026018 R213C 0 Deleterious 0.03 2.13 Benign 0.749 Early-onset obesity; 
Japanese population; loss of 
repressor activity 
 
NR0B2/SHP VAR_026019 R216H 0.01 Deleterious 0.01 2.13 Possibly 
damaging
1.86 No effect on repressor 
activity 
 
NR1D1/Rev-ErbAα rs12943899 L297I 0.12 Tolerated 0.33 2.59 Benign 0.468    
NR1D2/Rev-ErbAβ rs17854365 H20P Not 
scored
Tolerated 1 2.57 Probably 
damaging
2.025    
NR1D2/Rev-ErbAβ rs17857305 K281Q Not Tolerated 0.71 2.43 Benign 1.097    
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scored
NR1D2/Rev-ErbAβ rs17857306 R287P Not 
scored
Tolerated 1 2.4 Benign 0.258    
NR1D2/Rev-ErbAβ rs4858097 M385L Not 
scored
Tolerated 1 2.25 Benign 1.423    
NR1H2/LXRα rs41379547  S2F   Deleterious 0 3.32 Benign N/A    
NR1H3/LXRβ rs11545529 I38V Not 
scored
Tolerated 0.62 2.71 Benign 0.225    
NR1H3/LXRβ rs41481445  G52V   Deleterious 0.04 2.42 Benign 0.674    
NR1H4/FXR rs11608438 P13H Not 
scored
Tolerated 0.1 3.32 Possibly 
damaging
1.727    
NR1I2/PXR rs59371185  E18K   Tolerated 0.89 2.14 Benign 1.15    
NR1I2/PXR rs1063955 A50T 0.28* Tolerated 0.38 2.32 Benign 0.25    
NR1I2/PXR rs12721613 P65S 0.45 Tolerated 0.17 2.03 Benign 0.492    
NR1I2/PXR rs12721607 G74R 0.19 Tolerated 0.28 2.18 Benign 1.372    
NR1I2/PXR VAR_018340 R98C 0 Deleterious 0 1.94 Probably 
damaging
3.065    
NR1I2/PXR VAR_018341 R148Q 0.88 Tolerated 0.7 1.96 Benign 0.675    
NR1I2/PXR rs1140968 K148N 0.03 Damaging 0.02 2.74 Benign 0.92    
NR1I2/PXR rs12721608 R160Q 0.04 Damaging 0.01 2.75 Possibly 
damaging
1.976    
NR1I2/PXR rs35761343  A370T   Tolerated 0.46 1.93 Benign 0.268    
NR1I2/PXR VAR_018342 R381W 0.01 Tolerated 0.06 1.93 Probably 
damaging
2.233    
NR1I2/PXR VAR_018343 I403V 0.05 Deleterious 0.01 1.93 Benign 0.636    
NR1I2/PXR rs56162473  Q426E   Tolerated 1 1.98 Possibly 
damaging
1.59    
NR1I3/CAR rs34161743  R97W   Deleterious 0 2.27 Probably 
damaging
2.087    
NR1I3/CAR VAR_018344 V133G 0.4 Tolerated 0.52 2.3 Benign 0.658    
NR1I3/CAR rs1140627  P270T   Damaging 0.01 2.32 Benign 1.128    
NR1I3/CAR rs41270857  M168T   Tolerated 1 2.27 Possibly 
damaging
1.697    
NR1I3/CAR rs2307414 G313S Not 
scored
Tolerated 0.8 2.26 Benign 1.029    
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NR1I3/CAR rs2307414 G313R Not 
scored
Tolerated 0.52 2.26 Possibly 
damaging
1.126    
NR1I3/CAR rs3813629  G326E   Deleterious 0.01 2.27 Possibly 
damaging
1.02    
NR1I3/CAR rs2307416  G332S   Tolerated 0.18 3.69   N/A    
NR2C1/TR2 rs1063831 Q519L Not 
scored
Tolerated 0.29 2.96 Benign 1.475    
NR2C2/TR2 rs7617704 F35L Not 
scored
Tolerated 0.26 2.99 Benign 0.283    
NR2C2/TR2 rs1042123 A612V Not 
scored
Tolerated 1 3.79 Benign 0.784    
NR2E3/PNR rs449608  A19P   Tolerated 0.36 2.45 Benign 1.268    
NR2E3/PNR rs4442764  A19G   Tolerated 0.37 2.45 Benign 1.219    
NR2E3/PNR rs1805020 E140G   Tolerated 0.38 2.18 Benign 0.742    
NR2E3/PNR rs1805021 M163T   Tolerated 0.27 2.18 Benign 1.464    
NR2E3/PNR rs1805023  V232I   Tolerated 0.16 1.98 Benign 0.612    
NR2E3/PNR rs1805025  V302I   Tolerated 0.57 2 Benign 0.18    
NR2E3/PNR rs28937873 R311Q   Tolerated 0.1 1.98 Benign 0.761 Enhanced S-cone syndrome [419, 420] 
NR2E3/PNR rs35004053  R366C   Not found       Not 
found 
   
NR2F6/COUP-TFI rs12974913 D30H Not 
scored
Tolerated 0.16 3 Benign 0.45    
NR2F6/COUP-TFI rs12974411 S83N Not 
scored
Damaging 0.01 2.66 Possibly 
damaging
1.876    
NR2F6/COUP-TFI rs12974387 S89N Not 
scored
Tolerated 0.17 2.66 Benign 0.818    
NR2F6/COUP-TFI rs1057060 L236M Not 
scored
Tolerated 0.22 2.66 Benign 0.578    
NR3C1/GR rs6190 R22K 0.13* Tolerated 0.26 3.75 Benign 1.354    
NR3C1/GR VAR_015628 F29L 0.18* Tolerated 0.63 3.2 Benign 1.021    
NR3C1/GR rs6192 F64V 0.04* Tolerated 0.48 3.35 Benign 1.416    
NR3C1/GR rs6192 F64I Not 
scored
Tolerated 0.71 2.89 Benign 0.518    
NR3C1/GR rs6192 F64L Not 
scored
Tolerated 0.67 2.89 Benign 0.71    
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NR3C1/GR VAR_015629 L112F 0.02* Tolerated 0.63 2.96 Benign 0.109    
NR3C1/GR VAR_015630 D233N 0.06* Tolerated 0.35 3.18 Possibly 
damaging
1.762    
NR3C1/GR rs28395802 D345H Not 
scored
Deleterious 0 2.95 Possibly 
damaging
1.743    
NR3C1/GR rs6195 N362S 0.85 Tolerated 0.58 3.32 Benign 0.006    
NR3C1/GR rs6195 N362T Not 
scored
Tolerated 1 2.93 Benign 0.17    
NR3C1/GR rs6195 N362I Not 
scored
Tolerated 0.16 2.93 Benign 0.527    
NR3C1/GR rs1800445 N364S 0.07 Tolerated 0.14 3.32 Benign 0.81 Glucocorticoid receptor 
polymorphism 
[421] 
NR3C1/GR VAR_015631 C421Y 0 Deleterious 0 2.76 Probably 
damaging
3.608 A glucocorticoid resistant 
leukemia cell line 
[422] 
NR3C1/GR VAR_013472 R477H 0 Deleterious 0 2.75 Probably 
damaging
2.238 Glucocorticoid resistance [293] 
NR3C1/GR rs33391 N516K 0.94 Tolerated 0.79 3.29 Benign 1.378    
NR3C1/GR VAR_015632 I559N 0.14 Deleterious 0 2.75 Probably 
damaging
2.203 Glucocorticoid resistance; 
altered translocation to the 
nucleus and thereby strongly 
reduced transcription 
activation 
[423] 
NR3C1/GR VAR_025014 V571A 0 Deleterious 0.01 2.75 Possibly 
damaging
1.733 Pseudohermaphroditism; 
female with hypokalemia 
due to glucocorticoid 
resistance; 6-fold reduction  
binding affinity compared 
with the wild-type receptor;   
[424] 
NR3C1/GR VAR_004676 D641V 0.16 Deleterious 0 2.75 Probably 
damaging
2.492 Glucocorticoid resistance [425] 
NR3C1/GR rs258751 D677E Not 
scored
Tolerated 1 2.75 Benign 0.398    
NR3C1/GR VAR_013473 G679S 0.03 Deleterious 0 2.75 Possibly 
damaging
1.843 Glucocorticoid resistance 
(generalized with 50% 
binding affinity)     
[293] 
NR3C1/GR VAR_004677 V729I 0.07 Deleterious 0 2.75 Benign 1.277 Glucocorticoid resistance [426] 
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NR3C1/GR VAR_015633 I747M 0.06 Deleterious 0 2.75 Benign 1.354 Glucocorticoid resistance; 
altered interaction with 
NCOA2 and strongly 
reduced transcription 
activation; dominant 
negative mutant     
[427] 
NR3C1/GR VAR_004678 L753F 0.05 Deleterious 0.01 2.75 Possibly 
damaging
1.792 Two glucocorticoid resistant 
leukemia cell lines lacking 
the normal allele 
[428] 
NR3C1/GR rs6196 N765K Not 
scored
Tolerated 0.31 2.75 Benign 1.282    
NR3C2/MR rs13306591 R149H 0.00* Tolerated 0.12 3.01 Possibly 
damaging
1.55    
NR3C2/MR rs5522 V179I Not 
scored
Tolerated 0.83 3.53 Benign 0.306    
NR3C2/MR VAR_015625 A241V 1.00* Tolerated 1 3.39 Benign 1.383 High frequency  healthy 
individuals; found  a patient 
with sporadic 
pseudohypoaldosteronism 
type I; reduces transcription 
transactivation upon 
aldosterone binding 
[429, 430]  
NR3C2/MR rs5523 N443T 0.00* Damaging 0.04 3.65 Benign 1.474    
NR3C2/MR rs12509135 S455L 0.00* Damaging 0 3.65 Possibly 
damaging
1.677    
NR3C2/MR rs5526 R536Q 0.1* Tolerated 0.15 3.39 Benign 0.537    
NR3C2/MR rs5527 N553S 0.13* Tolerated 0.82 3.35 Benign 0.25    
NR3C2/MR VAR_015626 S810L 0.76* Tolerated 0.26 2.89 Possibly 
damaging
1.713 Early onset hypertension; 
altered receptor specificity 
and leading to constitutive 
activation;   hypertension, 
early-onset, autosomal 
dominant, with exacerbation 
pregnancy 
[431] 
NR3C2/MR rs13306592 F825Y 0.08* Damaging 0.05 3.18 Benign 0.188    
NR3C2/MR VAR_015627 L924P 0.00* Deleterious 0 2.89 Probably 
damaging
2.243 PHA1; abolished 
transcription transactivation 
[432] 
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upon aldosterone binding   
NR4A1/NGFIB rs1882118 L25V 0.01* Damaging 0.02 3.4 Benign 1.343    
NR4A1/NGFIB rs1042315 G261R 0.48 Tolerated 0.64 2.58 Possibly 
damaging
1.68    
NR4A1/NGFIB rs1042316 G261A 0.67 Tolerated 0.76 1.87 Benign 1.23    
NR4A3/NOR1 rs12344570 S239G 1 Tolerated 0.48 2.56 Benign 0.39    
NR4A3/NOR1 rs56313530 G296E   Deleterious 0.01 2.02 Probably 
damaging
2.274    
NR5A1/SF1 VAR_004737 G35E 0.01 Deleterious 0 1.85 Probably 
damaging
2.367 XY sex reversal with adrenal 
failure 
[433] 
NR5A1/SF1 VAR_016982 R92Q 0.16 Deleterious 0.01 1.99 Possibly 
damaging
1.892 XY sex reversal with adrenal 
failure 
[434] 
NR5A1/SF1 rs1110061 G145A 1 Tolerated 0.84 2.5 Benign 0.204    
NR5A1/SF1 VAR_016983 R255L 0.23 Tolerated 0.31 1.94 Probably 
damaging
2.489 Adrenocortical insufficiency 
without ovarian defect 
[414] 
NR5A2/LRH-1 rs4255412 E468K Not 
scored
Tolerated 0.1 2.69 Benign 1.015    
PGR/NR3C3 rs11571143 A49T 0.03* Tolerated 0.21 2.83 Benign 1.242    
PGR/NR3C3 rs3740754 G56R 0.54* Tolerated 0.82 2.83 Benign 0.178    
PGR/NR3C3 rs11571144 A119V 0.03* Tolerated 0.24 3.23 Benign 1.164    
PGR/NR3C3 rs11571145 P185L 0.00* Tolerated 0.34 2.75 Probably 
damaging
2.55    
PGR/NR3C3 rs11571146 M300R 0.01* Tolerated 0.83 2.39 Probably 
damaging
2.458    
PGR/NR3C3 rs3740753 S343T Not 
scored
Tolerated 0.55 2.5 Benign 1.096    
PGR/NR3C3 rs11571147 C346S 1.00* Tolerated 0.79 2.8 Benign 0.763    
PGR/NR3C3 rs11571148 P351L 0.00* Tolerated 0.22 2.46 Probably 
damaging
2.55    
PGR/NR3C3 rs11571149 S377R 0 Tolerated 0.32 2.56 Benign 1.379    
PGR/NR3C3 rs11571150 A443S 0.96 Tolerated 0.86 2.79 Benign 0.072    
PGR/NR3C3 rs11571151 V528L 0.15 Tolerated 0.65 2.38 Benign 1.239    
PGR/NR3C3 rs11571152 Q535P 0.1 Tolerated 0.18 2.36 Probably 
damaging
2.121    
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PGR/NR3C3 VAR_019227 Q536P 0.19 Tolerated 0.3 2.56 Probably 
damaging
2.121    
PGR/NR3C3 rs2020874 R624I 0.01 Damaging 0 2.36 Probably 
damaging
2.006    
PGR/NR3C3 rs11571222 L650V 0.13 Tolerated 0.36 2.44 Benign 0.825    
PGR/NR3C3 rs1042838 V659L Not 
scored
Tolerated 0.34 2.51 Benign 0.086    
PGR/NR3C3 rs2020880 S864L 0.13 Tolerated 0.08 2.35 Possibly 
damaging
1.532    
PPARA/NR1C1 rs1800204 R126Q Not 
scored
Deleterious 0 2.09 Probably 
damaging
2.013    
PPARA/NR1C1 rs1800206 L161V Not 
scored
Tolerated 0.08 2.09 Possibly 
damaging
1.508 Susceptibility to 
hyperapobetalipoproteinemi
a 
[435] 
PPARA/NR1C1 rs1800234 V226A Not 
scored
Tolerated 1 2.2 Benign 0.119    
PPARA/NR1C1 rs1042311 A267V Not 
scored
Tolerated 0.43 2.33 Benign 0.048    
PPARA/NR1C1 rs1800242 D303N Not 
scored
Deleterious 0.02 2.1 Possibly 
damaging
1.999    
PPARA/NR1C1 rs2229245 G395R   Tolerated 0.28 2.1 Benign 0.844    
PPARA/NR1C1 rs1800243 R408T Not 
scored
Deleterious 0.02 2.1 Benign 1.37    
PPARA/NR1C1 rs9615759 Q412L Not 
scored
Tolerated 0.31 2.1 Benign 0.806    
PPARD/NR1C2                   
PPARG/NR1C3 rs1801282 P11A 0.00* Damaging 0 4.32 Possibly 
damaging
1.8 Modifier of NIDDM [436, 437] 
PPARG/NR1C3 rs1805192 P39A 0.05* Deleterious 0.04 3.36 Possibly 
damaging
1.74    
PPARG/NR1C3 rs1800571 P112Q 0.01 Deleterious 0.03 2.48 Possibly 
damaging
1.999    
PPARG/NR1C3 VAR_010725 Q314P 0.04 Deleterious 0.05 2.24 Probably 
damaging
2.516 Colon cancer; sporadic; 
somatic mutation; loss of 
ligand- binding 
[295] 
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PPARG/NR1C3 rs28936407 R315H 0.13 Tolerated 0.08 2.24 Probably 
damaging
1.715 Colon cancer; sporadic; 
somatic mutation; partial 
loss of ligand- binding 
[295] 
PPARG/NR1C3 VAR_010727 V318M 0.03 Tolerated 0.1 2.27 Probably 
damaging
1.572 Diabetes [438] 
PPARG/NR1C3 VAR_022700 F388L 0.05 Tolerated 0.12 2.22 Probably 
damaging
2.204 FPLD3 [439] 
PPARG/NR1C3 VAR_022701 R425C 0 Deleterious 0.02 2.22 Probably 
damaging
2.913 FPLD3 [440] 
PPARG/NR1C3 VAR_010728 P495L 0.00* Deleterious 0 2.28 Probably 
damaging
3.054 Diabetes; FPLD3 [438] 
RARG/NR1B3 rs4523774 L181V 0.45 Tolerated 0.2 3.21 Benign 0.349    
RARG/NR1B3 rs2229774 S426L 0.1* Tolerated 0.08 4.32 Possibly 
damaging
1.625    
RORC/NR1F3 rs17582155 R9* Not 
scored
No score       Not 
found 
   
RORC/NR1F3 rs41263732  S229N   Not found       N/A    
RXRA/NR2B1 rs55836231  P22L   Tolerated 0.14 3.24 Benign 1.271    
RXRA/NR2B1 rs2234960 P260L Not 
scored
Tolerated 0.64 2.93 Benign 1.321    
RXRA/NR2B1 rs1805345 S335I Not 
scored
Deleterious 0 2.83 Probably 
damaging
2.236    
RXRA/NR2B1 rs11542209 A397V Not 
scored
Deleterious 0.05 2.83 Benign 0.539    
RXRB/NR2B2 rs17847931 V94A Not 
scored
Tolerated 0.87 3.52 Benign N/A    
RXRB/NR2B2 rs11970403 L521F 0.06 Damaging 0.05 2.97 Benign 0.879    
THRA/NR1A1 rs1126503 T36S Not 
scored
Tolerated 1 3.21 Benign 0.212    
THRA/NR1A1 rs11545238 S176I 0.2 Damaging 0.03 3.65 Benign 1.5    
THRA/NR1A1 rs11545237 V294I 0.43 Tolerated 0.06 3.59 Benign 0.889    
THRB/NR1A2 rs9865746 D215G Not 
scored
Tolerated 0.29 3.34 Benign 0.833    
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THRB/NR1A2 VAR_004632 A234T 0.45 Tolerated 0.52 2.65 Benign 1.324 GTHR (autosomal 
dominant) 
[441] 
THRB/NR1A2 VAR_004633 R243W 0.04 Deleterious 0.02 2.7 Probably 
damaging
2.382 GTHR (autosomal 
dominant) 
[442] 
THRB/NR1A2 VAR_004634 R316H 0.08 Deleterious 0 2.61 Probably 
damaging
1.973 GTHR (selective pituitary) [443] 
THRB/NR1A2 VAR_004635 A317T 0.39 Tolerated 0.23 2.61 Benign 1.256 GTHR (autosomal 
dominant) 
[444] 
THRB/NR1A2 VAR_004636 R320C 0 Deleterious 0 2.61 Probably 
damaging
2.274 GTHR (autosomal 
dominant) 
[445] 
THRB/NR1A2 VAR_004637 R320H 0 Deleterious 0 2.61 Probably 
damaging
1.844 GTHR (autosomal 
dominant) 
[446] 
THRB/NR1A2 rs28999969 G332R 0.03 Deleterious 0.03 2.61 Possibly 
damaging
1.536  GTHR [444] 
THRB/NR1A2 rs1054624 T336I Not 
scored
Tolerated 0.08 3.34 Possibly 
damaging
1.777    
THRB/NR1A2 VAR_004640 R338W 0 Deleterious 0 2.61 Probably 
damaging
2.41 GTHR (autosomal 
dominant) 
[445] 
THRB/NR1A2 VAR_004641 Q340H 0.02 Deleterious 0.02 2.61 Probably 
damaging
2.163 GTHR (autosomal 
dominant) 
[447] 
THRB/NR1A2 VAR_004642 K342I 0.03 Deleterious 0.04 2.61 Probably 
damaging
2.408 GTHR [448] 
THRB/NR1A2 VAR_004645 G345R 0 Tolerated 0.09 2.61 Possibly 
damaging
1.959 GTHR (autosomal 
dominant) 
[449] 
THRB/NR1A2 VAR_004644 G345S 0.01 Tolerated 0.12 2.61 Benign 1.493 GTHR (autosomal 
dominant) 
[450] 
THRB/NR1A2 rs28999970 G345V 0 Tolerated 0.05 2.61 Probably 
damaging
0.792 GTHR [444] 
THRB/NR1A2 rs28999971 G347E 0.08 Deleterious 0 2.61 Possibly 
damaging
1.484 GTHR [444] 
THRB/NR1A2 VAR_004647 V348E 1 Tolerated 0.92 2.61 Benign 0.334 GTHR [448] 
THRB/NR1A2 rs28934868 R383H   Deleterious 0 2.63 Benign 0.296    
THRB/NR1A2 VAR_004648 T426I 0.02 Deleterious 0 2.63 Probably 
damaging
2.024 GTHR  
THRB/NR1A2 VAR_004649 R438H 0.12 Tolerated 0.09 2.64 Possibly 
damaging
1.907 GTHR (autosomal 
dominant) 
[445] 
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THRB/NR1A2 VAR_004650 M442V 0.01 Tolerated 0.1 2.64 Probably 
damaging
2.09 GTHR (autosomal 
dominant) 
[444] 
THRB/NR1A2 VAR_004651 K443E 0 Deleterious 0 2.64 Possibly 
damaging
1.852 GTHR (autosomal 
dominant) 
[451] 
THRB/NR1A2 VAR_004652 C446R 0.02* Tolerated 0.14 3.07 Possibly 
damaging
1.421 GTHR (autosomal 
dominant) 
[452] 
THRB/NR1A2 rs28933408 P452T Not 
scored
Deleterious 0 2.76 Probably 
damaging
2.094    
THRB/NR1A2 VAR_004653 P453H 0 Deleterious 0.01 2.76 Probably 
damaging
2.254 GTHR (autosomal 
dominant) 
[453] 
THRB/NR1A2 VAR_004654 P453S 0 Deleterious 0.01 2.76 Possibly 
damaging
1.981 GTHR [454] 
VDR/NR1I1 rs10735810 M1T Not 
scored
Deleterious 0 3.37 Probably 
damaging
2.716    
VDR/NR1I1 VAR_004656 G33D 0 Deleterious 0 2.11 Probably 
damaging
2.436 Rickets; VDDR-II [455] 
VDR/NR1I1 VAR_004657 H35Q 0 Deleterious 0 2.1 Probably 
damaging
3.296 Rickets [456] 
VDR/NR1I1 VAR_004658 K45E 0 Deleterious 0 2.09 Probably 
damaging
2.155 Rickets [457] 
VDR/NR1I1 VAR_004659 G46D 0 Deleterious 0 2.09 Probably 
damaging
2.471 Rickets; VDDR-II [458] 
VDR/NR1I1 VAR_004660 F47I 0 Deleterious 0 2.09 Probably 
damaging
2.722 Rickets [457] 
VDR/NR1I1 VAR_004661 R50Q 0 Deleterious 0 2.09 Probably 
damaging
2.341 Rickets [459] 
VDR/NR1I1 VAR_004662 R73Q 0 Deleterious 0 2.09 Probably 
damaging
2.341 Rickets; VDDR-II [455] 
VDR/NR1I1 VAR_004663 R80Q 0 Deleterious 0.01 2.09 Benign 1.374 Rickets [460, 461] 
VDR/NR1I1 rs11574090 L229V Not 
scored
Tolerated 0.06 2.31 Benign 0.674    
VDR/NR1I1 VAR_004664 R274L 0.13 Deleterious 0 2.09 Probably 
damaging
2.806 Rickets; decreases affinity 
for ligand by a factor of 1000
[462] 
VDR/NR1I1 VAR_004665 H305Q 0.07 Tolerated 0.29 2.14 Probably 
damaging
1.238 Rickets; VDDR-II [463] 
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VDR/NR1I1 VAR_004666 I314S 0.02 Deleterious 0.01 2.09 Possibly 
damaging
1.606 Rickets; VDDR-II [464] 
VDR/NR1I1 rs11574115 T361I Not 
scored
Damaging 0.04 2.27 Probably 
damaging
0.65    
VDR/NR1I1 VAR_004667 R391C 0 Deleterious 0 2.08 Probably 
damaging
3.187 Rickets; VDDR-II [464] 
Abbreviations used: CAH, congenital adrenal hypoplasia; CAIS, complete androgen insensitivity syndrome; FPLD3, familial partial lipodystrophy type III; GTHR, 
generalized thyroid hormone resistance; MAIS, mild androgen insensitive syndrome; MODY1, type I maturity-onset diabetes of the young; NIDDM, 
non-insulin-dependent diabetes mellitus; NCOA2, NR coactivator 2; PAIS, partial androgen insensitivity syndrome; PAHI, pseudohypoaldosteronism type 1; THR, 
thyroid hormone resistance; VDDR-II, type II vitamin D-dependent rickets. 
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of nsSNPs (n = 216), followed by THRB/NR1A2 (n = 26), GR/NR3C1 (n = 24), and DAX1/NR0B1 
(n = 17).  
 
On the other hand, there were no nsSNP recorded in the following NR genes: estrogen receptor-β 
gene (ESR2/NR3A2), human homologue of the Drosophila tailless gene (NR2E1/TLX), chicken 
ovalbumin upstream promoter transcription factor-1 gene (NR2F1/COUP-TFI), chicken 
ovalbumin upstream promoter transcription factor-2 gene (NR2F2/COUP-TFII), NR related 1 
gene (NR4A2/NURR1), germ cell nuclear factor gene (NR6A1/GCNF), peroxisome 
proliferator-activated receptor-β/δ gene (PPARD/PPARβ/δ/NR1C2), retinoic acid receptor-α gene 
(RARA/NR1B1), retinoic acid receptor-β gene (RARB/NR1B2), RAR-related orphan receptor-α 
gene (RORA/NR1F1), RAR-related orphan receptor-β gene (RORB/NR1F2), and retinoid X 
receptor-γ gene (RXRG/NR2B3).  
 
2.3.2 Prediction of functional effect of nsSNPs of human NR genes 
Among the 442 nsSNPs of human NR genes, 289 (65.38%) and 269(60.86%) of which were  
 
Table 2-3. The prediction results of nsSNPs of human NR genes using SIFT and PolyPhen algorithms. 
SIFTa PolyPhenb Prediction 
result Number of 
nsSNPs 
% Number of 
nsSNPs 
% 
Deleterious 289 65.38 269 60.86 
Tolerated 150 33.94 169 38.24 
Not scored 3 0.68 4 0.90 
Total 442 100 442 100 
aSee website: SIFT (http://blocks. fhcrc.org/sift/SIFT.html); Positions with normalized probabilities < 0.05 are 
predicted to be deleterious, those≥0.05 are predicted to be tolerated. 
bSee website: PolyPhen (http://genetics.bwh.harvard.edu/pph/) Positions with normalized probabilities < 1.5 are 
predicted to be tolerated, those≥1.5 are predicted to be deleterious. 
 
 
Table 2-4.The prediction results of nsSNPs of human AR using SIFT and PolyPhen algorithms. 
SIFTa PolyPhenb Prediction 
result Number of 
nsSNPs 
% Number of 
nsSNPs 
% 
Deleterious 187 86.57 159 73.61 
Tolerated 29 13.43 57 26.39 
Not scored - - - - 
Total 216 100 216 100 
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predicted to be deleterious, whereas 150 (33.94%) and 169 (38.24%) were predicted as tolerated 
by SIFT and PolyPhen, respectively (Table 2-3). Among the 216 nsSNPs of the AR/NR3C4 gene, 
187 (86.57%) and 159 (73.61%) of which were predicted to be deleterious, whereas 29 (13.43%) 
and 57 (26.39%) were predicted as tolerated by SIFT and PolyPhen, respectively (Table 2-4). Thus, 
a slightly higher number of deleterious nsSNPs was obtained when the SIFT algorithm was used 
compared to the PolyPhen algorithm.  
 
There was a significant similarity in the distribution of top 10 NR genes with most frequent 
deleterious nsSNPs (Table 2-5). When SIFT was applied for prediction, the 10 NR genes with 
most frequent deleterious nsSNPs were AR/NR3C4 (number of deleterious nsSNPs: 187), 
NR0B1/DAX1 (17), THRB/NR1A2 (15), VDR/NR1I1 (13), GR/NR3C1 (10), PPARG/NR1C3 (6), 
HNF4A/NR2A1 (5), pregnane X receptor (NR1I2/PXR, 4), NR3C2/MR (4), and estrogen 
receptor-α (ESR1/NR3A1, 3), accounting for 91.35% (264/289) of predicted deleterious nsSNPs.  
 
The top NR genes with most frequent deleterious nsSNPs predicted using PolyPhen were 
AR/NR3C4 (n = 159), THRB/NR1A2 (20), NR0B1/DAX1 (14), VDR/NR1I1 (13), GR/NR3C1 (9), 
PPARG/NR1C3 (9), progesterone receptor (PGR/NR3C3, 7), HNF4A/NR2A1 (4), NR1I2/PXR (4), 
and NR3C2/MR (4), accounting for 90.33% (243/269) of deleterious nsSNPs. The 10 NR genes 
containing most deleterious nsSNPs predicted by either SIFT or PolyPhen were AR/NR3C4 (194), 
THRB/NR1A2 (21), NR0B1/DAX1 (17), VDR/NR1I1 (14), NR3C1/GR (11), PPARG/NR1C3 (9), 
PGR/NR3C3 (7), NR1I2/PXR (6), NR3C2/MR (6) and HNF4A/NR2A1 (5) (Table 2-5). 
 
2.3.3 Effect of predicted deleterious nsSNPs on amino acid changes 
Typical deleterious nsSNPs and the corresponding amino acid substitutions of various human NR 
genes predicted simultaneously by both SIFT and PolyPhen algorithms are listed in Table 2-6. 
These included 144 nsSNPs from AR/NR3C4, 14 from NR0B1/DAX1, 14 from THRB/NR1A2, 12 
from VDR/NR1I1, 8 from NR3C1/GR, 8 from PPARG/NR1C3, and 4 from HNF4A/NR2A1. The 
percentage predicted deleterious by both SIFT and PolyPhen ranged from 53.8% to 66.75 for these 
NR genes. 
 
Table 2-7 shows the common amino acid change of deleterious nsSNPs in human NR genes 
predicted by SIFT and PolyPhen. The most common amino acid of contig reference (wild-type) 
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was Arg, while Val and Thr were the most common amino acid of missense and Arg→His was the 
most frequent substitution due to nsSNPs in human NR genes. 
 
Potential effects of amino acid substitution due to nsSNPs in human NR genes as predicted by 
PolyPhen are shown in Table 2-8. These included disruption of ligand binding site, disruption of 
annotated functional site, overpacking at buried site, contact with functional site, and 
hydrophobicity change at buried site. 
 
2.3.4 Concordance analysis of predicted results by SIFT and PolyPhen 
To compare the prediction ability, we conducted a concordance analysis between the functional 
consequences for 442 nsSNPs predicted by either SIFT or PolyPhen (Table 2-9). Raw scores 
rather than the arbitrarily defined categories were used for the correlation analysis. There was a 
significant concordance between the predictions using both SIFT and PolyPhen (Spearman's ρ = 
-0.601, p ≤ 0.001). 
 
2.3.5 Validation of the prediction of the functional impact of nsSNPs 
2.3.5.1 Overall prediction accuracy 
When one nsSNP predicted as “deleterious” was found experimentally to be associated with a 
remarkable change of phenotype such as altered receptor activity or transcription activation and 
binding affinity or disease, it was considered that the prediction of this nsSNPs was correct. The 
prediction was defined as an error if such a deleterious nsSNP was predicted as tolerant.  
 
Based on the results of published in vitro and in vivo studies, 229 nsSNPs of human NR genes in 
the databases and literatures have been reported to alter receptor activity or transcription activation 
and binding affinity and correlate with diseases. For each NR gene, the amino acid substitutions 
and consequent phenotypic implications have been compiled (see Table 2-10). These confirmed 
phenotypes of nsSNPs were related to alteration of receptor activity or transcription activation and 
ligand affinity, and then connected to susceptibility to disease such as complete androgen 
insensitivity (CAIS), thyroid hormone resistance (THR), congenital adrenal hypoplasia (CAH), 
vitamin D-dependent rickets, type II and glucocorticoid resistance, and loss of ligand-binding.  
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Table 2-5. Distribution of deleterious nsSNPs in human NR genes predicted by SIFT and/or PolyPhen. 
NR gene No. of deleterious nsSNPs 
predicted by SIFT 
NR gene No. of deleterious nsSNPs 
predicted by PolyPhen 
NR gene No. of deleterious nsSNPs  
predicted by either SIFT or PolyPhen 
AR/NR3C4 187 AR/NR3C4 159 AR/NR3C4 194 
NR0B1/DAX1 17 THRB/NR1A2 20 THRB/NR1A2 21 
THRB/NR1A2 15 NR0B1/DAX1 14 NR0B1/DAX1 17 
VDR/NR1I1 13 VDR/NR1I1 13 VDR/NR1I1 14 
NR3C1/GR 10 NR3C1/GR 9 NR3C1/GR 11 
PPARG/NR1C3 6 PPARG/NR1C3 9 PPARG/NR1C3 9 
HNF4A/NR2A1 5 PGR/NR3C3 7 PGR/NR3C3 7 
NR1I2/PXR 4 HNF4A/NR2A1 4 NR1I2/PXR 6 
NR3C2/MR 4 NR1I2/PXR 4 NR3C2/MR 6 
ESR1/NR3A1 3 NR3C2/MR 4 HNF4A/NR2A1 5 
NR0B2/SHP 3 NR1I3/CAR 4 NR1I3/CAR 5 
PPARANR1C1 3 ESR1/NR3A1 3 ESR1/NR3A1 4 
NR1I3/CAR 3 PPARA/NR1C1 3 PPARA/NR1C1 4 
ESRRG/NR3B3 2 NR5A1/SF1 3 NR5A1/SF1 3 
NR5A1/SF1 2 NR0B2/SHP 2 NR0B2/SHP 3 
RXRANR2B1 2 HNF4G/NR2A2 2 HNF4G/NR2A2 2 
ESRRA/NR3B1 1 RXRA/NR2B1 1 RXRA/NR2B1 2 
ESRRB/NR3B2 1 ESRRA/NR3B1 1 NR4A1/NGFIB 2 
NR1H2/LXRα 1 ESRRB/NR3B2 1 ESRRG/NR3B3 2 
NR1H3/LXRβ 1 NR2F6/EAR-2 1 ESRRA/NR3B1 1 
NR2F6/EAR-2 1 NR4A1/NGFIB 1 ESRRB/NR3B2 1 
NR4A1/NGFIB 1 NR4A3/NOR1 1 NR2F6/EAR-2 1 
NR4A3/NOR1 1 NR1D2/Rev-ErbAβ 1 NR4A3/NOR1 1 
PGR/NR3C3 1 NR1H4/FXR 1 NR1D2/Rev-ErbAβ 1 
RXRB/NR2B2 1 RARG/NR1B3 1 NR1H4/FXR 1 
THRA/NR1A1 1   RARG/NR1B3 1 
    NR1H2/LXRα 1 
    NR1H3/LXRβ 1 
    RXRB/NR2B2 1 
    THRA/NR1A1 1 
Total 289  269  328 
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Table 2-6. Deleterious nsSNPs of human NR genes predicted by both SIFT and PolyPhen. 
Gene Symbol SNP ID Amino acid 
change 
Gene Symbol SNP ID Amino acid 
change 
Gene Symbol SNP ID Amino acid 
change 
AR/NR3C4 VAR_009712 Gln112His AR/NR3C4 VAR_004699 Gly743Val ESRRA/NR3B1 rs7996600 Leu 385 Pro 
AR/NR3C4 VAR_009715 Gly214Arg AR/NR3C4 VAR_009797 Met745Thr ESRRB/NR3B2 rs4277274 Asp 222 Tyr 
AR/NR3C4 VAR_009716 Met266Thr AR/NR3C4 VAR_009799 Ala748Asp HNF4A/NR2A1 VAR_004668 Arg 127 Trp 
AR/NR3C4 VAR_009226 Pro390Arg AR/NR3C4 VAR_009802 Met749Ile HNF4A/NR2A1 VAR_010601 Glu 276 Gln 
AR/NR3C4 VAR_009228 Gln443Arg AR/NR3C4 VAR_004700 Met749Val HNF4A/NR2A1 rs6093980 Leu 289 Phe 
AR/NR3C4 VAR_009720 Asp528Gly AR/NR3C4 VAR_004701 Gly750Asp HNF4A/NR2A1 rs6031602 Pro 429 Leu 
AR/NR3C4 VAR_009722 Pro548Ser AR/NR3C4 VAR_009803 Gly750Ser NR0B1/DAX1 VAR_004738 Arg 267 Pro 
AR/NR3C4 VAR_009723 Cys559Tyr AR/NR3C4 VAR_009804 Trp751Arg NR0B1/DAX1 rs28935482 Trp 291 Cys 
AR/NR3C4 VAR_009725 Gly568Val AR/NR3C4 VAR_004702 Arg752Gln NR0B1/DAX1 VAR_004742 Leu 295 Pro 
AR/NR3C4 VAR_009726 Gly568Trp AR/NR3C4 VAR_009805 Phe754Leu NR0B1/DAX1 VAR_018304 Ala 300 Pro 
AR/NR3C4 VAR_009727 Tyr571Cys AR/NR3C4 VAR_004703 Phe754Val NR0B1/DAX1 rs41402346  Gln 359 Thr 
AR/NR3C4 VAR_009728 Ala573Asp AR/NR3C4 VAR_009807 Asn756Ser NR0B1/DAX1 VAR_018300 Tyr 380 Asp 
AR/NR3C4 VAR_009729 Leu574Pro AR/NR3C4 VAR_009809 Asn758Thr NR0B1/DAX1 VAR_018301 Leu 381 His 
AR/NR3C4 VAR_009730 Thr575Ala AR/NR3C4 VAR_009810 Ser759Phe NR0B1/DAX1 rs28935180 Lys 382 Asn 
AR/NR3C4 VAR_009731 Cys576Phe AR/NR3C4 VAR_004704 Leu762Phe NR0B1/DAX1 VAR_004744 Val 385 Gly 
AR/NR3C4 VAR_009732 Cys576Arg AR/NR3C4 VAR_004705 Tyr763Cys NR0B1/DAX1 rs11550590 Gln 401Leu 
AR/NR3C4 VAR_009733 Cys579Phe AR/NR3C4 VAR_009812 Tyr763His NR0B1/DAX1 VAR_004745 Arg 425 Gly 
AR/NR3C4 VAR_009734 Cys579Tyr AR/NR3C4 VAR_009813 Phe764Leu NR0B1/DAX1 VAR_018302 Ile 439 Ser 
AR/NR3C4 VAR_009736 Val581Phe AR/NR3C4 VAR_004707 Ala765Thr NR0B1/DAX1 rs28935481 Asn 440 Ile 
AR/NR3C4 VAR_009737 Phe582Ser AR/NR3C4 VAR_009814 Ala765Val NR0B1/DAX1 VAR_018306 Leu 466 Arg 
AR/NR3C4 VAR_009740 Arg585Lys AR/NR3C4 VAR_009815 Pro766Ser NR0B2/SHP VAR_026015 Arg 57 Trp 
AR/NR3C4 VAR_009741 Ala586Val AR/NR3C4 VAR_009816 Asp767Glu NR0B2/SHP VAR_026019 Arg 216 His 
AR/NR3C4 VAR_009743 Ala596Thr AR/NR3C4 VAR_009817 Leu768Pro NR1I2/PXR VAR_018340 Arg 98 Cys 
AR/NR3C4 VAR_009745 Ser597Thr AR/NR3C4 VAR_009818 Asn771His NR1I2/PXR rs12721608 Are 161 Gln 
AR/NR3C4 VAR_009746 Cys601Phe AR/NR3C4 VAR_009819 Glu772Ala NR1I3/CAR rs34161743  Arg 97 Trp 
AR/NR3C4 VAR_009747 Asp604Tyr AR/NR3C4 VAR_009820 Glu772Gly NR1I3/CAR rs3813629  Gly 326 Glu 
AR/NR3C4 VAR_004684 Arg607Gln AR/NR3C4 VAR_004709 Arg774Cys NR2F6/EAR-2 rs12974411 Ser 83 Asn 
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AR/NR3C4 VAR_004685 Arg608Lys AR/NR3C4 VAR_004708 Arg774His NR3C1/GR rs28395802 Asp 345 His 
AR/NR3C4 VAR_009748 Asn610Thr AR/NR3C4 VAR_004710 Arg779Trp NR3C1/GR VAR_015631 Cys 421 Tyr 
AR/NR3C4 VAR_009749 Cys611Tyr AR/NR3C4 VAR_004711 Met780Ile NR3C1/GR VAR_013472 Arg 477 His 
AR/NR3C4 VAR_009751 Arg615His AR/NR3C4 VAR_004712 Cys784Tyr NR3C1/GR VAR_015632 Ile 559 Asn 
AR/NR3C4 VAR_009752 Arg615Pro AR/NR3C4 VAR_004713 Met787Val NR3C1/GR VAR_025014 Val 571 Ala 
AR/NR3C4 VAR_009753 Leu616Pro AR/NR3C4 VAR_009822 Arg788Ser NR3C1/GR VAR_004676 Asp 641 Val 
AR/NR3C4 VAR_009754 Leu616Arg AR/NR3C4 VAR_009824 Ser791Pro NR3C1/GR VAR_013473 Gly 679 Ser 
AR/NR3C4 VAR_009755 Arg617Pro AR/NR3C4 VAR_004714 Phe794Ser NR3C1/GR VAR_004678 Leu 753 Lys 
AR/NR3C4 VAR_009756 Cys619Tyr AR/NR3C4 VAR_004715 Gln798Glu NR3C2/MR rs12509135 Ser 455 Leu 
AR/NR3C4 VAR_009757 Arg629Gln AR/NR3C4 VAR_009826 Cys806Tyr NR3C2/MR VAR_015627 Leu 924 Pro 
AR/NR3C4 VAR_009758 Lys630Thr AR/NR3C4 VAR_004716 Met807Arg NR4A3NOR1 rs56313530  Gly 296 Glu 
AR/NR3C4 VAR_009761 Gln670Arg AR/NR3C4 VAR_009827 Met807Thr NR5A1/SF1 VAR_004737 Gly 35 Glu 
AR/NR3C4 VAR_009762 Pro671His AR/NR3C4 VAR_004717 Met807Val NR5A1/SF1 VAR_016982 Arg 92 Gln 
AR/NR3C4 VAR_004688 Leu677Pro AR/NR3C4 VAR_009829 Gly820Ala PGR/NR3C3 rs2020874 Arg 625 Ile 
AR/NR3C4 VAR_009764 Glu681Lys AR/NR3C4 VAR_009830 Leu821Val PPARG/NR1C3 rs1801282 Pro 11 Ala 
AR/NR3C4 VAR_013474 Pro682Thr AR/NR3C4 VAR_009831 Leu830Pro PPARG/NR1C3 rs1805192 Pro 39 Ala 
AR/NR3C4 VAR_009768 Ala687Val AR/NR3C4 VAR_004719 Arg831Leu PPARG/NR1C3 rs1800571 Pro 112 Gln 
AR/NR3C4 VAR_009769 Gly688Glu AR/NR3C4 VAR_004720 Arg831Gln PPARA/NR1C1 rs1800204 Arg 127 Gln 
AR/NR3C4 VAR_004691 Asp695Asn AR/NR3C4 VAR_009832 Tyr834Cys PPARA/NR1C1 rs1800242 Asp 303 Asn 
AR/NR3C4 VAR_004692 Asp695Val AR/NR3C4 VAR_004721 Arg840Cys PPARG/NR1C3 VAR_010725 Gln 314 Pro 
AR/NR3C4 VAR_009771 Leu700Met AR/NR3C4 VAR_004722 Arg840Gly PPARG/NR1C3 VAR_022701 Arg 425 Cys 
AR/NR3C4 VAR_009772 Leu701Phe AR/NR3C4 VAR_009229 Arg840Ser PPARG/NR1C3 VAR_010728 Pro 495 Leu 
AR/NR3C4 VAR_009773 Leu701His AR/NR3C4 rs9332969 Arg840His RXRA/NR2B1 rs1805345 Ser 335 Ile 
AR/NR3C4 VAR_009775 Ser703Cys AR/NR3C4 VAR_009833 Ile841Ser THRB/NR1A2 VAR_004633 Arg 243 Trp 
AR/NR3C4 VAR_004693 Ser703Gly AR/NR3C4 rs9332970 Ile842 Thr THRB/NR1A2 VAR_004634 Arg 316 His 
AR/NR3C4 VAR_009776 Asn705Ser AR/NR3C4 rs9332971 Arg855Cys THRB/NR1A2 VAR_004636 Arg 320 Cys 
AR/NR3C4 VAR_013475 Asn705Tyr AR/NR3C4 rs9332971 Arg855His THRB/NR1A2 VAR_004637 Arg 320 His 
AR/NR3C4 VAR_004694 Leu707Arg AR/NR3C4 VAR_009837 Leu863Arg THRB/NR1A2 rs28999969 Gly 332 Arg 
AR/NR3C4 VAR_009777 Gly708Ala AR/NR3C4 VAR_004727 Asp864Asn THRB/NR1A2 VAR_004640 Arg 338 Trp 
AR/NR3C4 VAR_009778 Gly708Val AR/NR3C4 VAR_009839 Ser865Pro THRB/NR1A2 VAR_004641 Gln 340 His 
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AR/NR3C4 VAR_009779 Arg710Thr AR/NR3C4 VAR_004728 Val866Glu THRB/NR1A2 VAR_004642 Lys 342 Ile 
AR/NR3C4 VAR_013476 Gln711Glu AR/NR3C4 VAR_013479 His874Arg THRB/NR1A2 rs28999971 Gly 347 Glu 
AR/NR3C4 VAR_009780 Leu712Phe AR/NR3C4 VAR_009843 His874Tyr THRB/NR1A2 VAR_004648 Thr 426 Ile 
AR/NR3C4 VAR_009782 Lys717Glu AR/NR3C4 VAR_004732 Thr877Ala THRB/NR1A2 VAR_004651 Lys 443 Glu 
AR/NR3C4 VAR_009783 Lys720Glu AR/NR3C4 VAR_013480 Asp879Tyr THRB/NR1A2 rs28933408 Pro 452 Thr 
AR/NR3C4 VAR_009785 Leu722Phe AR/NR3C4 VAR_009845 Leu880Gln THRB/NR1A2 VAR_004653 Pro 453 His 
AR/NR3C4 VAR_009786 Pro723Ser AR/NR3C4 VAR_009846 Leu881Val THRB/NR1A2 VAR_004654 pro 453 Ser 
AR/NR3C4 VAR_009787 Gly724Asp AR/NR3C4 VAR_004733 Pro892Leu VDR/NR1I1 rs2228570  
rs8179174     
rs10735810     
rs17881966 
Met 1 Thr  
AR/NR3C4 VAR_009788 Phe725Leu AR/NR3C4 VAR_004734 Met895Thr VDR/NR1I1 VAR_004656 Gly 33 Asp 
AR/NR3C4 VAR_009789 Arg726Leu AR/NR3C4 VAR_009852 Ile898Thr VDR/NR1I1 VAR_004657 His 35 Gln 
AR/NR3C4 VAR_009790 Asn727Lys AR/NR3C4 VAR_009855 Pro904His VDR/NR1I1 VAR_004658 Lys 45 Glu 
AR/NR3C4 VAR_009791 Leu728Ser AR/NR3C4 VAR_009856 Pro904Ser VDR/NR1I1 VAR_004659 Gly 46 Asp 
AR/NR3C4 VAR_004696 Asp732Asn AR/NR3C4 VAR_004735 Leu907Phe VDR/NR1I1 VAR_004660 Lys 47 Ile 
AR/NR3C4 VAR_004697 Asp732Tyr AR/NR3C4 VAR_009857 Gly909Glu VDR/NR1I1 VAR_004661 Arg 50 Gln 
AR/NR3C4 VAR_009792 Gln733His AR/NR3C4 VAR_009858 Gly909Arg VDR/NR1I1 VAR_004662 Arg 73 Gln 
AR/NR3C4 VAR_009793 Ile737Thr AR/NR3C4 VAR_004736 Pro913Ser VDR/NR1I1 VAR_004664 Arg 274 Leu 
AR/NR3C4 VAR_009794 Trp741Arg AR/NR3C4 VAR_009861 Phe916Leu VDR/NR1I1 VAR_004666 Ile 314 Ser 
AR/NR3C4 VAR_004698 Met742Ile AR/NR3C4 VAR_009862 His917Arg VDR/NR1I1 rs11574115 Thr 362 Ile  
AR/NR3C4 VAR_009795 Met742Val ESR1 VAR_004672 Val364Glu VDR/NR1I1 VAR_004667 Arg 391 Cys 
AR/NR3C4 VAR_013477 Gly743Glu ESR1 VAR_004673 Gly400Val    
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Table 2-7. Common amino acid change of deleterious nsSNPs in Human NR genes predicted by SIFT 
and/or PolyPhen. 
Contig 
Reference 
Number Missense Number Common amino acid change Number 
Arg 55 Val 27 Arg → His 12 
Leu 34 Thr 27 Arg → Gln 10 
Gly 29 Arg 26 Leu → Phe 10 
Pro 25 His 25 Leu → Pro 9 
Met 19 Leu 23 Arg → Cys 8 
Ser 18 Ser 22 Val → Met 8 
Val 17 Pro 20 Arg → Trp 7 
Ala 16 Gln 17 Cys → Tyr 7 
Asp 15 Glu 17 Pro → Ser 7 
Gln 15 Phe 17 Ala → Val 6 
Phe 14 Ile 15 Gly → Arg 6 
Cys 13 Tyr 15 Gly → Val 6 
Ile 11 Cys 14 Met → Thr 6 
Asn 9 Met 12 Met → Val 6 
Lys 9 Ala 10 Pro → Leu 6 
Thr 8 Asn 10 Ala → Thr 5 
Glu 7 Gly 9 Asp → Asn 5 
His 6 Asp 8   
Tyr 5 Trp 8   
Trp 3 Lys 6   
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Table 2-8. Potential effect of amino acid substitution for nsSNPs in human NR genes according to PolyPhen. 
Gene symbol Protein 
Access SNP ID 
Allelic 
variants 
PolyPhen 
prediction
PolyPhe
n score 
Substitution effect 
(according to PolyPhen) 
 
Phenotype Experiment SDM 
AR/NR3C4 NP_000035 VAR_009767 Cys686Arg Probably 
damaging
2.577 Disruption of ligand 
binding site 
PAIS     
AR/NR3C4 NP_000035 VAR_009776 Asn705Ser Probably 
damaging
1.838 Disruption of annotated 
functional site 
CAIS in vitro/in vivo yes 
AR/NR3C4 NP_000035 VAR_013475 Asn705Tyr Probably 
damaging
2.513 Disruption of annotated 
functional site 
CAIS in vitro/in vivo no 
AR/NR3C4 NP_000035 VAR_009783 Lys720Glu Probably 
damaging
1.618 Disruption of annotated 
functional site 
Prostate cancer; bone 
metastases 
in vitro yes 
AR/NR3C4 NP_000035 VAR_009790 Asn727Lys Probably 
damaging
1.821 Disruption of ligand 
binding site 
MAIS in vitro/in vivo yes 
AR/NR3C4 NP_000035 VAR_004698 Met742Ile Probably 
damaging
2.266 Disruption of ligand 
binding site 
PAIS in vitro yes 
AR/NR3C4 NP_000035 VAR_009795 Met742Val Probably 
damaging
2.266 Disruption of ligand 
binding site 
PAIS in vitro/in vivo yes 
AR/NR3C4 NP_000035 VAR_004699 Gly743Val Probably 
damaging
1.799 Overpacking at buried 
site 
PAIS and CAIS in vitro yes 
AR/NR3C4 NP_000035 VAR_009802 Met749Ile Probably 
damaging
1.901 Disruption of ligand 
binding site 
Prostate cancer in vitro yes 
AR/NR3C4 NP_000035 VAR_004700 Met749Val Probably 
damaging
2.019 Disruption of ligand 
binding site 
PAIS and CAIS in vitro/in vivo no 
AR/NR3C4 NP_000035 VAR_004702 Arg752Gln Probably 
damaging
1.696 Disruption of annotated 
functional site 
CAIS in vitro  yes 
AR/NR3C4 NP_000035 VAR_004705 Tyr763Cys Probably 
damaging
2.758 Contact with functional 
site 
PAIS and prostate 
cancer; partial loss of 
androgen binding 
in vitro yes 
AR/NR3C4 NP_000035 VAR_009812 Tyr763His Possibly 
damaging
1.858 Contact with functional 
site 
CAIS in vitro  yes 
AR/NR3C4 NP_000035 VAR_009813 Phe764Leu Probably 
damaging
2.153 Disruption of ligand 
binding site 
CAIS in vitro no 
AR/NR3C4 NP_000035 VAR_004713 Met787Val Probably 
damaging
2.234 Disruption of ligand 
binding site 
CAIS in vitro/in vivo no 
AR/NR3C4 NP_000035 VAR_009832 Tys834Cys Probably 2.758 Disruption of ligand CAIS; loss of in vitro/in vivo no 
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damaging binding site androgen binding 
AR/NR3C4 NP_000035 VAR_004721 Arg840CYs Probably 
damaging
2.596 Disruption of ligand 
binding site 
PAIS in vitro/in vivo yes 
AR/NR3C4 NP_000035 VAR_004722 Arg840Gly Probably 
damaging
2.371 Disruption of ligand 
binding site 
PAIS in vitro/in vivo no 
AR/NR3C4 NP_000035 VAR_009229 Arg840Ser Probably 
damaging
2.076 Disruption of ligand 
binding site 
PAIS in vitro no 
AR/NR3C4 NP_000035 rs9332969 Arg840His Probably 
damaging
1.98 Disruption of ligand 
binding site 
      
AR/NR3C4 NP_000035 VAR_009837 Leu863Arg Probably 
damaging
1.849 Hydrophobicity change at 
buried site 
CAIS     
AR/NR3C4 NP_000035 VAR_004728 Val866Glu Probably 
damaging
1.863 Hydrophobicity change at 
buried site 
CAIS     
AR/NR3C4 NP_000035 VAR_013479 His874Arg Probably 
damaging
2.373 Contact with functional 
site 
CAIS in vitro/in vivo yes 
AR/NR3C4 NP_000035 VAR_009843 His874Tyr Probably 
damaging
2.144 Contact with functional 
site 
Prostate cancer in vitro yes 
AR/NR3C4 NP_000035 VAR_004732 Thr877Ala Probably 
damaging
1.591 Disruption of annotated 
functional site 
Prostate cancer; 
affects steroid binding 
characteristics and 
response to 
antiandrogens; bone 
metastases 
in vitro yes 
AR/NR3C4 NP_000035 VAR_009845 Leu880Gln Probably 
damaging
1.847 Disruption of ligand 
binding site 
Prostate cancer in vitro yes 
AR/NR3C4 NP_000035 VAR_009850 Phe891Leu Probably 
damaging
2.15 Contact with functional 
site 
Prostate cancer in vitro yes 
AR/NR3C4 NP_000035 VAR_004733 Pro892Leu Probably 
damaging
2.846 Contact with functional 
site 
CAIS in vitro yes 
AR/NR3C4 NP_000035 VAR_004734 Met895Thr Probably 
damaging
2.452 Disruption of ligand 
binding site 
CAIS; low androgen 
binding and 
transactivation 
in vitro/in vivo yes 
AR/NR3C4 NP_000035 VAR_009852 Ile898Thr Probably 
damaging
1.969 Disruption of ligand 
binding site 
CAIS     
PPARG/NR1 NP_056953 VAR_010725 Gln314Pro Probably 2.516 Disruption of ligand Colon cancer; In vitro  yes 
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C3 damaging binding site sporadic; somatic 
mutation; loss of 
ligand- binding 
PPARG/NR1
C3 
NP_056953 rs28936407 Arg315His Probably 
damaging
1.715 Disruption of ligand 
binding site 
Colon cancer; 
sporadic; somatic 
mutation; partial loss 
of ligand- binding 
In vitro  yes 
THRB/NR1A
2 
NP_000452 VAR_004634 Arg316His Probably 
damaging
1.973 Disruption of ligand 
binding site 
Generalized THR; 
selective pituitary 
in vitro/in vivo yes 
THRB/NR1A
2 
NP_000452 VAR_004636 Arg320Cys Probably 
damaging
2.274 Disruption of ligand 
binding site 
Generalized THR in vitro/in vivo no 
THRB/NR1A
2 
NP_000452 VAR_004637 Arg320His Probably 
damaging
1.844 Disruption of ligand 
binding site 
Generalized THR,   
autosomal dominant 
in vitro/in vivo yes 
THRB/NR1A
2 
NP_000452 rs28999970 Gly345Val Probably 
damaging
0.792 Overpacking at buried 
site 
Generalized THR in vitro/in vivo yes 
VDR/NR1I1 NP_0010175
35 
VAR_004664 Arg274Leu Probably 
damaging
2.806 Disruption of ligand 
binding site 
Rickets; decreases 
affinity for ligand 
in vitro/in vivo no 
VDR/NR1I1 NP_0010175
35 
VAR_004665 His305Gln Probably 
damaging
1.238 Disruption of ligand 
binding site 
Rickets; vitamin 
D-dependent rickets, 
type II 
in vitro yes 
VDR/NR1I1 NP_0010175
35 
rs11574115 Thr361Ile Probably 
damaging
0.65 Hydrophobicity change at 
buried site 
      
Abbreviations: CAIS, complete androgen insensitivity syndrome; PAIS, partial androgen insensitivity syndrome; SDM, site-direction mutagenesis; THR, thyroid hormone 
resistance;  
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Table 2-9. Concordance analysis between the functional consequences of each nsSNP predicted by SIFT 
and PolyPhen. 
SIFT prediction 
Tolerant Borderline 
Potentially 
intolerant Intolerant Total PolyPhen prediction Score 
1.000~0.201 0.200~0.101 0.100~0.050 0.049~0.000  
Benign 0.000~0.999 57 12 10 16 95 
Borderline 1.000~1.249 16 1 3 7 27 
Potentially damaging 1.250~1.499 15 3 3 30 51 
Possibly damaging 1.500~1.999 5 2 11 94 112 
Probably damaging ≥2.000 9 5 7 130 151 
Total  102 23 34 277 436 
Spearman's ρ = -0.601; P≤ 0.001 
Data are analyzed by Spearman’s rank correlation test. 
 
 
Table 2-10. A summary of nsSNPs of human NR genes with known phenotypes. 
Gene Symbol nsSNP 
number 
Phenotype 
AR/NR3C4 149 CAIS; MAIS; PAIS; reduced transcription and DNA binding capacity; somatic 
mutation; breast cancer; prostate cancer; Reifenstein syndrome, hypospadias 
THRB/NR1A2 21 GTHR, autosomal dominant; selective pituitary 
NR0B1/DAX1 15 CAH 
VDR/NR1I1 12 Rickets; type 2 vitamin D-dependent rickets; decreased affinity for ligand 
NR3C1/GR 10 Glucocorticoid resistant leukemia; glucocorticoid resistance (generalized); 
reduced transcription activation and binding affinity; pseudohermaphroditism, 
hypokalemia (female) 
PPARG/NR1C3 7 Colon cancer; poradic; somatic mutation; loss of ligand-binding; FPLD3; 
diabetes mellitus, partial loss of ligand-binding 
HNF4A/NR2A1 4 MODY1; late-onset NIDDM; reduced transactivation activity  
NR3C2/MR 3 PHA1 autosomal dominant; abolished or reduced transcription transactivation 
upon aldosterone binding; early onset hypertension; altered receptor specificity 
NR5A1/SF1 3 XY sex reversal with adrenal failure; adrenocortical insufficiency without 
ovarian defect 
ESR1/NR3A1 2 Estrogen resistance; decreased the receptor affinity for estradiol 
NR0B2/SHP 1 Mild, early-onset obesity in Japanese population; slight decrease of repressor 
activity 
NR2E3/PNR 1 Enhanced S-cone syndrome 
PPARA/NR1C1 1 Hyperapobetalipoproteinemia 
Total 229  
Abbreviations: CAH, congenital adrenal hypoplasia; CAIS, complete androgen insensitivity syndrome; FPLD3, 
familial partial lipodystrophy type 3; GTHR, generalized thyroid hormone resistance; MAIS, mild androgen 
insensitivity syndrome; MODY1, type I maturity-onset diabetes of the young; NIDDM, non-insulin-dependent 
diabetes mellitus; PAIS, partial androgen insensitivity syndrome; PHA1, pseudohypoaldosteronism type 1. 
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Most amino acid changes of human NRs cause decreased receptor activity such as decreased 
sensitivity for hormone, loss of hormone binding or impaired binding of the receptor to specific 
DNA sequences, but with some exceptions. For example, the twenty mutant ARs of Lys580Arg, 
Val715Met, His874Tyr, and Thr877Ala exhibited activity that was greater than wild-type AR in 
the presence of 10-7 M dehydroepiandrosterone (DHEA) [289]. A Ser597Gly amino acid 
substitution in AR/NR3C4 is able to partially restore DNA-binding activity to a mutant receptor 
protein that carries an Arg617Pro substitution [290]. The phenotype of nsSNPs in human NR 
genes also varied with different receptor activity and stability such as Gly400Val in 
ESR1/NR3A1 which destabilized the receptor and decreased its affinity for estradiol at 25°C 
[291], but not at 4°C; Met807Val in AR/NR3C4 lost 75% androgen binding ability [292]; 
Gly679Ser in GR/NR3C1 reduced transactivation capacity and lost 50% ligand binding affinity 
compared to the wild-type NR3C1/GR [293]; Val393Ile in HNF4A/NR2A1 reduced the 
transactivation activity [294]; and Arg315His in PPARG/NR1C3 lost partial ligand-binding 
ability [295]. 
 
In 229 confirmed phenotypes of human NR genes, more than half of the allelic variants were 
presented in AR/NR3C4 (149/229, 65%). Besides AR/NR3C4, confirmed phenotypes were mainly 
distributed in THRB/NR1A2 (21/229, 9%), NR0B1/DAX1 (15/229, 7%), VDR/NR1I1 (12/229, 5%) 
and NR3C1/GR (10/229, 4%) (Table 2-10). These genes also have a high frequency of deleterious 
nsSNP. However, the NR1I2/PXR and PGR/NR3C3 genes, which were among the top ten genes 
with most frequent deleterious nsSNPs, had no phenotype confirmed so far.  
 
Figure 2-2 displays the prediction for the functional impact of the 229 nsSNPs in human NR genes 
by SIFT and PolyPhen. Both algorithms had high prediction accuracy. According to the above 
criteria, approximately 83.84% and 78.86% of the 229 nsSNPs were correctly predicted as 
deleterious using SIFT and PolyPhen, respectively; while the error prediction was 16.16% and 
23.14%, respectively (Table 2-11). Based on the data from SDM assays, 83.80% and 76.06% of 
the prediction was correct using SIFT and PolyPhen, respectively. The error prediction was 
16.20% and 23.94%, respectively. In nsSNPs predicted as deleterious, the prediction scores by 
SIFT and PolyPhen were correlated with the numbers of functional nsSNPs confirmed by 
available phenotype data, whereas only PolyPhen scores were correlated with numbers of 
functional nsSNPs when confirmed by SDM studies (Table 2-12). 
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Figure 2-2. Pie diagrams displaying the accuracy for nsSNPs in human NR genes using (A) SIFT and (B) 
PolyPhen Programs. 
 
Table 2-11. Evaluation of predicting accuracy of SIFT and PolyPhen on human NR gene nsSNPs based 
on in vivo/in vitro and site-directed mutagenesis studies. 
SIFT prediction PolyPhen prediction Criteria 
Number % Number % 
Based on in vivo/in vitro studies     
Correct prediction 192 83.84 176 78.86 
Error prediction 37 16.16 53 23.14 
Not scored     
Total 229 100 229 100 
Based on site-directed mutagenesis assays     
Correct prediction 119 83.80 108 76.06 
Error prediction 23 16.20 34 23.94 
Not scored     
Total 142 100 142 100 
 
SIFT prediction
Correct prediction
Error prediction
PolyPhen prediction
Correct prediction
Error prediction
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Table 2-12. Correlation analysis between prediction score for deleterious nsSNPs and number of functional nsSNPs confirmed by in vivo/in vitro 
experiments. 
nsSNPs predicted  
as deleterious 
nsSNPs with phenotypical effect  
conformed by in vivo/in vitro studies 
nsSNPs with phenotypical effect  
conformed by site-directed mutagenesis
Algorithm Category 
Number Number %a Number %b 
SIFT prediction 0 208 151 53.93 94 33.57 
 0~0.05 81 42 51.85 26 32.1 
 Sum 289 193 66.78 120 41.52 
 P value  0.001  0.042  
PolyPhen prediction Probably damaging 170 118 69.41 70 41.18 
 Possibly damaging 99 58 58.59 38 38.38 
 Sum 269 176 65.43 108 40.15 
 P value   0.072    0.652    
a%=100* (number of nsSNPs with phenotypical effect conformed by in vivo/in vitro studies/ number of nsSNPs predicted as deleterious). 
b%=100* (number of nsSNPs with phenotypical effect conformed by site-directed mutagenesis / number of nsSNPs predicted as deleterious). 
Data are analyzed by Pearson χ2 test. 
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In addition to the above experimental results, additional deleterious nsSNPs were predicted by 
both SIFT and PolyPhen algorithms. These deleterious nsSNPs comprised 54 RefSNPs and 67 
SWISS SNPs. However, the phenotypic prediction of these nsSNPs as deleterious has not been 
confirmed by functional studies (Table 2-6). 
 
2.3.5.2 Prediction for individual NRs 
Androgen plays an important role in male reproductive development and function. These steroid 
hormones transfer their action by binding to AR/NR3C4. AR/NR3C4 signalling leads to 
development of male sexual phenotype, and maturation of the secondary sex characteristics such 
as muscle mass, bone density and male libido. Disruption of this signalling can lead to androgen 
insensitivity syndromes (AIS) which genotypic males are affected by a spectrum of 
differentiation abnormalities of the genital apparatus and of the secondary sexual characteristics 
[296]. Besides its role in AIS, AR/NR3C4 is important for prostate cell proliferation, 
differentiation, and play a role in the development of prostate cancer [289]. AR/NR3C4 acts to 
regulate gene expression in response to androgens such as dihydrotestosterone and testosterone. 
Among 48 human NR genes, SNPs of AR/NR3C4 have been researched widely. Among 216 
nsSNPs recorded in the MutDB database, 187 and 159 nsSNPs were predicted to have 
phenotypical effect by SIFT and PolyPhen, respectively (Table 2-4). 149 nsSNPs predicted as 
deleterious using PolyPhen were confirmed to have phenotypes by in vitro and/or in vivo studies. 
 
VDR/NR1I1 presents function in over 30 types of tissues and organs and plays a key role in the 
activation and regulation of vitamin D and calcium. VDR/NR1I1 involves multiple pathways and 
points of convergence within these pathways such as insulin-like growth factor signalling and 
estrogen-related pathways. Meanwhile, it has an importance in the aetiology of cancer [297]. 
Most studies of VDR/NR1I1 and cancer have focused on six polymorphisms: rs10735810 on 
exon 2, rs1544410 on intron 8, rs731236 on exon 9, rs7975232 on intron 8, rs757343 on intron 8, 
and the poly (A) mononucleotide repeat at the 3’-untranslated region (UTR) of the gene. Different 
polymorphisms may have different functions depending on the location [298, 299]. For the two 
SNPs which are on the exons, rs10735810 was successfully predicted as a deleterious nsSNP by 
these two algorithms, while rs731236 is a synonymous mutation 
(http://mutdb.org/cgi-bin/mutdb.pl) and was not included in this prediction.  
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PXR/NR1I2 activation is ligand dependent, and regarded as a sensor activated by exogenous and 
endogenous chemicals, regulates a large number of enzymes and transporters involved in the 
response of mammals to their chemical environment [300, 301]. Arg98Cys (VAR_018340) and 
Arg160Gln (rs12721608) of PXR/NR1I2 were predicted to be deleterious by both SIFT and 
PolyPhen, and Lys148Asn (rs17404869) was predicted as deleterious by SIFT. Arg381Trp 
(VAR_018342) and Gln426Glu (rs56162473) were also predicted to be damaging by PolyPhen. 
To date, there is no recorded phenotype related to these variants. 
 
Thyroid hormones play a key role in embryonic development, especially of the central nervous 
system and musculoskeletal system, regulation of cellular metabolic activity and co-regulate cell 
proliferation, apoptosis, and differentiation [302, 303]. Generalized thyroid hormone resistance 
(GTHR, autosomal dominant) was caused by mutations in THRB/NR1A2. These include 
following 12 variants: Arg243Trp (VAR_004633), Ala317Thr (VAR_004635), Arg320Cys 
(VAR_004636), Arg320His (VAR_004637), Arg338Trp (VAR_004640), Gln340His 
(VAR_004641), Gly345Ser (VAR_004644), Gly345Arg (VAR_004645), Arg438His 
(VAR_004649), Lys443Glu (VAR_004651), Cys446Arg (VAR_004652), and Pro453His 
(VAR_004653). Six of these 12 variants were successfully predicted to affect protein function by 
both SIFT and PolyPhen programs. For Gly345Arg and Cys446Arg, PolyPhen predicted correctly 
but SIFT did not. Both SIFT and PolyPhen were not correct in prediction for variants Ala317Thr, 
Gly345Ser, Arg438His, and Pro453His.  
 
2.4 DISCUSSION 
A total of 442 validated nsSNPs were obtained from 48 validated human NR genes from the NCBI 
dbSNP, MutDB and SWISS-Prot databases. Each NR gene had an average of 9.21 nsSNPs. About 
52% (229/442) nsSNPs in the dataset of validated nsSNPs in NR genes were found to attribute to 
alteration of enzyme activity and correlate with disease according to published in vivo and in vitro 
studies. These confirmed phenotypes of nsSNPs are related to alteration of hormone sensitivity 
and NR activity of binding to DNA regulatory regions and specific ligands, and then connected to 
susceptibility to disease such as complete or partial androgen insensitivity syndrome, generalized 
thyroid hormone resistance, type 3 familial partial lipodystrophy (FPLD3), type I maturity-onset 
diabetes of the young, non-insulin-dependent (Type II) diabetes mellitus, type1 
pseudohypoaldosteronism, vitamin D-dependent rickets, congenital adrenal hypoplasia, prostate 
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cancer, and reduced transcription and DNA binding capacity. In 229 confirmed allelic variants in 
NR genes, 65% of the allelic variants were presented in AR (149/229). Other confirmed 
phenotypes are mainly distributed in THRB (21/229, 9%), NR0B1 (15/229, 7%), VDR (12/229, 
5%) and NR3C1/GR (10/229, 4%).  
 
In addition, the Pearson χ2 test shows that, of nsSNPs predicted as deleterious, the prediction 
scores by SIFT and PolyPhen were significantly correlated with the numbers of nsSNPs with 
known phenotype. This result supports that nsSNPs with less scores in SIFT and more scores in 
PolyPhen have more probability to have phenotypical effects. Using oligonucleotides for in vitro 
synthesis of mutant DNA, site-directed mutagenesis, providing direct evidence for SNP functions, 
has been widely used in the study of protein structure-function relationships, gene expression and 
vector modification [304]. Furthermore, site-directed mutagenesis has widely been employed to 
explore genotype-phenotype relationships in human genes. However, the prediction accuracy of 
SIFT and PolyPhen based on site-directed mutagenesis were 83.80% and 76.06%, respectively, in 
this study, similar to that based on the benchmark results. 
 
There are several factors affecting the prediction accuracy. First of all, many nsSNPs are common 
and probably “neutral” variations within the human genome and are not associated with any overt 
clinical phenotype but incorrectly annotated as causing disease. It is easy to get the wrong 
conclusion because these mutations were observed in vitro or in patients or are in linkage 
disequilibrium with other substitutions that can result in disease phenotype [305]. Secondly, there 
exists a 19% false positive error in SIFT and a 9% false positive error in PolyPhen [306]. If all of 
the nsSNPs from the dbSNP were functionally neutral, there are 19% or 9% predicted as 
deleterious nsSNPs. Finally, damaging mutations in redundant motifs partially accounts for 
erroneous predictions [305]. Programs like SIFT and PolyPhen that identify SNPs by aligning 
ESTs or genomic sequences possibly detect base differences between the functional gene and a 
pseudogene or another gene of the genome with redundant motifs that actually have lost their 
function. Thus, programs would erroneously report these differences as SNPs in functional genes.  
 
In conclusion, the present study has identified 61-65 % of nsSNPs of human NR genes to be 
deleterious using in silico methods. A prediction accuracy analysis found that about 80% of 
nsSNPs were predicted correctly as damaging. Of the nsSNPs predicted as deleterious, the 
  87
prediction scores by SIFT and PolyPhen were significantly associated with the numbers of 
nsSNPs with known phenotype confirmed by benchmarking studies including site-directed 
mutagenesis analysis and clinical studies. These amino acid substitutions are supposed to be the 
pathogenetic basis of increased susceptibility to certain diseases. The prediction of nsSNPs in 
human NR genes would be useful for further genotype-phenotype studies on the individual 
difference in hormone sensitivity, NR capability to regulate expression of target genes, and 
clinical response to drugs. 
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CHAPTER 3 PHENOTYPE PREDICTION OF NON-SYNONYMOUS SINGLE 
NUCLEOTIDE POLYMORPHISMS IN HUMAN ABC TRANSPORTER 
GENES  
 
In the human genome, SNP is the most common type of genetic variation [273, 274]. Some SNPs 
are called non-synonymous SNPs when they occur in coding regions and cause amino acid 
change in the corresponding proteins [278]. Furthermore, some nsSNPs alter the amino acid in 
important position and result in functional change of the corresponding protein. A small number 
of the SNPs have been found to be associated with some rare human genetic diseases. Half of all 
genetic changes related to human diseases are attributed to nsSNP variants [465, 466]. These 
nsSNPs with dramatic phenotypic consequences are so-called ‘deleterious’ nsSNPs, in contrast to 
“tolerant nsSNPs” without phenotypic changes.  
 
Differentiating deleterious nsSNPs from tolerant nsSNPs is of great importance for understanding 
the genetic basis of human diseases and individual variations in drug clearance and drug response. 
However, considering the large number of SNPs in ABC transporter genes, it is unlikely to 
explore the functional impact of these SNPs by functional experiments. Alternatively, 
bioinformatics approaches, based on the biochemical severity of the amino acid substitution, and 
the protein sequence and structural information, can offer a more feasible means for phenotype 
prediction. As such, two algorithms Sorting Intolerant from Tolerant (SIFT) and Polymorphism 
Phenotyping (PolyPhen) approaches were used to investigate the potential effect of nsSNPs on 
protein function of human ABC transporter in this study. 
 
3.1 Materials and Methods 
3.1.1 Nomenclature and validation of human ABC transporter genes 
Human ABC transporter genes investigated in this study were named in accordance with the 
Human Genome Organization (HUGO) Gene Nomenclature Committee 
(http://www.genenames.org/genefamily/abc.php). Genomic sequence numbers of these genes are 
available at the ABC transporter gene nomenclature website and GenBank. The data on human 
ABC transporter genes were all collected from Entrez Gene at NCBI website 
(http://www.ncbi.nlm.nih.gov/sites/entrez) and HUGO gene database 
(http://www.genenames.org/). With improved knowledge of molecular biology, some previously 
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used gene names have expired and some genes have no formal names, with only codes. Since such 
genes cannot be retrieved from current databases, they were excluded from this study. 
 
3.1.2 Data mining for nsSNPs of human ABC transporter genes 
For the creation of our own nsSNP database of human ABC transporter genes identified so far, 
information on all the nsSNPs was collected from the NCBI dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) and SWISS-Prot databases 
(http://ca.expasy.org/sprot/). Critical fields including gene symbol, gene name, mRNA accession 
number, protein accession number, SNP ID, amino acid residue 1 (wild-type), amino acid position, 
and amino acid residue 2 (mutant) were captured.  
 
3.1.3 Data compiling for phenotype of SNPs of human ABC transporter genes 
For the creation of the phenotype datasets, information on all the phenotypes of SNPs of human 
ABC transporter genes was compiled from the PubMed (http://www.ncbi.nlm.nih.gov/PubMed/), 
OMIM (http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim) and UniProtKB/Swiss-Prot 
databases (http://ca.expasy.org/sprot/). The information on the effect of the nsSNP on protein 
activity and the correlation between the nsSNP and diseases obtained from in vivo and in vitro 
studies (e.g. site-directed mutagenesis analysis and clinical genetic studies) was collected. 
 
3.1.4 Prediction of the phenotype of nsSNPs in human ABC transporter genes 
Predicting the putative effects of nsSNPs of human ABC transporter genes on protein function 
was performed using SIFT (http://blocks.fhcrc.org/sift/SIFT.html) and PolyPhen 
(http://genetics.bwh.harvard.edu/pph/) as described in Section 2.2.4. 
 
3.1.5 Validation of the prediction 
nsSNPs of human ABC transporter genes predicted as “damaging” were considered “really” 
deleterious when there was evidence of altered transporting activity or disease association. The 
phenotypic data are from both in vivo and in vitro studies, in which the site-directed mutagenesis 
analyses often provide direct evidence indicating the functional impact of nsSNPs. Prediction 
accuracy was analysed according to these positive findings compared with the data from 
benchmarking studies. 
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3.1.6 Statistical Analyses 
The concordance between the functional consequences of each nsSNP predicted by the two in 
silico methods was assessed using Spearman’s rank correlation coefficient ρ. Correlation analysis 
between prediction score for deleterious nsSNPs and number of functionally important nsSNPs 
confirmed by in vivo/in vitro studies was performed by a Pearson χ2 test. A P value below 0.05 
was considered statistically significant. 
 
3.2 Results 
3.2.1 Selection of nsSNPs in human ABC transporter genes 
A total of 1632 nsSNPs were collected from 49 human ABC transporter genes, with a mean value 
of 33.3 nsSNP per gene (see Table 3-1). In our data search, some previously reported SNPs in 
dbSNP have been identified as invalid by later studies due to wrong sequencing and alignment. 
These erroneous SNPs have expired or have merged with other SNPs.  Some ABC transporter 
genes have been renamed. We have carefully cross-examined the databases and removed those 
obsolete names and invalid SNPs. The nsSNPs mainly occurred in the following human ABC 
transporter genes: ABCA4 (238 nsSNPs), CFTR/ABCC7 (236 nsSNPs), ABCD1 (134 nsSNPs), 
ABCC8 (68 nsSNPs), ABCC6 (65 nsSNPs), ABCA13 (57 nsSNPs), ABCB1 (56 nsSNPs), ABCA1 
(55 nsSNPs), ABCC11 (47 nsSNPs), ABCB4 (38 nsSNPs), ABCC12 (38 nsSNPs), and ABCC2 (35 
nsSNPs). The nsSNPs of these ten genes accounted for 70% of all nsSNPs in human ABC 
transporter genes. Notably, none of nsSNPs is found in ABCC13. 
 
3.2.2 Prediction of functional impact of nsSNPs in human ABC transporter genes 
Among the 1632 nsSNPs of human ABC transporter genes, 683 (41.8%) and 875 (53.6%) of 
which were predicted to be deleterious by SIFT and PolyPhen, respectively, whereas 899 (55.1%) 
and 707 (43.3%) were predicted to be tolerated (Table 3-2). Thus, a slightly higher number of 
deleterious nsSNPs was obtained when the PolyPhen algorithm was used compared to the SIFT 
algorithm. There was a significant similarity in the distribution of top 10 ABC transporter genes 
with most frequent deleterious nsSNPs predicted by the two different algorithms, but some 
differences were noted (Table 3-3). When SIFT was applied for prediction, the 10 ABC 
transporter genes with most frequent deleterious nsSNPs were ABCA4 (number of deleterious 
nsSNPs: 112), CFTR/ABCC7 (102), ABCD1 (112), ABCC6 (33), ABCC8 (33), ABCA13 (20), 
ABCA1 (19), ABCC11 (17), ABCB4 (16), and ABCC2 (15), accounting for 70.6% (482/683) of 
  91
predicted deleterious nsSNPs. The top ABC transporter genes with most frequent deleterious 
nsSNPs were ABCA4 (183), CFTR/ABCC7 (153), ABCD1 (114), ABCC8 (45), ABCC6 (36), 
ABCA1 (36), ABCA13 (21), ABCA9 (17), ABCC11 (16), and ABCG8 (16), accounting for 72.8% 
(637/875) of deleterious nsSNPs predicted using PolyPhen. The 10 ABC transporter genes 
containing most deleterious nsSNPs predicted by either SIFT and PolyPhen were ABCA4 (105), 
ABCD1 (104), CFTR/ABCC7 (93), ABCC6 (31), ABCC8 (29), ABCA1 (19), ABCB4 (13), ABCC2 
(12), ABCA13 (11), and ABCB11 (11) (Table 3-3).  
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Table 3-1．A list of 49 human ABC transporter genes and their chromosomal location, number of amino acids, exons and nsSNPs, and associated diseases. 
Gene Other aliases Chromosomal location Function 
No. of 
amino 
acids 
Gene 
length 
(kb) 
No. of
exons
No. of 
nsSNPs Associated diseases 
ABCA subfamily 
ABCA1 ABC-1, ABC1, CERP, 
FLJ14958, HDLDT1, 
MGC164864, 
MGC165011, TGD 
9q31.1 Major regulator of cellular 
cholesterol & phospholipid 
homeostasis 
2261 6.9 52 55 Tangier disease, 
FHDLD, 
atherosclerosis, 
protector against atrial 
fibrillation, 
susceptibility to 
coronary artery disease 
ABCA2 RP11-229P13.8, ABC2, 
MGC129761 
9q34 May play a role in macrophage 
lipid metabolism and neural 
development, MDR 
2436 8.0 48 15 Alzheimer’s disease? 
ABCA3 ABC-C, ABC3, 
LBM180, SMDP3 
16p13.3 Involved in surfactant secretion 1704 6.5 33 16 SMDP3, other nonlethal 
lung diseases 
ABCA4 ABC10, ABCR, 
ARMD2, CORD3, 
FFM, RMP, RP19, 
STGD, STGD1 
1p22.1-p21 A retina-specific ABC 
transporter with 
N-retinylidene-PE as a substrate
2273 7.3 50 238 STGD, AMD2, RP, 
CRD3, FFM, 
early-onset severe 
retinal dystrophy 
ABCA5 ABC13, 
DKFZp451F117, 
FLJ16381 
17q24.3 Possible role in intracellular 
trafficking 
1642 6.5 30 17 Lysosomal diseases? 
ABCA6 EST155051, FLJ43498 17q24.3 May play a role in macrophage 
lipid homeostasis 
1617 5.3 39 11  
ABCA7 ABCA-SSN, ABCX, 
FLJ40025 
19p13.3 A possible role in lipid 
homeostasis in cells of the 
immune system, cellular 
phospholipid metabolism 
2146 6.6 47 18 Sjogren’s syndrome? 
ABCA8 KIAA0822, 
MGC163152 
17q24 Has a substrate specificity 
similar to ABCC2 
1581 5.7 38 21  
ABCA9 EST640918, 
MGC75415 
17q24.2 Monocyte differentiation and 
macrophage lipid homeostasis 
1624 6.0 39 29  
ABCA10 EST698739 17q24 A cholesterol-responsive gene, 
a possible role in intestinal lipid 
transport 
1543 6.18 40 10  
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ABCA12 DKFZp434G232, 
FLJ41584, ICR2B, LI2
2q34 Regulating keratinocyte 
differentiation and transporting 
specific proteases associated 
with desquamation 
2595 7.0 53 28 Harlequin ichthyosis, 
LI2 
ABCA13 FLJ16398, FLJ33876, 
FLJ33951 
7p12.3 Possible role in xenobiotics 
transport and hematopoiesis 
5058 450 62 57 A candidate gene in 
schizophrenia, bipolar 
disorder, and depression 
ABCB subfamily 
ABCB1 ABC20, CD243, CLCS, 
GP170, MDR1, 
MGC163296, P-gp, 
PGY1 
7q21.1 MDR, broad substrate 
specificity 
1280 4.5 28 56 Inflammatory bowel 
disease 
ABCB2 
/TAP1 
DAAP-57C1.5, 
ABC17, ABCB2, 
APT1, FLJ41500, 
PSF1, RING4, 
TAP1*0102N, TAP1N 
6p21.3 Antigen presentation 808 2.5 11 29 Ankylosing spondylitis, 
insulin-dependent 
diabetes mellitus, and 
celiac disease 
ABCB3 
/TAP2 
DAAP-57C1.2, 
ABC18, ABCB3, 
APT2, D6S217E, PSF2, 
RING11 
6p21.3 Antigen presentation 653 2.8 11 21 Ankylosing spondylitis, 
insulin-dependent 
diabetes mellitus, celiac 
disease, type I bare 
lymphocyte syndrome, 
class I HLA deficiency 
ABCB4 ABC21, GBD1, MDR2, 
MDR2/3, MDR3, 
PFIC-3, PGY3 
7q21.1 Biliary phosphatidylcholine 
secretion from hepatocytes 
1279 4.5 28 38 Cholelithiasis, PFIC3, 
ICP,  
ABCB5 ABCB5α, ABCB5β, 
EST422562 
7p15.3 Participate in ATP-dependent 
transmembrane transport of 
small ions, sugars, and peptides, 
regulation of progenitor cell 
fusion and cell membrane 
potential 
812 7.5 19 31  
ABCB6 ABC, ABC14, 
FLJ22414, MTABC3, 
PRP, umat 
2q36 Required for mitochondrial 
porphyrin uptake 
842 3.5 19 16 Lethal neonatal 
metabolic syndrome 
ABCB7 ABC7, ASAT, Atm1p Xq12-q13 Transport of heme from the 
mitochondria to the cytosol 
753 2.4 16 12 XLSA/A 
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ABCB8 M-ABC1, MABC1 7q36 Compartmentalization and 
transport of heme 
718 2.4 16 12  
ABCB9 KIAA1520, TAPL 12q24 Lysosomal function 766 3.5 10 5  
ABCB10 M-ABC2, MTABC2 1q42.13 Transport peptides? 738 4.1 13 7  
ABCB11 ABC16, BSEP, PFIC-2, 
PFIC2, PGY4, SPGP 
2q24 Canalicular bile salt export 
pump 
1321 5.4 28 34 BRIC2, PFIC2, chronic 
intrahepatic cholestasis, 
ABCC subfamily 
ABCC1 ABC29, ABCC, GS-X, 
MRP, MRP1 
16p13.1 MDR, multispecific organic 
anion transporter 
1531 6.5 31 23  
ABCC2 ABC30, CMOAT, DJS, 
KIAA1010, MRP2, 
cMRP 
10q24 Biliary transport of anionic 
conjugates 
1545 5.5 32 35 DJS 
ABCC3 ABC31, MLP2, 
MOAT-D, MRP3, 
cMOAT2 
17q22 Transport of biliary and 
intestinal excretion of organic 
anions including bile salts 
1527 6.5 31 28  
ABCC4 RP11-74A12.1, 
MOAT-B, MOATB, 
MRP4 
13q32 Transports cyclic nucleotides 
and some nucleoside 
monophosphate analogs 
1325 6.5 31 27  
ABCC5 ABC33, 
DKFZp686C1782, 
MOAT-C, MOATC, 
MRP5, SMRP, pABC11
3q27 Transports cyclic nucleotides 
and some nucleoside 
monophosphate analogs 
1437 6.6 30 7  
ABCC6 ABC34, ARA, MLP1, 
MOATE, MRP6, PXE, 
PXE1 
16p13.1 Transport small peptides 
(BQ123) and GSH conjugates 
1503 6.5 31 65 PXE, AR-PXE 
ABCC7/CFT
R 
tcag7.78, ABC35, 
ABCC7, CF, 
CFTR/MRP, MRP7, 
TNR-CFTR 
7q31.2 Chloride channel and controls 
the regulation of other transport 
pathways 
1480 6.0 27 236 CF, CBAVD, 
oligospermia, thoracic 
sarcoidosis, 
susceptibility to 
idiopathic pancreatitis 
ABCC8 ABC36, HHF1, HI, 
HRINS, MRP8, PHHI, 
SUR, SUR1, TNDM2 
11p15.1 Modulator of ATP-sensitive 
potassium channels and insulin 
release 
1581 5.0 39 68 FPHHI, PNDM, 
transient neonatal 
diabetes mellitus 
ABCC9 ABC37, CMD1O, 
FLJ36852, SUR2 
12p12.1 Form ATP-sensitive potassium 
channels in cardiac, skeletal, 
and vascular and non-vascular 
smooth muscle 
1549 5.0 38 13 CMD1O 
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ABCC10 RP5-895C5.1, MRP7, 
SIMRP7 
6p21.1 Transport estradiol2-17β 
glucuronide and LTC4 
1464 5.5 22 14  
ABCC11 EWWD, MRP8, WW 16q12.1 Transport bile acids, conjugated 
steroids, and cyclic nucleotides
1382 4.6 30 47 Dry ear wax 
ABCC12 EWWD, MRP8, WW 16q12.1 Paroxysmal kinesigenic 
choreoathetosis 
1359  29 38  
ABCC13 PRED6; C21orf73 21q11.2 A pseudogene? 325  14 0  
ABCD subfamily 
ABCD1 ABC42, ALD, ALDP, 
AMN 
Xq28 Peroxisomal import of fatty 
acids and/or fatty acyl-CoAs in 
the organelle 
745 2.8 10 134 ALD, X-ALD 
ABCD2 ABC39, ALDL1, 
ALDR, ALDRP, 
hALDR 
12q11-q12 Peroxisomal import of fatty 
acids and/or fatty acyl-CoAs in 
the organelle. 
740 3.5 9 3 ALD, ZWS-2 
ABCD3 ABC43, PMP70, 
PXMP1 
1p22-p21 Peroxisomal import of fatty 
acids and/or fatty acyl-CoAs in 
the organelle 
659 3.3 23 5 ZWS-2 
ABCD4 ABC41, P70R, P79R, 
PMP69, PXMP1L 
14q24.3 Peroxisomal import of fatty 
acids and/or fatty acyl-CoAs in 
the organelle 
606 2.9 19 11  
ABCE subfamily 
ABCE1 ABC38, OABP, RLI, 
RNASEL1, RNASELI, 
RNS4I 
4q31 Oligoadenylate binding protein 
& RNase L inhibitor 
599 2.9 15 4  
ABCF subfamily 
ABCF1 DADB-129D20.7, 
ABC27, ABC50 
6p21.33 Enhancement of protein 
synthesis and the inflammation 
process 
807 3.14 24 9  
ABCF2 ABC28, HUSSY-18, 
M-ABC1 
7q36 Iron inhibited 
ABC-transporter? 
634 2.2 16 8  
ABCF3 EST201864, FLJ11198 3q27.1 Unknown 709 2.8 21 8  
ABCG subfamily 
ABCG1 ABC8, MGC34313, 
White 
21q22.3 Macrophage cholesterol efflux 
to HDL 
678 2.7 15 5  
ABCG2 ABC15, ABCP, BCRP, 
BCRP1, BMDP, 
4q22 MDR, transport organic anions 
but also steroids &  
655  16 23  
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MGC102821, MRX, 
MXR, MXR1 
certain chlorophyll metabolites, 
side population phenotype 
ABCG4 White 2 11q23.3 May involve cholesterol 
transport to HDL 
646 3.5 15 2  
ABCG5 Sterolin 1, STSL, White 
3 
2p21 Limit intestinal absorption and 
promote biliary excretion of 
sterols 
651 2.3 13 16 Sitosterolemia 
ABCG8 GBD4, MGC142217, 
sterolin 2, STSL, White 
4 
2p21 Limit intestinal absorption and 
promote biliary excretion of 
sterols 
673 2.0 13 27 Sitosterolemia, 
gallbladder disease 4 
Abbreviations: ALD, adrenoleukodystrophy; AMD2, age-related macular degeneration 2; BRIC2, benign recurrent intrahepatic cholestasis type 2; CBAVD, congenital 
bilateral absence of the vas deferens; CF, cystic fibrosis; CMD1O, cardiomyopathy dilated type 1O; CRD3, cone-rod dystrophy 3; DJS, Dubin-Johnson syndrome; FFM, 
fundus flavimaculatus; FHDLD, familiar high-density lipoprotein deficiency; FPHHI, persistent hyperinsulinemic hypoglycemia of infancy; ICP, intrahepatic cholestasis 
of pregnancy; LI2, lamellar ichthyosis type 2; STGD, Stargardt disease 1; PFIC2, progressive familial intrahepatic cholestasis-2; PNDM, permanent neonatal diabetes 
mellitus; PXE, pseudoxanthoma elasticum; RP, retinitis pigmentosa 19; SMDP3, pulmonary surfactant metabolism dysfunction type 3; X-ALD, X-linked 
adrenoleukodystrophy; XLSA/A, X-linked sideroblastic anemia with ataxia; ZWS-2, Zellweger syndrome type 2.
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Table 3-2. Prediction results of nsSNPs in human ABC transporter genes. 
SIFT Polyphen 
Prediction 
result 
No. of 
nsSNPs % No. of nsSNPs % 
Deleterious 683 41.85 875 53.62 
Tolerated 899 55.09 707 43.32 
not scored 50 3.064 50 3.064 
Total 1632 100 1632 100 
 
 
Table 3-3. Distribution of deleterious nsSNPs in human ABC transporter genes predicted by SIFT and/or 
PolyPhen. 
Gene 
No. of deleterious 
nsSNPs predicted 
by SIFT 
No. of deleterious 
nsSNPs predicted 
by PolyPhen 
No. of deleterious 
nsSNPs predicted 
by SIFT or 
PolyPhen 
No. of deleterious 
nsSNPs predicted by 
both SIFT and 
PolyPhen 
ABCA4 112 183 190 105 
ABCC7/CFTR 102 153 162 93 
ABCD1 112 114 122 104 
ABCC8 33 45 49 29 
ABCC6 36 36 41 31 
ABCA1 19 36 36 19 
ABCA13 20 21 30 11 
ABCC11 17 16 24 9 
ABCA9 9 17 20 6 
ABCG8 13 16 19 10 
ABCB4 16 14 17 13 
ABCC2 15 13 16 12 
ABCB11 14 13 16 11 
ABCB5 13 11 15 9 
ABCA12 9 13 14 8 
ABCB1 13 8 14 7 
ABCA8 9 13 13 9 
ABCC12 7 10 12 5 
ABCB2/TAP1 6 9 11 4 
ABCB6 10 9 10 9 
ABCC4 9 5 10 4 
ABCC3 8 8 9 7 
ABCG2 7 9 9 7 
ABCB7 8 7 8 7 
ABCG5 6 8 8 6 
ABCA3 4 8 8 4 
ABCB3/TAP2 4 6 8 2 
ABCD4 2 7 7 2 
ABCA7 1 6 7 0 
ABCA5 4 6 6 4 
ABCC10 5 4 6 3 
ABCC1 4 5 6 3 
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ABCB8 5 3 6 2 
ABCF3 4 3 6 1 
ABCC9 4 5 5 4 
ABCA6 3 5 5 3 
ABCA10 1 5 5 1 
ABCA2 1 4 5 0 
ABCE1 4 4 4 4 
ABCF1 3 4 4 3 
ABCC5 2 3 4 1 
ABCF2 2 2 4 0 
ABCG1 0 3 3 0 
ABCB10 2 1 2 1 
ABCB9 2 1 2 1 
ABCD2 2 1 2 1 
ABCD3 1 2 2 1 
ABCG4 0 0 0 0 
Total 683 875 982 576 
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3.2.3 Effect of nsSNPs in human ABC transporter genes predicted to be deleterious on 
amino acids and protein structures 
Representative deleterious nsSNPs and the corresponding amino acid substitutions of various 
human ABC transporter genes are listed in Table 3-4.  
 
Table 3-5 shows common amino acid changes of deleterious nsSNPs in human ABC transporter 
genes predicted by SIFT and PolyPhen. Arg was the most common amino acid of contig reference 
(wild-type) and missense, while Arg→Gln was the most frequent substitution due to nsSNPs in 
ABC transporter genes. Potential effects of amino acid substitution due to nsSNPs in ABC 
transporter genes according to PolyPhen are shown in Table 3-6. These included disruption of 
ligand binding site, hydrophobicity change at buried site and improper substitution in the 
transmembrane region. 
 
Table 3-4. Deleterious nsSNPs in human ABC transporter genes predicted by both SIFT and PolyPhen. 
Gene nsSNPs (amino acid substitutions) 
ABCA1 G788W, D831N, S1181F, L1648P, S1731C, V2244G 
ABCA3 V839F, P1078H 
ABCA4 R212H, L232P, S752I, T771P, D846H, T972N, S1116P, L1125H, L1126H, R1128L,V1686G, 
V1921M, R2107S, A2216V 
ABCA5 I871T, V1323M, G1348S, V1499G 
ABCA6 T1262P, N1322S 
ABCA8 T245P, F419S, L619R, T632S, L641V, G732R, S1075F, C1137W, C1244Y 
ABCA9 G620S, N785I/S, K1306I, K1415M, V1418M 
ABCA10 R1322W 
ABCA12 R287G, A1219E, R1417Q, R1546C, T2000P 
ABCA13 G66D, H1416R, F1540L, I1889K, S2154L, K2306T, F3263C, S3704R, D4084V, P4335A, 
R4843C 
ABCB1 E566K, R593C, R593H, D613Y, I736K, G1063A, C1074W 
ABCB2/TAP1 S346F, P576L, Q788K 
ABCB3/TAP2 R273G, Q551H 
ABCB4 W138R, S346I, E395G, I541F, R590Q, L591Q, R788Q, I1185V, I1192V 
ABCB5 F155V, Q262K, D370G, D742G, G810V, P996Q, C1054W, K1056E, D1187G 
ABCB6 R276W, L293V, V310F, R343L/P, V454E/G, T754K/R 
ABCB7 L272P, G291C, R315G, F346I 
ABCB8 R304C, S560C 
ABCB9 V296G 
ABCB10 R242G 
ABCB11 E186G, V597M, R1050C 
ABCC1 R433S, V472G, G671V 
ABCC2 D333G, T486I, K495E, N718S, S789F, R1181L, P1291L, A1450T 
ABCC3 S314I, E408G, T809M, R1297H, P1300L, L1362V, R1381S 
ABCC4 C171G, G187W, R820I, M1272V 
ABCC5 T1383N 
ABCC6 N497K, R887C, P1279L, G1327E, G1327R, L1416R 
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ABCC7/CFTR L138P, S182G, K464N, F508C, S605F, R668C, I807M, R1162L, R1453W 
ABCC8 Y356C, C418R, L508P, V560M, R620C, D809N, R833C, S956F, V1359G, S1386F, A1457T, 
G1478R, A1492T, T1508P, L1543P 
ABCC9 W1014L, R1217K, Q1488K, Y1527S 
ABCC10 N394D, A707D, A969P 
ABCC11 T546K/R, R630W, V648F, V687F, R995L/P, N1277Y/I 
ABCC12 R17W, G260E, H685N, G1159R, T1284P 
ABCD1 R389H, V583E, A634V, S636N 
ABCD2 K349N 
ABCD4 F458S, R471W 
ABCE1 V32F, D136V, P243A, S489C 
ABCF1 V380G, V619E, V657E 
ABCF3 P465R 
ABCG2 I206T, I206S, I206N, F208S, D296H, F431L, L525R 
ABCG5 V47F, R50C, C600Y 
ABCG8 Y54C, R164Q, G575R 
 
 
Table 3-5. Common amino acid change of deleterious nsSNPs in human ABC transporter genes predicted 
by SIFT and PolyPhen. 
Contig reference 
(wild-type) Number Missense Number 
Common amino acid 
change Number 
Arg  268 Arg  125 Arg→Gln 54 
Val  136 Leu  119 Leu→Pro 46 
Gly  122 Val  114 Glu→Lys 45 
Leu  116 Pro  110 Arg→Cys 43 
Ala  116 Ser  106 Ala→Thr 39 
Ser  102 Lys  95 Arg→His 37 
Thr  90 Thr  92 Arg→Trp 37 
Ile  84 His  84 Val→Ile 35 
Glu  80 Ile  78 Gly→Arg 34 
Asn  68 Cys  78 Pro→Leu 30 
Asp  64 Gly  75   
Pro  62 Gln  70   
Lys  56 Met  70   
Gln  54 Glu  65   
Phe  50 Asn  61   
Tyr  39 Asp  60   
Met  37 Phe  55   
Cys  34 Trp  51   
His  28 * 50   
Trp  26 Ala  45   
  Tyr  29   
  * refers to a termination code.
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Table 3-6. Potential structural impact of amino acid substitution in human ABC transporter genes predicted to be probably damaging by PolyPhen. 
Impact on protein structure/function Gene Allelic variant (s) Known phenotype(s) 
Disruption of ligand binding site ABCB5 K1056E  
 ABCB11 K461E  PFIC2 
 ABCC7/CFTR K464N, K532E  
Hydrophobicity change at buried site ABCC7/CFTR A455E, A554E, A559T, A561E, I618T CF 
Improper substitution in the transmembrane 
region 
ABCA4 D846H, P1380L, L1388P, I1562T, G1577R, V1686G/R, 
S1689P, L1729P, S1736P, A1762D, L1763P, P1776L, 
P1780A, A1794D, R1843W, V1884E, E1885K, G1886E 
CRD3, STGD, reduced 
ATP-binding capacity 
 ABCA5 G342C, I871T  
 ABCA7 Q1686R  
 ABCA8 S1075F, C1137W  
 ABCA9 I288N, I288S, I288T  
 ABCA10 P277T  
 ABCA12 A1219E  
 ABCB2/TAP1 G77R, G131V, G307R, W408L, G479C  
 ABCB3/TAP2 R273G  
 ABCB4 W138R, S346I, S978F  
 ABCB6 R276W  
 ABCC1 V472G, V499G,   
 ABCC3 S314I  
 ABCC4 V854F  
 ABCC7/CFTR G85E, G91R, E92K, Q98R, P205S, L206W, C225R, 
G314R/E, R334W, I336K, T338I, L346P, R347H/L, 
R347P, S912L, Y913C, Y917C, G1003E, I1005R, A1006E
CF 
 ABCC8 L77R, A116P, S1013W  
 ABCC11 P279H, P279R, G1068C  
 ABCC12 G260E, I806N, V867F  
 ABCD1 A99D, S103R, R104C/H, T105P/I, L107P, S108W/L, 
P143S, T254P, K336M, W339R, S342P, G343D, P484R 
X-ALD, CALD, AMN, 
ADO, asymptomatic 
 ABCD3 Y98C  
 ABCD4 Q59R  
 ABCG1 S661P  
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 ABCG2 L525R  
 ABCG5 R389H Sitosterolemia 
 ABCG8 L501P, R543S, L572P, G574E/R, G575R Sitosterolemia 
Abbreviations: ADO, Addison disease only; ALD, adrenoleukodystrophy; AMN, adrenomyeloneuropathy; CALD, cerebral childhood adrenoleukodystrophy; CF, cystic 
fibrosis; PFIC2, progressive familial intrahepatic cholestasis 2; STGD, Stargardt disease; X-ALD, X-linked adrenoleukodystrophy. 
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3.2.4 Concordance analysis of predicted results by SIFT and PolyPhen 
To compare the prediction capacity, we conducted a concordance analysis between the 
functional consequences for 1578 nsSNPs in human ABC transporter genes predicted by SIFT 
and PolyPhen (Table 3-7). Raw scores rather than the arbitrarily defined categories were used for 
the correlation analysis. There was significant concordance between the predictions using both 
SIFT and PolyPhen (Spearman's ρ = -0.651, P≤ 0.001). 
 
Table 3-7. Concordance analysis between the functional consequence of nsSNPs in human ABC 
transporter genes predicted by SIFT and PolyPhen. 
SIFT prediction 
Tolerant Borderline Potentially intolerant Intolerant Total 
PolyPhen 
prediction Score 
1.000~0.201 0.200~0.101 0.100~0.050 0.049~0.000  
Benign 0.000~0.999 342 57 36 36 471 
Borderline 1.000~1.249 61 11 11 21 104 
Potentially 
damaging 1.250~1.499 52 27 12 40 131 
Possibly 
damaging 1.500~1.999 88 31 34 155 308 
Probably 
damaging ≥2.000 76 36 40 412 564 
Total  619 162 133 664 1578 
Spearman's ρ =-0.621; P< 0.001
Data are analysed by Spearman’s rank correlation test. 
 
3.2.5 Overall prediction accuracy 
When one nsSNP, found experimentally to be associated with a remarkable change of phenotype 
such as altered transporting activity or a disease, was predicted as deleterious, it was considered 
that the prediction on this nsSNPs was correct. The prediction was defined as an error if such a 
deleterious nsSNP was predicted as tolerant. Based on the results of published in vitro and in 
vivo studies, 654 nsSNPs of human ABC transporter genes in the databases and literatures have 
been reported to correlate with various diseases (Table 3-8). For each ABC transporter gene, the 
amino acid substitutions and consequent phenotypic implications have been compiled (see Table 
3-8). These confirmed phenotypes of nsSNPs in human ABC transporter genes included various 
diseases such as adrenoleukodystrophy (ALD), age-related macular degeneration 2 (AMD2), 
cardiomyopathy dilated type 1O (CMD1O), CBAVD, CF, Dubin-Johnson syndrome (DJS), 
familial persistent hyperinsulinemic hypoglycemia of infancy (FPHHI), progressive familial 
intrahepatic cholestasis (PFIC), pseudoxanthoma elasticum (PXE), Stargardt disease 1 (STGD), 
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Tangier disease, and Zellweger syndrome type 2 (ZWS-2). When the mutation of an ABC 
transporter gene causes only partial loss of the protein function, the carriers may have mild 
symptoms or be asymptomatic. In 654 confirmed phenotypes of human ABC transporter genes, 
about 77% of allelic variants were present in ABCA4 (194/654, 29.7%), CFTR/ABCC7 (187/654, 
28.3%), and ABCD1 (127/654, 19.4%) (Table 3-8).  
 
According to the above criteria, approximately 63.1% and 85.1% of these nsSNPs were correctly 
predicted as deleterious using SIFT and PolyPhen, respectively; while the error prediction was 
36.9% and 14.9%, respectively (Table 3-9). In nsSNPs predicted to be deleterious, the prediction 
scores by SIFT and PolyPhen were not correlated with the number of deleterious nsSNPs 
confirmed by available phenotype data (Table 3-10). Additional nsSNPs were predicted to be 
deleterious by both SIFT and PolyPhen. These deleterious nsSNPs comprised 198 RefSNPs and 
15 SWISS SNPs. However, the phenotypic prediction of these nsSNPs as deleterious has not 
been verified by data from benchmarking studies (Table 3-4).  
 
3.3 Prediction accuracy for individual ABC transporter genes. 
3.3.1 ABCA members 
In 12 members of this subfamily, a total of 515 nsSNPs have been found. ABCA1 functions as an 
engulfment receptor on macrophages and play an crucial role in cellular lipid homeostasis [176]. 
Disruption of the mouse Abca1 gene resulted in a low level of HDLs and accumulation of 
cholesterol in tissues [178]. The mutations in the ABCA1 gene have been associated with Tangier 
disease [467] and familiar high-density lipoprotein deficiency (FHDLD) [468]. In heterozygotes, 
HDL cholesterol levels are about one-half those of normal individuals. Impaired cholesterol 
efflux from macrophages leads to the presence of foam cells throughout the body, which may 
explain the increased risk of coronary artery disease in some patients with Tangier disease. 
Several mutations of ABCA1 including Tyr573*, Asn935Ser/His, and Arg1680Trp cause 
Tangier disease, whereas the mutations Pro85Leu, Arg230Cys, Ala255Thr, Arg587Trp, 
Trp590Ser, Gln597Arg,  Thr929Ile, Ala937Val, Ala1046Asp, Met1091Thr, Asp1099Tyr, 
Asp1289Asn, Cys1477Arg, Ser1506Leu, Ile1517Arg, Asn1800His, Phe2009Ser, Arg2081Trp, 
and Pro2150Leu are associated with FHDLD. Most of these nsSNPs were predicted to be 
deleterious by SIFT and/or PolyPhen. 
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Table 3-8.  A summary of nsSNPs of human ABC transporter genes with known phenotypes. 
Gene nsSNP number No. of deleterious nsSNPs 
with known phenotype
Known phenotypes 
ABCA4 194 162 STGD, AMD2, FFM, CRD3, susceptibility to AMD2, early-onset severe retinal dystrophy 
ABCC7/CFTR 185 140 CBAVD, CF, sweat chloride elevation without CF, oligospermia, thoracic sarcoidosis, 
susceptibility to idiopathic pancreatitis 
ABCD1 127 117 ALD, AMN, X-ALD 
ABCC6 31 27 PXE, AR-PXE, abolished leukotriene C4 and N-ethylmaleimide glutathione transport 
ABCC8 29 26 PNDM, TNDM, FPHHI 
ABCA1 25 21 FHDLD, Tangier disease, protection against coronary heart disease in familial 
hypercholesterolemia, atherosclerosis, ABCA1 (Alabama) 
ABCG8 15 11 Gallbladder disease 4, sitosterolemia 
ABCB11 11 9 PFIC2, chronic intrahepatic cholestasis 
ABCA12 7 6 LI2, Harlequin ichthyosis 
ABCB4 6 4 Cholelithiasis, ICP, PFIC2, PFIC3 
ABCA3 5 4 SMDP3 
ABCG5 5 3 Sitosterolemia 
ABCC2 4 4 DJS 
ABCB7 3 3 XLSA/A, impaired maturation of cytosolic Fe/S proteins 
ABCB1 2 1 MDR, altered oral bioavailability of drugs, susceptibility to inflammatory bowel disease 
ABCC11 1 1 Dry ear wax 
ABCC9 1 0 CMD1O 
ABCD3 1 1 ZWS-2 
ABCB2/TAP1 1 1 Deficient in MHC class I presentation 
ABCB3/TAP2 1 0 Type I bare lymphocyte syndrome 
Total 654 541  
Abbreviations: ADO, Addison disease only; ALD, adrenoleukodystrophy; AMN, adrenomyeloneuropathy; AMD2, age-related macular degeneration 2; AR-PXE, 
autosomal recessive pseudoxanthoma elasticum; CALD, cerebral childhood adrenoleukodystrophy; CBAVD, congenital bilateral absence of the vas deferens; CF, cystic 
fibrosis; CMD1O, cardiomyopathy dilated type 1O; CRD3, cone-rod dystrophy 3; DJS, Dubin-Johnson syndrome; FFM, fundus flavimaculatus; FHDLD, familiar 
high-density lipoprotein deficiency; FPHHI, familiar persistent hyperinsulinemic hypoglycemia of infancy; ICP, intrahepatic cholestasis of pregnancy; LI2, lamellar 
ichthyosis type 2; PFIC2, progressive familial intrahepatic cholestasis-2; PNDM, permanent neonatal diabetes mellitus; PXE, pseudoxanthoma elasticum; SMDP3, 
pulmonary surfactant metabolism dysfunction type 3; STGD, Stargardt disease 1; TNDM, transient neonatal diabetes mellitus; X-ALD, X-linked adrenoleukodystrophy; 
XLSA/A, X-linked sideroblastic anemia with ataxia; ZWS-2, Zellweger syndrome. 
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Table 3-9. Evaluation of predicting accuracy of SIFT and PolyPhen on nsSNPs in human ABC 
transporter genes based on in vivo and site-directed mutagenesis studies. 
SIFT prediction PolyPhen prediction Criteria 
Number % Number % 
Based on in vivo/in vitro studies 
Correct prediction 385 63.11 519 85.08 
Error prediction 225 36.88 91 14.92 
Total 610 100 610 100 
Based on site-directed mutagenesis assays 
Correct prediction 11 78.57 14 100 
Error prediction 3 21.43 0 0 
Total 14 100 14 100 
 
 
Table 3-10. Correlation analysis between prediction score for deleterious nsSNPs of human ABC 
transporter genes and number of functional nsSNPs confirmed by in vivo/in vitro experiments. 
nsSNPs predicted 
as deleterious 
nsSNPs with phenotypical effect 
conformed by in vivo/in vitro studies
Algorithm Category 
Number Number %a 
SIFT 
prediction 
0 392 250 63.78 
 0.01~0.05 308 135 43.83 
 Sum 700 385 55 
 P value  0.004  
PolyPhen 
prediction 
Probably damaging 497 331 66.6 
 Possibly damaging 378 188 49.74 
 Sum 875 519 59.31 
 P value 0.01 
a%=100 × (number of nsSNPs with phenotypical effect conformed by in vivo/in vitro studies/number of nsSNPs 
predicted as deleterious). 
b%=100 × (number of nsSNPs with phenotypical effect conformed by site-directed mutagenesis/number of 
nsSNPs predicted as deleterious). 
Data are analysed by Pearson’s χ2 test.  
 
Defective ABCA3 function is associated with the development of fatal surfactant deficiency 
due to SMDP3 and other nonlethal lung diseases in newborns [469]. Many subjects suffering 
from these severe pulmonary diseases carried nonsense mutations in ABCA3 including 
Leu101Pro, Asn568Asp, Trp1142*, Leu1553Pro, and Gln1591Pro [469]. All these nsSNPs 
were predicted to be deleterious by SIFT and PolyPhen. On the other hand, several nsSNPs 
including Asn140His, Pro766Ser, His778Arg, Val138Ile, Val1056Ile, and Ser1262Gly were 
predicted to be tolerated by both SIFT and PolyPhen. These mutations are not found in 
SMDP3 and other lung diseases. In addition, Val839Phe, Pro1078His and Leu1552Pro were 
predicted to be probably damaging, but there is no clinical evidence supporting this 
prediction. 
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Numerous mutations of ABCA4 are associated with several retinal degenerations including 
STGD, AMD2, fundus flavimaculatus (FFM), cone-rod dystrophy 3 (CRD3), and retinitis 
pigmentosa 19 (RP) [470, 471]. A complete loss of ABCA4 function leads to RP, whereas 
patients with at least one missense allele have STGD, an inherited disease characterized by 
juvenile to early adult-onset macular dystrophy with loss of central vision. Most missense 
mutations in ABCE4 cause STGD [471]. Patients with AMD2 display a variety of phenotypic 
features, including the loss of central vision, after 60 years of age. To date, 423 SNPs have 
been identified in ABCA4 and more than 220 nsSNPs have been reported. Among the nsSNPs, 
14 nsSNPs were predicted to affect protein function but without any evidence from human 
studies. These nsSNPs are Arg212His, Leu232Pro, Ser752Ile, Asp846His, Thr972Asn, 
Ser1116Pro, Leu1125His, Leu1126His, Arg1128Leu, Lys1148Thr, Val1686Gly, 
Val1921Met, Arg2107Ser, and Ala2216Val. Further benchmarking studies are requested for 
these nsSNPs, particularly, Asp846His and Val1686Gly, which are considered as deleterious 
substitutions in the transmembrane region by PolyPhen. 
 
Mutations in ABCA12 (e.g. Asn1380Ser, Gly1381Glu, Arg1514His, Glu1539Lys, and 
Gly1651Ser) were detected in patients with lamellar ichthyosis type 2 (LI2) [472], a rare 
hereditary disease characterized by skin desquamation over the whole body. Harlequin 
ichthyosis, the most severe form of this disease, was associated with mutations of ABCA12 
including Gly1179Arg and Asp2365Asn [473, 474]. All these nsSNPs except Asp2365Asn 
were predicted to be deleterious by SIFT or PolyPhen. In contrast, Asn237His, Gln274Arg, 
Ser459Thr, Glu550Gly, Ser777Thr, Glu1746Lys, Asp2047Asn, Glu2064Lys, and 
Val2209Leu were predicted to be benign. These mutations are not reported to be associated 
with LI2 or Harlequin ichthyosis. In addition, Trp199Cys, Arg287Gly, Gly1251Asp, and 
Arg1546Cys were predicted to be deleterious, but there is no phenotypical data supporting 
this prediction.  
 
3.3.2 ABCB members 
In 11 members of this subfamily, a total of 261 nsSNPs have been found and 66 of them were 
predicted to be deleterious. The ABCB1 gene extends over more than 100 kb and maps to 
7q21.1 [191]. To date, at least 1630 SNPs of ABCB1 have been identified and a small 
proportion of them are nsSNPs. Data on the functional impact of these nsSNPs of ABCB1 are 
scant. Notably, the most interesting mutation is a silent (synonymous) C3435T mutation in 
exon 26 that correlates with a reduced intestinal expression of ABCB1. Patients with drug 
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resistance epilepsy were more likely found to be 3435C>T homozygous compared with those 
with drug responsive epilepsy [475]. In a Swiss study, HIV patients with the 3435TT 
genotype experienced a significantly higher increase in CD4+ cell counts and marked 
improvement in viral infection than those patients with the CT or CC genotype when treated 
with efavirenz and nelfinavir [476]. For the SNP 2677G>T causing Ile893Pro, a significant 
associations between the 2677G>T genotype and better treatment response were found in 
schizophrenic patients treated with olanzapine [477]. In comparison with wild-type protein, 
maximal transport rates for vincristine of Ile893Pro ABCB1 increased 50-300% in vitro 
[477]. 
 
To date, 694 SNPs and 33 nsSNPs in ABCB4 have been identified in the ABCB4 gene. 
Among the naturally-occurring nsSNPs, Thr175Ala, Ser320Phe, Tyr403His, Ala546Asp, 
Arg957*, and Pro1161Ser are associated with PFIC3 or ICP [199]. All these nsSNPs except 
Ser320Phe were predicted to be deleterious. Arg788Gln and Ile1185Val were also predicted 
to be deleterious, but there are no clinical data to support this.  
 
To date, more than 30 mutations in the ABCB11 gene have been identified in patients with 
ABCB11-deficiency syndrome. The majority of these mutations affect evolutionary 
conserved amino acid residues, and the affected amino acids tend to be located in the large 
cytoplasmic loops of ABCB11. Individuals with low or very low expression levels of 
ABCB11 could be at risk of developing acquired forms of cholestasis such as primary biliary 
cirrhosis, primary sclerosing cholangitis, cholestasis associated with pregnancy, and 
drug-induced cholestasis [222]. Expression of various ABCB11 mutations affecting 
conserved amino acids in MDCK or HepG2 cells resulted in defects of apical trafficking 
and/or functional impairment of ABCB11 as well as in temperature-sensitive, unstable forms 
of ABCB11 [478]. In patients with PFIC2, mutations of ABCB11 include Glu297Gly, 
Lys461Glu, Asp482Gly, Arg575*, Gly982Arg, Arg1057*, Arg1153Cys, and Arg1268Glu 
[221, 479]. The Val284Leu and Gly1004Asp mutations in ABCB11 are found in patients 
with chronic intrahepatic cholestasis [480, 481]. In addition, the Arg432Thr substitution was 
reported in patients with BRIC2 [481].  All these nsSNPs were correctly predicted to be 
functionally damaging by SIFT and/or PolyPhen.  
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3.3.3 ABCC members 
In 13 members of this subfamily, a total of 601 nsSNPs have been found. To date, 2352 SNPs 
have been identified in ABCC1 and about 1% of them are non-synonymous. When expressed 
in HEK293T cells, none of the nsSNPs significantly changed the expression level of ABCC1 
[482], but these nsSNPs had a moderate affect on transporting activities towards substrates. 
The Ala989Thr substitution caused by the 2965G>A mutation was found to have the lowest 
transport capacity [482]. However, this nsSNP was predicted to be tolerated by both SIFT 
and PolyPhen. A mutation in exon 16 (2012G>T causing Gly671Val) did not affect transport 
activities when compared to the wild-type [483].  This is in contrast to a naturally-occurring 
mutation in exon 10 (1299G>T causing Arg433Ser) that resulted in decreased transport of 
LTC4 and increased resistance to doxorubicin [484]. A mutation, 128G>C in exon 2 resulting 
a Cys43Ser substitution impairs the plasma membrane location of ABCC1 and leads to 
reduced resistance to vincristine and arsenite when compared to the wild-type [485]. 
Cys43Ser and Arg433Ser were correctly predicted to be deleterious by either SIFT or 
PolyPhen, but Gly671Val was predicted to be damaging by both SIFT and PolyPhen. Further 
studies are needed to explore the functional impact of Gly671Val using more substrates. 
 
The mutations of the ABCC2 gene include point mutations and deletions that can cause rapid 
degradation of mRNA, impaired protein maturation, or inappropriate ABCC2 trafficking 
[486]. Among 570 SNPs of ABCC2, there are 26 nsSNPs. The ABCC2 gene is mutated in 
individuals with DJS. Mutations of ABCC2 in DJS include Arg768Trp, Arg1150His, 
Ile1173Phe, and Gln1382Arg. These four nsSNPs were correctly predicted to be deleterious 
by SIFT and PolyPhen. A rare missense mutation, 2302C>T (Arg768Trp), found in the C 
motif within the fist nucleotide binding domain, is the main causative gene for DJS. The 
homozygous mutations normally cause a complete lack of detectable ABCC2 in DJS patients. 
Several mutations of ABCC2 have been identified in individuals not resulting in DJS. One of 
these mutations is 1249G>A causing a substitution from the Val residue to an Ile residue at 
position 417 in exon 10. This nsSNP was predicted to be tolerated by both SIFT and 
PolyPhen. It has been reported that a patient receiving a high dose methotrexate infusion for 
B-cell lymphoma had a 3-fold decrease in methotrexate elimination and exhibited 
nephrotoxicity [487].  The patient was heterozygous for a 1271A>G mutation causing the 
Arg412Gly substitution in ABCC2 and its product did not efflux methotrexate and other 
substrates [487].  In addition, the 3972C>T mutation in exon 28 (a synonymous mutation) 
could affect ABCC2-mediated irinotecan clearance, where patients carrying homozygous 
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3972C alleles could have an increased exposure for irinotecan and its metabolite SN-38 
[488]. 
 
To date, 86 SNPs have been identified in ABCC3 and 28 of them are non-synonymous. The 
functional impacts of these nsSNPs are unknown. SIFT or PolyPhen predicted Ser314Ile, 
Glu408Gly, Lys718Met, Thr809Met, Arg1166Cys, Arg1297His, Pro1300Leu, Leu1362Val, 
and Arg1381Ser to be deleterious. The 2221C>T variation resulting in an early stop codon at 
position 741 and 2798—2799-delAG causing termination at codon 997 produced shortened 
and inactive proteins [489].   
 
To date, 943 SNPs with 46 nsSNPs have been identified in ABCC6. The vast majority of 
missense and nonsense mutations occur in cytoplasmatic domains and the carboxy-terminal 
end of the ABCC6 protein [490]. Mutations especially target the nucleotide-binding domains, 
and the 8th intracellular loop which may be important for substrate recognition [490]. Most 
mutations in this protein cause PXE [491]. PXE is primarily an autosomal recessive disorder 
of the connective tissue, affecting the skin, eye, and the cardio-vascular system [492]. In PXE, 
progressive mineralization and fragmentation of elastic fibers in skin, Bruch’s membrane in 
the retina, as well as vessel walls are the major clinical manifestations. A number of 
heterozygote carriers manifest mild symptoms of the disease. At least 30% of all mutations 
cause a frameshift and the introduction of a stopcodon, which leads to premature chain 
termination. Among these mutations, Arg1141* and del (ex23_29) are the most common 
mutations, accounting for about 70% of the total individual mutations in all patients with 
PXE [493, 494]. Arg1141* probably gives rise to an instable ABCC6 mRNA which is rapidly 
degraded by nonsense mediated RNA decay. These two mutations are not predictable using 
SIFT or PolyPhen in this study. In families with PXE, other mutations in ABCC6 have been 
identified, such as G3341C, C3389T, C3412T, G3413A, G3892T, G3904A, C3940T, 
G3961A, and C4015T, resulting in Arg1114Pro, Thr1130Met, Arg1138Trp, Arg1138Gln, 
Val1298Phe, Gly1302Arg, Arg1314Trp, Gly1321Ser, and Arg1339Cys, respectively [491, 
493, 495]. These mutations were all predicted as deleterious by SIFT and PolyPhen. Recently, 
Arg419Gln, Glu422Lys and Glu1427Lys were detected in Japanese patients with angioid 
streaks, an eye disease caused by breaks in Bruch's membrane [496]. Asn497Lys was 
predicted to affect the function of ABCC6 by both SIFT and PolyPhen. However, whether 
Asn497Lys is a deleterious or tolerant nsSNP needs to be answered by functional studies.  
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The ABCC7/CFTR gene is located in chromosomal 7q31.2. CFTR is a cAMP-activated 
ATP-gated chloride channel that transports chloride and thiocyanate ions across epithelial 
cell membranes [205]. CFTR is made up of five domains: two membrane-spanning domains 
that form the chloride ion channel, two nucleotide-binding domains that bind and hydrolyze 
ATP, and a regulatory (R) domain. There are at least 1404 SNPs identified in the CFTR gene, 
and more than 220 of them are nsSNPs. Mutations in CFTR can cause two genetic disorders, 
CBAVD and CF [204]. In CBAVD, the protein may be only partially functional, leading to 
the production of thick mucus, which blocks the developing vas deferens. In people with 
mutations giving rise to CF, the blockage in ion transport occurs in epithelial cells that line 
the passageways of the lungs, liver, pancreas, intestines, reproductive tract, and skin [204]. 
This leads to chronic dysfunction, disability, and a reduced life expectancy. In sweat glands, 
CFTR defects result in reduced transport of sodium chloride and sodium thiocyanate. The 
most common mutation of CFTR in CF patients, ΔF508 results from a deletion of three 
nucleotides which results in a loss of Phe508 on the protein, occurring in the DNA sequence 
that codes for the first nucleotide-binding domain. Little of the ΔPhe508 CFTR protein is 
properly delivered to the cell surface because the protein is defective in folding [497] and the 
protein is rapidly degraded [498]. The Phe508 position is also important for folding of other 
ABC transporters as deletion of the equivalent residue in human ABCB1/MDR1 (ΔTyr490) 
also causes defective folding of the protein and rapid degradation [499]. Gly542*, 
Gly551Asp, and Arg553* are also common mutations in CFTR. As a result the protein does 
not fold normally and is more quickly degraded. Mutations in the CFTR gene include 
replacements, duplications, deletions or shortenings. This may result in proteins that may not 
function, work less effectively, are more quickly degraded, or are present in inadequate 
numbers. The majority of 221 nsSNP mutations (185/221) in the CFTR gene have been 
observed in patients with CF, CBAVD, oligospermia, and thoracic sarcoidosis [500]. 
Thirteen of 221 nsSNPs were predicted to be deleterious by SIFT or PolyPhen, but there are 
no phenotypical data to support this prediction. These nsSNPs are Arg75Gln, Leu138Pro, 
Ser182Gly, Val322Met, Lys464Asn, Ile506Met, Phe508Cys, Ile506Val, Ser605Phe, 
Arg668Cys, Ile807Met, Arg1162Leu, and Arg1453Trp. Lys464Asn may affect protein 
function since it disrupts ligand-binding site. 
 
The ABCC8 gene maps to 11p15.1. ABCC8 is a modulator of ATP-sensitive potassium 
channels and associated with insulin release [501]. The ABCC8 protein is one subunit of the 
ATP-sensitive potassium (K-ATP) channel that is found to across cell membranes in the 
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β-cells of the pancreas. Mutations and deficiencies in ABCC8 have been found in patients 
with FPHHI and neonatal diabetes mellitus type II (e.g. PNDM) [502, 503]. More than 150 
mutations in the ABCC8 gene have been found to cause FPHHI. Some ABCC8 mutations 
prevent the SUR1 protein from reaching the cell membrane, interfering with the proper 
formation of the K-ATP channel. Other mutations interfere with the K-ATP channel’s 
function or its responses to outside molecules. Defective K-ATP channels lead to the 
constant release of insulin from β-cells. Mutations in the ABCC8 gene are also associated 
with a condition called PNDM [502]. Individuals with this condition often have a low birth 
weight and develop hyperglycemia within the first six months of life. Mutations in the 
ABCC8 gene that cause PNDM result in a K-ATP channel with increased activity, leading to 
reduced insulin secretion from β-cells. Other ABCC8 gene mutations that have a smaller 
effect on K-ATP channel function cause a condition called transient neonatal diabetes 
mellitus (TNDM) [503]. Infants with this condition have hyperglycemia during the first six 
months of life, but their blood sugar returns to normal by age 18 months. Mutations of 
Val86Gly, Phe132Leu, Val187Asp, Arg1353Pro, Arg1421Cys, and Arg1494Trp in ABCC8 
are associated with FPHHI and PNDM [504, 505]. These mutations were all predicted as 
deleterious correctly. However, the phenotype of Tyr356Cys, Val560Met, Arg620Cys, 
Asp809Asn, Arg833Cys, and Val1359Gly, predicted as deleterious, need to be further 
verified by site-directed mutagenesis and clinical genetic studies. 
 
3.3.4 ABCD members 
In 4 members of this subfamily, a total of 153 nsSNPs have been identified. To date, 1084 
mutations have been reported in the ABCD1 gene (http://www.x-ald.nl/). Disease-causing 
mutations reported to the database include missense mutations (~61%), frameshift mutations 
(~23%), nonsense mutations (~10%), in-frame deletions/insertions (~4%), and large 
deletions (~3%) [226]. The most common recurring mutation is c.1415_1416delAG in exon 
5. This mutation has been reported in 7% of families and has been observed with 
approximately the same frequency in all ethnic groups [226]. Missense mutations have been 
found in all exons of the gene but are most common in the membrane domain or the 
ATP-binding domain, emphasizing the importance of these two domains for the function of 
ABCD1. Almost all nsSNPs in the ABCD1 gene (99%, 125/126) are related to ALD, and 
92% (117/127) of these disease-causing nsSNPs were predicted to be deleterious by SIFT 
and/or PolyPhen. Only Arg389His predicted as deleterious is not confirmed by functional 
studies. 
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3.3.5 ABCG members 
In 5 members of this subfamily, a total of 73 nsSNPs have been identified. ABCG2 contains 
17 nsSNPs: Val12Met, Gln141Glu/Lys, Gln166Glu, Ile206Thr/Ser/Asn/Leu, Phe208Ser, 
Ser248Pro, Pro269Ser, Asp296His, Glu334*, Phe431Leu, Phe489Leu, Leu525Arg, 
Ala528Thr, Thr542Ala, Phe571Ile, Asn590Tyr, and Asp620Asn. SIFT and/or PolyPhen 
predicted Ile206Thr/Ser/Asn, Phe208Ser, Ser248Pro, Asp296His, Phe431Leu, Phe489Leu, 
and Leu525Arg to be deleterious, while Val12Met, Gln141Glu/Lys, Gln166Glu, Ile206Leu, 
Ala528Thr, Thr542Ala, Phe571Ile, Asn590Tyr, and Asp620Asn were predicted to be 
tolerated. However, no experimental data can support these predictions. 
 
The Val12Met polymorphism located in exon 2 of ABCG2 influenced the N-terminal 
intracellular region of the protein. Both the wild-type (Val) and the variant (Met) amino acids 
have uncharged, hydrophobic side chains. The Gln141Glu/Lys polymorphism located in 
exon 5 leads to the replacement of the negatively charged Glu residue with a positively 
charged Lys residue. This polymorphism affects the ATP-binding domain, between the 
Walker A motif (located at residues 83–89) and the signature region (residues 186–189). The 
expression levels of Val14Met and Gln141Lys ABCG2 protein is lower than the wild-type 
when expressed in PA317 or HEK-293 cells [506]. It was also found that a portion of 
Gln141Lys remained intracellular despite having a low level of expression, as both 
Val12Met and Gln141Lys ABCG2 could reach the plasma membrane in the HEK-293 cells 
[506]. Individuals homozygous for the Gln141Lys variant had significantly lower expression 
levels of ABCG2 in the placenta while the heterozygous samples displayed an intermediate 
expression level [507]. There was a 10-fold decrease in drug resistance compared with the 
wild-type ABCG2 when the Val12Met or Gln141Lys-transfected LLC-PKI cells were 
treated with mitoxantrone or topotecan [508]. In contrast, when compared to wild-type 
ABCG2-transfected cells, Gln141Lys variant alone had a fairly lower level resistance against 
mitoxantrone and topotecan. In addition, there was a 1.3- and 1.8-fold lower basal ATPase 
activity, respectively, for Val12Met and Gln141Lys compared to the wild-type [509]. When 
transport activities of wild-type are compared against variants for estrone 3-sulfate, 
dehydroepiandrosterone sulfate, or methotrexate, no major differences were seen, when the 
transport activities were normalized for the expression levels of ABCG2 protein [508]. 
Further studies are required to clarify the mechanism of a reduced protein expression for 
Gln141Lys, and the change of cellular localization for the Val12Met and Gln141Lys 
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mutations. Clinical studies are also needed to explore the impact of ABCG2 mutations on the 
clearance of its substrate drugs. 
 
The ABCG5 and ABCG8 genes are closely arranged with an insertion of 85-140 bases in 
opposing orientation. Both ABCG5 and 8 are expressed mainly in liver and intestine. 
Mutations in ABCG5 and ABCG8 are associated with sitosterolemia [236-238], a rare 
inherited disease characterized by elevated concentration of plant or fish sterols in plasma, 
most importantly sitosterol (24-ethyl cholesterol). ABCG5 and ABCG8 may form a 
functional (and obligatory) heterodimer. The absorption of plant sterols in the intestine is 
strongly increased in sitosterolemic patients who also suffer from hypercholesterolemia and 
decreased biliary cholesterol secretion. Asian sitosterolemia patients have almost exclusive 
mutations in ABCG5, and Caucasian patients have mutations in ABCG8. Several nsSNPs of 
ABCG5 including Glu146Gln, Arg243*, and Arg389His are associated with sitosterolemia 
[236, 237]. Arg389His was correctly predicted to be damaging by both SIFT and PolyPhen, 
but Glu146Gln was predicted to be benign which is a false negative error. Arg50Cys and 
Cys600Tyr in ABCG5 were predicted to be damaging, but there is no clinical evidence 
supporting our prediction. More nsSNPs in ABCG8 including Arg184His, Pro231Thr, 
Arg263Gln, Trp361*, Arg405His, Arg408*, Arg412*, Leu501Pro, Arg543Ser, Leu572Pro, 
Gly574Glu/Arg, Leu596Arg, and Tyr658* are associated with sitosterolemia [236-238]. All 
these nsSNPs excluding those resulting in a termination code were correctly predicted to be 
deleterious by either SIFT or PolyPhen. Tyr54Cys and Gly575Arg in ABCG8 were predicted 
to be deleterious by SIFT or PolyPhen, but the prediction should be verified by site-directed 
mutagenesis and clinical genetic studies. Interestingly, two variants in ABCG8 (Asp19His 
and Thr400Lys) were associated with lower concentrations of sterols in parents and their 
offspring [510]. These two nsSNPs were predicted to be deleterious by PolyPhen but benign 
by SIFT. 
 
3.4 Discussion 
In ABC transporter genes, about half (654/1632) of their nsSNPs were found to correlate 
with a variety of diseases according to data from published clinical association studies. In 
654 nsSNPs of ABC transporter genes with known associated diseases, about 80% of them 
were distributed in ABCA4 (39.7%), CFTR/ABCC7 (28.3%), and ABCD1 (19.4%). Most 
clinical genetic studies are focused on these three important genes. Mutations in ABCA4 have 
been detected in monogenic STGD, CRD, and RP [470, 471]. Two ABCA4 variants, 
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Asp2177Asn and Gly1961Glu, increase the susceptibility to develop AMD by 3- and  4-fold, 
respectively [511]. The lack or partial loss of functional CFTR/ABCC2 due to mutations is 
the cause of CF and CBAVD [204]. In addition, a number of nsSNPs in ABCD1 are 
associated with ALD/X-ALD [226-228]. 
 
In addition to ABCA4, CFTR/ABCC7, and ABCD1, mutations in other ABC transporter genes 
have also been associated with monogenic or complex multigenic disorders. For example, 
some nsSNPs in ABCA1 can cause FHDLD [468]. In patients with PFIC2, mutations of 
ABCB11 have been identified [221, 479]. A number of nsSNPs in ABCC6 have been 
identified in patients with PXE [493, 494]. Mutations in the ABCC8 gene have been 
identified in patients with FPHHI, hyperinsulinemia and type 2 diabetes mellitus [502, 503]. 
Furthermore, nsSNPs in ABCC9 have been associated with dilated cardiomyopathy [512]. 
Although many nsSNPs in these ABC transporters have been associated with known human 
diseases, some nsSNPs predicted to be deleterious by bioinformatics approaches need to be 
further verified by functional studies. 
 
Many ABC transporter genes were originally discovered during the positional cloning of 
human genetic disease genes. To date, at least 14 ABC transporter genes have been linked to 
disorders displaying Mendelian inheritance. Because the ABC transporter genes typically 
encode structural proteins, all of the diseases are recessive or X-linked recessive and are 
attributable to a severe reduction or lack of function of the transporting protein. 
Heterozygous variants in ABC transporter gene mutations are implicated in the susceptibility 
to specific complex disorders and the clinical phenotype is highly variable. Notably, only few 
ABC transporter gene mutations are lethal. Untreated CF due to ABCC7/CFTR mutations is 
typically lethal in the first decade [204], and X-ALD due to ABCD1/ALD mutations can also 
be fatal in the first 10 years of life [227, 228]. The mutations described in ABCB7 are 
missense alleles (e.g. Leu272Pro, Gly291Cys, Arg315Gly, Ile321Met, Phe346Ile, Ile400Met, 
Val411Leu, and Glu433Lys [513, 514]; all were predicted to be deleterious by 
SIFT/PolyPhen in this study), and the yeast homolog is essential to mitochondrial, suggesting 
that this gene is essential. Mutations in ABCB7 have been associated with XLSA/A [513, 
514], a recessive disorder characterized by an infantile to early childhood onset of 
non-progressive cerebellar ataxia and mild anemia with hypochromia and microcytosis. The 
expression of mutated ABC7 (Glu433Lys) protein in Deltaatm1 cells led to a low efficiency 
of cytosolic Fe/S protein maturation [514]. The only developmental defect ascribed to an 
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ABC transporter gene is CBAVD that occurs in both CF patients and patients with less severe 
mutations that present male sterility as their only phenotype [204]. Thus, most ABC 
transporter genes do not play an essential role in development. 
 
Several sophisticated in silico approaches have been used to predict the function of nsSNPs 
on protein structure and activity, the underpinnings for these algorisms are protein sequence 
alignment [515], physiochemical differences [515], mapping to known protein 
three-dimensional structures [515], and combinations thereof [516]. We choose the SIFT 
algorithm and the PolyPhen algorithm, the main representatives in this field, as tools to 
analyse phenotype of nsSNPs in ABC genes. A significant concordance was observed 
between the functional consequences of nsSNP predicted by SIFT and PolyPhen. In this 
study, 43.15 and 57.51% of the nsSNPs in human transporter genes were predicted to have 
functional effects on protein function by SIFT and PolyPhen algorithms, respectively. Based 
on the dbSNP build 126, 18.6% of all nsSNPs were predicted to be possibly damaging and 
14.6% were predicted to be probably damaging by PolyPhen predictions 
(http://genetics.bwh.harvard.edu/pph/data/index.html). Ramensky et al. [278] reported that 
28% of validated nsSNPs in the human genome variation database are predicted to affect 
protein function. Ng and Henikoff [277] found that 25% of 3,084 nsSNPs from dbSNP may 
affect protein activity using SIFT. Recently, 39 to 43% of nsSNPs in human cytochromes 
P450 genes were predicted to have functional impacts on enzyme activities in our previous 
study [517]. In our another study, SIFT predicted 35.5% of the nsSNPs in 21 human uridine 
diphosphate glucuronosyltransferase genes as deleterious, while PolyPhen identified 46.0% 
of the nsSNPs as potentially damaging and damaging [518]. We also found that both SIFT 
and PolyPhen classified 60.9-65.4% of nsSNPs in human NR genes as being deleterious 
[519].  
 
The prediction accuracy for these in silico algorithms is also investigated based on evidence 
from functional studies. A number of in vivo and in vitro studies published in the literature 
can provide direct and indirect evidence for verifying nsSNPs’ functional effect. It has been 
reported that 60-75% of amino acid substitutions were predicted successfully by SIFT and 
PolyPhen [278, 287]. In this study, SIFT and PolyPhen predicted correctly the effect of about 
63-85% of nsSNPs in ABC transporter genes. The prediction accuracy is affected not only by 
limitations of the in silico algorithms such as false positive error and interference of 
redundant motifs but also by the accuracy of phenotype information from in vivo study. Ng 
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and Henikoff [306] have reported that the false-positive error in SIFT and PolyPhen are 19% 
and 9%, respectively. In addition, if there is a pseudogene or a gene of the genome with 
redundant motifs that have lost their function, the althorithms can not identify them and only 
align expressed sequence tags or genomic sequences mechanically. Thus, it is likely to 
erroneously report these differences as SNPs in functional gene [305]. 
 
In summary, 41.8-53.6% of nsSNPs in human ABC transporter genes have been predicted to 
be deleterious using an in silico method. The prediction accuracy is up to 63.1-85.1% based 
on the results from in vivo and in vitro functional studies. Of nsSNPs predicted as deleterious, 
the prediction scores by SIFT and PolyPhen are significantly related to the numbers of 
nsSNPs with known phenotype confirmed by in vitro experiments and human genetic studies. 
These amino acid substitution variants are supposed to be the pathogenetic basis of increased 
susceptibility to certain diseases and associated with altered drug response. The largely 
correct prediction of nsSNPs in human ABC transporter genes would be useful hints for 
further genotype-phenotype studies. 
  118
CHAPTER 4 REGULATION OF HUMAN PREGNANE X RECEPTOR AND ITS 
TARGET GENE CYTOCHROME P450 3A4 BY CHINESE HERBAL 
COMPOUNDS 
 
4.1 Introduction 
Chinese herbal medicines play an important role as an established segment of the healthcare 
system in China. Herbal medicines are also widely used by Western people in the hope of 
promoting health and managing common maladies such as cold, inflammation, heart diseases, 
and diabetes. The 2002 National Health Interview Survey of the United States indicates that 
19% of adults used some form of herbal supplements within the past 12 months [520]. To 
date, there are more than 11,000 species of herbal plants worldwide and about 500 species are 
commonly used in Asian and other countries. A large number of active ingredients from 
Chinese herbal medicines have been identified, and these naturally-occurring compounds 
offer major opportunities for discovering novel lead structures against a wide range of 
therapeutic targets [521, 522]. However, the clinical efficacy, mechanisms of action and 
safety profiles of most herbal medicines are not established. Moreover, herbal medicines are 
often co-administered with therapeutic drugs, raising the potential of clinical herb-drug 
interactions [244, 270]. The underlying mechanism for most reported herb-drug interactions 
has not been elucidated, but induction and inhibition of drug metabolizing enzymes and drug 
transporters are implicated.  
 
Human CYPs, a superfamily containing 57 functional genes and 58 pseudogenes, metabolize 
a number of endogenous substrates such as steroids and eicosanoids and xenobiotics 
including various carcinogens, toxins, and more than 90% of therapeutic drugs [523]. Based 
on amino acid sequence similarity, CYPs are grouped into different families, subfamilies, 
and specific enzymes, of which CYP1, CYP2 and CYP3 members are the main enzymes 
contributing to the oxidative metabolism of more than 95% of clinical drugs. A wide 
interindividual variation has been observed in hepatic CYP content and activity, which 
contributes to the in vivo differences in the response to drugs [524]. The human CYP3A 
subfamily, including CYP3A4, 3A5, 3A7 and 3A43, with CYP3A4 having the highest 
abundance in the human liver (∼40%) and metabolizing more than 50% of the clinically used 
drugs and a variety of other compounds such as steroid hormones, toxins, and carcinogens 
[142].  
 
  119
Induction of CYP3A4 by xenobiotics contributes to the pronounced interindividual 
variability of its expression and often results in clinically relevant drug–drug and herb-drug 
interactions [142, 525]. The induction of CYP3A4 in the liver is mainly mediated by the 
xenobiotics sensors prognane X receptor (PXR/NR1I2, also known as SXR or PAR) and, to 
a smaller degree, CAR/NR1I3, VDR/NR1I1, GR/NR3C1, HNF4α/NR2A1, and 
RXRα/NR2B1 [99, 526-528]. In addition, basal (constitutive) CYP3A4 expression correlates 
with expression of CAR, PXR and HNF4α in the liver [527-529]. With its large and flexible 
ligand-binding domain, PXR can be activated by a wide variety of small, hydrophobic 
endogenous and exogenous compounds including steroids, antibiotics, antimycotics, bile 
acids, and hyperforin, a constituent of the herbal antidepressant St. John’s wort [527]. Upon 
activation by a ligand, PXR unites with RXRα to bind and transactivate several specific 
elements, such as the everted repeat with a six-nucleotide spacer (ER6) or a direct repeat with 
a three-nucleotide spacer (DR3), in the 5' upstream regulatory region of the CYP3A4 gene 
[528, 530]. The CYP3A4 gene contains an ER6 motif localized in the proximal promoter, 
while both DR3 and ER6 are present in the distal enhancer module. Cooperativity between 
the proximal and distal regulatory elements is critical for PXR-mediated maximal 
transactivation of CYP3A4. Similarly, CAR forms a heterodimer with RXRα and 
transactivates the PXR-responsive DR3 and ER6 motifs in the CYP3A4 promoter [144].  
 
The CYP3A4 expression among individuals is highly variable (40 to100-fold) [531, 532] and 
such remarkable expression differences can affect the pharmacokinetics of CYP3A4 
substrate drugs, either diminishing the therapeutic response, or triggering toxicity. Like other 
CYPs, CYP3A4 is subject to induction by a number of xenobiotics and endogenous 
substances [532]. Although there are a number of studies addressing the effect of xenobiotics 
on the expression of human CYP3A4, data on the impact of herbal compounds on the 
expression of human PXR are limited. Several herbal medicines including St John’s wort 
[533], ginkgo (Ginkgo biloba) [534], gugulipid (Commiphora mukul) [535], wuweizi 
(Schisandra chinensis) [536], licorice (Glycyrrhiza uralensis) [536], and tian xian [537] have 
been reported to activate PXR. Tian xian is a herbal formula consisting of 14 herbs including 
Panax ginseng, Radix Trichosanthis, Radix Clematidis, Radix Astragali seu hedysari,  
Radix glycyrrhizae, jixingzi (Impatientis Balsamina Semen), Venenum bufonis, Radix 
Gentianae, Caculus bovis, Polyporus umbellatus, and Radix Pulsatillae, which is used as an 
anticancer agent (http://www.tianxian.com). In this regard, we investigated the effect of an 
array of compounds isolated from commonly used Chinese herbal medicines on the activity 
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of PXR using a luciferase reporter gene assay in transiently transfected HepG2 and Huh7 
cells, two cell lines derived from human liver tumor. The effect of herbal compounds on the 
expression of PXR and its target gene CYP3A4 in human intestinal LS174T cells was further 
determined using real-time PCR and Western blot analysis. The herbal compounds tested 
included aloe-emodin, emodin, chrysophanol, physcion and rhein from Rheum palmatum 
(Rhubarb); praeruptorin A, C, D and E from Peucedanum praeruptorum (Qianhu); 
epifriedelanol and shionone from Radix Asteris (Ziyuan); morin and mulberroside A from 
Cortex Mori Radicis (Morus alba, Sangbaipi); cryptotanshinone, protocatechuic aldehyde, 
salvianolic acid B, sodium danshensu, tanshinone I, and tanshinone IIA from Salvia 
miltiorrhiza (Danshen) (see Table 4-1. & Figure 4-1).  
 
4.2 Materials and methods 
4.2.1 Chemicals and reagents 
Rifampin and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). RNAiso Plus and PrimeScriptTM RT Reagent were obtained from Takara (Kyoto, 
Japan). LipofectamineTM 2000 Transfection Reagent was purchased from Invitrogen 
(Carlsbad, CA, USA). Dual-Luciferase® Reporter Assay System was purchased from 
Promega (Madison, WI, USA). The primers used in real-time PCR were synthesized by 
Takara. SuperSingal®West Pico Chemilunesent Substrate was purchased from Pierce 
Biotechnology (Rockford, IL, USA). PlasmocinTM Ant-mpp and cOmplete protease inhibitor 
cocktail were purchased from InvivoGen (San Diego, CA, USA) and Roche Diagnostics 
(Basel, Switzerland), respectively. SDS-PAGE Gel Preparation Kit was purchased from 
Beyotiome Institute of Biotechnology (Haimen, Jiangsu, China).  All herbal compounds 
tested (Table 4-1) were of the highest grade (purity > 99%) available from Chinese National 
Institute for the Control of Pharmaceutical and Biological Products (Beijing, China) or other 
commercial sources. 
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Table 4-1. List of herbal compounds and their physicochemical properties investigated in this study. 
Name of herbal 
compound 
Herbal source Molecular 
weight 
cLogP No. of H  
bond acceptor 
No. of H  
bond donor 
Polar surface  
area (Å2) 
Surface tension  
(dyne/cm) 
Aloe-emodin Rheum palmatum 270.24 3.38 5 5 61.83 88.4 
Chrysophanol Rheum palmatum 254.24 5.03 4 2 52.6 73.1 
Cryptotanshinone Salvia miltiorrhiza 296.36 4.93 3 0 43.37 49.6 
Emodin Rheum palmatum 270.24 5.03 3 3 61.83 85.4 
Epifriedelanol Radix Asteris 428.73 11.45 1 1 9.23 37.4 
Morin Cortex Mori Radicis 302.24 1.61 7 5 72.45 114.8 
Mulberroside A Cortex Mori Radicis 568.52 -1.16 14 10 129.22 87.7 
Physcion Rheum palmatum 284.26 5.20 5 2 83.83 67.3 
Praeruptorin A Peucedanum praeruptorun 386.40 3.97 7 0 88.13 50.94 
Praeruptorin C Peucedanum praeruptorun 386.40 5.59 7 0 88.13 48.2 
Praeruptorin D Peucedanum praeruptorun 426.46 4.84 7 0 88.13 49.40 
Praeruptorin E Peucedanum praeruptorun 428.48 5.59 7 0 88.13 48.2 
Protocatechuic aldehyde Salvia miltiorrhiza  138.12 1.14 3 2 35.53 69 
Rhein Rheum palmatum 284.22 4.58 6 3 78.9 94.8 
Salvianolic acid B Salvia miltiorrhiza  718.62 2.14 16 9 179.04 96.3 
Shionone Radix Asteris 426.72 11.0 1 0 17.07 32 
Sodium danshensu Salvia miltiorrhiza  220.15 -0.29 5 4 53.99 85.4 
Tanshinone I Salvia miltiorrhiza  276.29 4.44 3 0 47.28 56.4 
Tanshinone IIA Salvia miltiorrhiza  294.33 5.47 3 0 47.28 45.4 
Data are from ChemSpider (www.chemspider.com).
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Figure 4-1. Chemical structures of 19 herbal compounds tested in this study.  
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4.2.2 Cell culture 
Human HepG2 (from hepatoma) and Huh7 (from hepatoblastoma) cells were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) (Hyclone, Logan, UT, USA) supplemented 
with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA). LS174T cells (derived 
from Caucasian colon adenocarcinoma) were maintained in Roswell Park Memorial Institute 
(RPMI) 1640 (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum. All 
cell lines were cultured at 37°C under a humidified atmosphere of 5% CO2. The cytotoxicity 
of herbal compounds was determined using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazonium bromide (MTT) assay. Cells were 
exposed to herbal compounds at varying concentrations for 48 hr and 100 µl MTT reagent 
(0.5 mg/ml) was added to each well after removal of medium, and cells incubated for a 
further 4 hr at 37°C. The absorbance of formazan, a metabolite of MTT, in the resulting 
solution was photometrically measured at a wavelength of 595 nm using a microplate 
reader (Tecan Instruments Inc., Research Triangle Park, NC).  
 
4.2.3 Plasmid construction 
The pSG5-hPXR expression vector was provided generously by Dr. Steven Kliewer 
(University of Texas Southwestern Medical Center, Dallas, TX, USA) [99], and the 
pGL3-CYP3A4-XREM luciferase reporter construct containing the basal promoter 
(-362/+53) with the proximal PXR response element (ER6) and the distal xenobiotic 
responsive enhancer module (XREM, -7836/-7208) of the CYP3A4 gene 5’-flanking region 
inserted to pGL3-Basic reporter vector was provided generously by Dr. Jeff Staudinger, 
Department of Pharmacology and Toxicology, University of Kansas, Lawrence, KS, USA 
[526]. The pRL-TK R. reniformis control vector and pGL3-Enhancer vector were obtained 
from Promega (Madison, WI, USA). Plasmids were checked by restriction enzyme digestion 
followed by PCR and agarose gel electrophoresis.   
 
4.2.4 Transient transfection of human hepatoma cells and reporter gene assays 
HepG2 and Huh7 cells were maintained in DMEM with a low or high glucose content 
supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C 
under a humidified atmosphere of 5% CO2. For transfection, cells were seeded at 60-75% 
confluence into 24-well plates at 1.2 × 105 cells/well or 48-well plates at 5 × 104 at 37°C, 5% 
CO2 for 24 hr. Transfection was performed in phenol red-free DMEM supplemented with 
10% charcoal/dextran-treated FBS using LipofectamineTM 2000 Transfection Reagent 
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according to supplier’s recommendation. Briefly, for each well of 24-well plate, the 
transfection mixes consisted of 50 ng pSG5-hPXR expression vector, 100 ng 
CYP3A4-XREM luciferase reporter, and 10 ng pRL-TK as an internal control. After 6 hr of 
incubation, the transfected HepG2 cells were exposed to rifampicin at 10 µM for 24 hr, which 
is a known prototypical PXR transactivator [526, 538], and herbal compounds at 0.01, 0.1, 
1.0, 10, and 25 µM. All herbal compounds except salvianolic acid B, sodium danshensu, and 
protocatechuic aldehyde were dissolved in DMSO at a final concentration of 0.1% (v/v). 
Salvianolic acid B, sodium danshensu, and protocatechuic aldehyde were dissolved in 
phosphate-buffered saline (PBS). Huh7 cells were treated with rifampicin or herbal 
compounds at 0.1, 1.0, 5, and 25 µM for 24 hr. pGL3-Enhancer empty vectors were 
transfected in varying amounts to ensure 160 ng of total DNA per transfection. Cells were 
then lysed, and firefly and Renilla luciferase activities were measured from three to six 
independent transfections with the Dual-Luciferase Reporter Assay System according to the 
manufacturer’s instructions (Promega) at Lumat LB 9507 Single Tube Luminometer 
(Berthold Technologies, Bad Wildbad, Germany). Transfection efficiency was expressed as 
the fold induction of firefly to Renilla luciferase activities relative to empty or vehicle control. 
The half maximal effective concentration (EC50) of herbal compounds was determined by 
non-linear fitting of data of log concentration versus fold of reporter gene activation. 
 
4.2.5 Total RNA isolation 
LS174T cells were seeded in 6-well plates at 1.5 × 106 cells per well and incubated overnight. 
Cells were then treated with herbal compounds at 1 and 25 μM for 48 hr. Incubations with 10 
μM rifampicin, 0.1% DMSO, or PBS, were also included as the controls. Cells were lysed 
and total RNA was extracted using the RNAisoTM Plus kit (Takara, Kyoto, Japan). Total 
RNA was quantified and reverse transcribed into cDNA using PrimeScriptTM RT reagent Kit 
(Takara, Kyoto, Japan).  
 
4.2.6 Real-time PCR analysis 
The primers for CYP3A4 and PXR mRNA detection were designed as described by Faucette 
et al. [539] and Svecova et al. [540] respectively. For CYP3A4, the forward primer was 
5’-TCAGCCTGGTGCTCCTCTATCTAT-3’ and reverse primer 
5’-AAGCCCTTATGGTAGGACAAAATATTT-3’. For PXR, the forward primer was 
5’-CCCAGCCTGCTCATAGGTTC-3’ and reverse primer, 
5’-CTGTGATGCCGAACAACTCC-3’. For the control gene β-actin, the forward primer 
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was 5’-GTCATCACCATTGGCAATGAG-3’ and reverse primer 
5’-CGTCATACTCCTGCTTGCTG-3’. All the PCR reactions were carried out using 
SYBR® Premix Ex TaqTM kit (Takara, Kyoto, Japan) and followed manufacturer’s 
instructions.  Amplification was performed in 96-well optical plates on an iQ5 Real Time 
Detection System (Bio-Rad, Hercules, CA, USA). Amplification of pre-denatured products 
was conducted at 95°C for 10 sec, followed by 50 cycles at 95°C for 5 sec and 60°C for 30 
sec.  Fold induction values were calculated according to the equation 2ΔΔCt, where ΔCt 
represents the differences in cycle threshold numbers between the target gene and β-actin, 
and ΔΔCt represents the relative change in the differences between control and treatment 
groups.  
 
4.2.7 Western blotting analysis  
Cells were treated with herbal compounds for 48-72 hr. The cells were lysed using radio 
immunoprecipitation assay (RIPA) buffer plus phenylmethylsulfonyl fluoride (PMSF); total 
protein was extracted by high-speed centrifugation and quantified using Pierce® BCA 
Protein Assay Kit (Pierce, Rockfold, IL,USA). CYP3A4 protein levels were measured by 
Western blot analysis. Briefly, proteins were separated in SDS-polyacrylamide gel (10% 
acrylamide) and transferred to PVDF (Millipore, Bedford MA, USA) by electrophoresis at 
70 V for 30 min, 100 V for 1 hr, and 250 mA for 1 hr using Mini-gel apparatus (Bio-Rad, 
Hercules, CA, USA). The PVDF membranes were blocked in blocking buffer for 1 to 2 hr at 
room temperature. PVDF membranes were incubated with the primary antibody for 1 hr at 
room temperature or 4°C overnight and with the second antibody at room temperature for 1 
hr. The rabbit anti-human CYP3A4 polyclonal antibody was purchased from Chemicon (now 
part of Millipore, Rosemont, IL, USA). Anti-rabbit IG-HRP antibody was purchased from 
R&D Systems (Minneapolis, MN, USA). The blots were detected by SuperSignal® West 
Pico Chemiluminescent Substrate kit was purchased from Thermo (Rockford, IL, USA). The 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control. 
 
4.2.8 Statistical analysis 
Data are presented as the mean ± SD. One-way analysis of variance (ANOVA) followed by 
Bonferroni’s test was performed for statistical comparison of the results from reporter gene 
assays and real-time PCR analysis. The two-group comparison was conducted by Student’s t 
test. Correlation analysis was performed to determine the relationship between CYP3A4 
reporter gene construct transactivation in PXR-transfected HepG2 and Huh7 cells and PXR 
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and CYP3A4 mRNA induction in LS174T cells. The criterion of significance was set at p < 
0.05, and tests were performed using SPSS version 17.0 software (SPSS Inc., Chicago, IL, 
USA).  
 
4.3 Results 
4.3.1 Effects of herbal compounds on PXR activity in PXR-transfected HepG2 and 
Huh7 cells 
To determine whether our herbal compounds transactivated CYP3A4 reporter gene construct 
through PXR-mediated pathway, HepG2 cells were cotransfected with pSG5-hPXR 
expression plasmids, CYP3A4-XREM luciferase reporter constructs and the internal control 
plasmid pRL-TK. Each herbal compound was tested at concentrations of 0.01, 0.1, 1, 10, and 
25 μM, which showed minor cytotoxicity towards native and transiently PXR-transfected 
HepG2 cells (data not shown). The results are shown in Figure 4-2. Rifampicin, 
cryptotanshinone, emodin, morin, praeruptorin A and C, protocatechuic aldehyde, 
salvianolic acid B, sodium danshensu and tanshinone IIA at 10 or 25 μM significantly 
transactivated CYP3A4 reporter gene construct in transiently PXR-transfected HepG2 cells 
(Figure 4-2 & Table 4-2). However, the CYP3A4 reporter gene construct was not 
significantly transactivated by aloe-emodin, chrysophanol, epifiedelanol, mulberroside A, 
physcion, praeruptorin D and E, rhein, and tanshinone (p > 0.05). Notably, shionone 
significantly suppressed the luciferase activities in PXR-transfected HepG2 cells (p < 0.05).  
 
We also performed the CYP3A4 luciferase reporter gene assays in transiently 
PXR-transfected Huh7 cells cultured in FBS-free DMEM to compare with the 
transactivation observed in transiently PXR-transfected HepG2 cells. Herbal concentrations 
were at 0.1, 1, 5, and 25 μM, which showed negligible cytotoxicity towards native and 
transiently PXR-transfected Huh7 cells (data not shown).  Rifampicin significantly 
transactivated CYP3A4 reporter gene construct (p < 0.001). As shown in Figure 4-3, the 
CYP3A4 luciferase reporter gene construct was significantly transactivated only by 
praeruptorin A and D at 25 μM and praeruptorin C at 1-25 μM in transiently PXR-transfected 
Huh7 cells (Table 4-2).  However, all other herbal compounds tested did not significantly 
transactivate the CYP3A4 reporter gene construct in PXR-transfected HepG2 cells (Figure 
4-3A, C, and D).  
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Table 4-2. Folds and EC50 values of CYP3A4 reporter gene construct transactivation by herbal compounds in PXR-transfected HepG2 and Huh7 cells. 
HepG2 cells Huh7 cells Herbal compound/ 
concentration 0.01 μM 0.1 μM 1 μM 10 μM 25 μM 
EC50 
(μM) 0.1 μM 1 μM 5 μM 25 μM 
EC50 
(μM) 
DMSO (0.1%, v/v) 1.04 ± 0.09 1.01 ± 0.12 
PBS 1.01 ± 0.16 1.03 ± 0.26 
Rifampicin 2.39 ± 0.78* 
 
2.64 ± 0.47*** 
 
Aloe-emodin 0.58 ± 0.15 0.91 ± 0.27 1.01 ± 0.42 1.43 ± 0.53 1.84 ± 1.06  1.12 ± 0.19 1.42 ± 0.89 0.94 ± 0.25 0.76 ± 0.10  
Chrysophanol 0.66 ± 0.11 0.91 ± 0.28 1.23 ± 0.43 1.14 ± 0.52 1.02 ± 0.15  1.31 ± 0.15 1.06 ± 0.27 1.28 ± 0.29 1.08 ± 0.33  
Cryptotanshinone 1.10 ± 0.60 1.42 ± 0.72 1.19 ± 0.33 0.87 ± 0.13 3.61 ± 1.02*** 17.06 - - - -  
Emodin 1.38 ± 0.12 0.89 ± 0.37 1.33 ± 0.62 1.41 ± 0.63 2.78 ± 0.21*** 3.41 0.99 ± 0.27 0.99 ± 0.21 0.96 ± 0.21 1.00 ± 0.17  
Epifriedelanol 0.96 ± 0.31 0.65 ± 0.11 0.97 ± 0.22 1.43 ± 0.66 1.43 ± 0.15  1.11 ± 0.35 1.03 ± 0.20 1.02 ± 0.41 1.23 ± 0.42  
Morin 0.42 ± 0.08 1.03 ± 0.21 1.15 ± 0.23 1.10 ± 0.22 3.20 ± 1.21*** 3.57 1.32 ± 0.56 1.06 ± 0.16 1.02 ± 0.21 1.07 ± 0.27  
Mulberroside A 0.92 ± 0.08 0.50 ± 0.23 1.03 ± 0.38 1.05 ± 0.20 2.25 ± 1.44  1.07 ± 0.24 0.90 ± 0.21 0.87 ± 0.14 1.09 ± 0.35  
Physcion 1.15 ± 0.51 0.98 ± 0.44 0.95 ± 0.29 1.15 ± 0.24 1.18 ± 0.16  1.28 ± 0.30 1.21 ± 0.37 1.18 ± 0.40 1.23 ± 0.47  
Praeruptorin A 0.66 ± 0.08 1.10 ± 0.20 1.57 ± 0.50 2.24 ± 0.59** 1.44 ± 0.20 
0.80 1.44 ± 0.36 1.26 ± 0.27 0.96 ± 0.18 2.48 ± 1.13* 12.97 
Praeruptorin C 0.53 ± 0.06 0.82 ± 0.14 1.58 ± 0.34 1.89 ± 0.38** 1.26 ± 0.34 
0.33 1.54 ± 0.31 2.27 ± 0.25*** 
2.46 ± 
0.53*** 
2.67 ± 
0.34*** 
1.80 
Praeruptorin D 0.40 ± 0.05 1.24 ± 0.28 1.45 ± 0.30 1.37 ± 0.24 1.10 ± 0.18  1.20 ± 0.38 1.38 ± 0.24 1.49 ± 0.23 2.61 ± 0.68*** 
18.13 
Praeruptorin E - 1.11 ± 0.51 1.63 ± 0.38 1.83 ± 0.73 1.34 ± 0.29  1.17 ± 0.26 1.15 ± 0.24 1.24 ± 0.44 1.73 ± 0.51 - 
Protocatechuic 
aldehyde 0.88 ± 0.13 1.05 ± 0.22 1.05 ± 0.21 0.96 ± 0.30 2.11 ± 0.44
*** 2.07 1.09 ± 0.31 0.99 ± 0.27 0.98 ± 0.32 1.20 ± 0.66 - 
Rhein 0.75 ± 0.07 1.03 ± 0.35 0.95 ± 0.32 1.27 ± 0.47 1.71 ± 0.15  1.10 ± 0.29 1.07 ± 0.23 1.09 ± 0.29 1.01 ± 0.15 - 
Salvianolic acid B 0.80 ± 0.20 0.42 ± 0.34 0.88 ± 0.38 1.10 ± 0.24 2.15 ± 0.50** 1.80 1.02 ± 0.40 0.90 ± 0.21 0.81 ± 0.27 0.80 ± 0.35 - 
Shionone 0.69 ± 0.06** 0.55 ± 0.05* 0.66 ± 0.06 0.85 ± 0.08 1.13 ± 0.28  1.14 ± 0.35 1.03 ± 0.24 0.99 ± 0.27 0.95 ± 0.33 - 
Sodium danshensu 0.59 ± 0.19 0.48 ± 0.29 0.94 ± 0.34 1.03 ± 0.26 2.31 ± 0.56*** 2.89 0.88 ± 0.29 0.86 ± 0.34 1.10 ± 0.47 0.98 ± 0.38 - 
Tanshinone I 0.84 ± 0.49 0.94 ± 0.45 0.85 ± 0.55 0.42 ± 0.07 1.39 ± 0.19  - - - - - 
Tanshinone IIA 0.67 ± 0.30 0.57 ± 0.18 0.97 ± 0.44 1.17 ± 0.86 4.12 ± 1.68*** 10.33 - - - - - 
Data are the mean ± SD of at least three independent experiments. 
*p < 0.05; **p < 0.01; ***p < 0.001, vs control vehicle by one-way ANOVA followed by Bonferroni’s test. 
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Figure 4-2. CYP3A4 reporter gene construct transactivation by herbal compounds in transiently PXR-transfected HepG2. HepG2 cells were transfected with 
pSG5-hPXR expression vector, pGL3-CYP3A4-XREM luciferase reporter construct and pRL-TK for 6 hr. The cells were then treated with a herbal compound for 
24 hr. The firefly luciferase activity was determined and normalized against Renilla luciferase activity. Values are expressed as the mean of the fold increase in 
activity compared with that in vehicle control treated cells from more than three independent experiments. A, B, C, and D show the effect of compounds from 
Rhubarb, Qianhu, Sangbaipi and Ziyuan, and Danshen on the transactivation of CYP3A4 reporter gene construct, respectively. *p < 0.05; **p < 0.01; ***p < 0.001, 
vs control vehicle by one-way ANOVA followed by Bonferroni’s test. 
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Figure 4-3. CYP3A4 reporter gene construct transactivation by herbal compounds in transiently PXR-transfected Huh7 cells. Huh7 cells were transfected with 
pSG5-hPXR expression vector, pGL3-CYP3A4-XREM luciferase reporter construct and pRL-TK for 6 hr. The cells were then treated with a herbal compound for 
24 hr. The firefly luciferase activity was determined and normalized against Renilla luciferase activity. Values are expressed as the mean of the fold increase in 
activity compared with that in vehicle control treated cells from more than three independent experiments. A, B, C, and D show the effect of compounds from 
Rhubarb, Qianhu, Sangbanpi and Ziyuan, and Danshen on the transactivation of CYP3A4 reporter gene construct, respectively. *p < 0.05; **p < 0.01; ***p < 0.001, 
vs control vehicle by one-way ANOVA followed by Bonferroni’s test. 
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We further performed a correlation study to check the relationships of CYP3A4 reporter gene 
construct transactivation folds by 19 herbal compounds in transiently PXR-transfected HepG2 
and Huh7 cells. The transactivation fold of CYP3A4 reporter gene construct by herbal 
compounds at 1 and 10 μM (but not at 0.01, 0.1 and 25 μM) in PXR-transfected HepG2 cells 
significantly correlated with that in PXR-transfected Huh7 cells (data not shown).  
 
4.3.2 Effects of herbal compounds on CYP3A4 protein expression in Huh7 cells 
We checked the expression level of CYP3A4 protein in intact Huh7 cells treated with several 
herbal compounds for 48 hr using Western blotting analysis. The results are shown in Figure 
4-4. Compared with the vehicle control, the expression of CYP3A4 protein was significantly 
(p < 0.001) induced by praeruptorin A (1.8-fold), praeruptorin C (2.2-fold), praeruptorin D 
(1.5-fold), and praeruptorin E (1.6-fold). 
 
 
 
Figure 4-4. Effect of selected herbal compounds on CYP3A4 expression at the protein level in Huh72 
cells. The CYP3A4 expression was normalized by that of GAPDH. A, DMSO (control vehicle, 0.1%, 
v/v); B, praeruptorin A; C, praeruptorin C; D, praeruptorin D; and E, praeruptorin E. *p < 0.05, vs 
control vehicle (DMSO) by ANOVA followed by Bonferroni’s test.  
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4.3.3 Induction of PXR mRNA expression by herbal compounds in LS174T Cells 
We investigated the effects of 19 herbal compounds at 1 and 25 μM on the expression of PXR mRNA 
in human intestinal LS174T cells cultured in FBS-free DMEM using the real-time PCR technique.  
Figure 4-5A illustrates the effect of herbal compounds on the PXR mRNA expression level in 
LS174T cells cultured in FBS-free DMEM.  The level of PXR mRNA expression was significantly 
(p < 0.01 or 0.001) induced by protocatechuic aldehyde (3.8-fold at 25 μM), salvianolic acid B 
(1.8-fold at 1 μM), and sodium danshensu (2.1-fold at 1 μM) ( 
Figure 4-5 & Table 4-3). However, aloe-emodin, chrysophanol, cryptoanshinone, emodin, 
physcion, praeruptorin A, C, and E, rhein, and shionone did not significantly (p > 0.05) change 
PXR mRNA expression in LS174T cells cultured in FBS-free DMEM. On the other hand, 
epifriedelanol, morin, mulberroside A, tanshinone I, and tanshinone IIA significantly 
down-regulated the expression of PXR mRNA in LS174T cells cultured in FBS-free DMEM 
(p < 0.05, 0.01 or 0.001). 
 
In LS174T cells cultured in DMEM containing 10% FBS, PXR mRNA expression levels were 
significantly (p < 0.05) induced by physcion (3.3-fold at 1 μM), chrysophanol (2.7-fold at 25 μM), 
and rhein (3.5-fold at 1 μM) ( 
Figure 4-5B). However, aloe-emodin, emodin, epifriedelanol, mulberroside A, praeruptorin A, C, D, 
and E, protocatechuic aldehyde, salvianolic acid B, and shionone insignificantly change the 
expression of PXR mRNA ( 
Figure 4-5B).  
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Table 4-3. A comparison of the expression of CYP3A4 and PXR mRNA in LS174T cells cultured in FBS-enriched or FBS-free medium.  
Fold PXR mRNA Expression  Fold CYP3A4 mRNA Expression 
FBS-free FBS-enriched FBS-free FBS-enriched Herbal compound/concentration 1 μM 25 μM 1 μM 25 μM 1 μM 25 μM 1 μM 25 μM 
DMSO (0.1%, v/v) 1.02 ± 0.21 1.05 ± 0.23 1.01 ± 0.13 1.05 ± 0.09 
PBS 1.03 ± 0.27 1.01 ± 0.07 1.05 ± 0.34 1.01 ± 0.12 
Rifampicin (positive control, 
10 μM) 
1.05 ± 0.16 3.31 ± 2.19 12.13 ± 1.39*** 3.64 ± 2.04* 
Aloe-emodin 0.67 ± 0.13 0.47 ± 0.11 1.78 ± 0.99 2.01 ± 0.87a 0.83 ± 0.08 0.83 ± 0.04 0.98 ± 0.46 1.75 ± 0.64a 
Chrysophanol 0.52 ± 0.10 0.61 ± 0.14 2.51 ± 1.05b 2.68 ± 1.16*,a 0.95 ± 0.04 0.75 ± 0.09 1.57 ± 0.65 1.31 ± 0.47 
Cryptotanshinone 0.54 ± 0.08 0.22 ± 0.04 - - 1.09 ± 0.11 0.27 ± 0.04 - - 
Emodin 0.82 ± 0.16 0.34 ± 0.07 1.24 ± 1.40 1.74 ± 1.32 0.93 ± 0.09 0.35 ± 0.03 0.97 ± 1.05 3.39 ± 2.70** 
Epifriedelanol 0.45 ± 0.06* 0.42 ± 0.08 0.58 ± 0.05a 0.50 ± 0.05 0.74 ± 0.12 0.50 ± 0.32 0.67 ± 0.16 0.67 ± 0.18 
Morin 0.26 ± 0.07** 0.47 ± 0.14 1.06 ± 0.08c 0.97 ± 0.08c 0.47 ± 0.05 0.86 ± 0.18 0.41 ± 0.06 0.62 ± 0.04a 
Mulberroside A 0.26 ± 0.12** 0.32 ± 0.17 0.19 ± 0.22 0.52 ± 0.08 0.33 ± 0.12 0.64 ± 0.22 0.28 ± 0.13 0.45 ± 0.12 
Physcion 0.58 ± 0.26 0.29 ± 0.06 3.29 ± 1.39**,b 2.44 ± 1.00b 0.65 ± 0.18 0.45 ± 0.03 3.61 ± 1.40***,b 4.31 ± 2.05***,b 
Praeruptorin A 0.68 ± 0.13 0.71 ± 0.21 0.86 ± 0.09 0.68 ± 0.08 2.51 ± 0.12 2.49 ± 0.36 0.78 ± 0.03c 1.16 ± 0.04c 
Praeruptorin C 0.79 ± 0.15 1.05 ± 0.20 0.61 ± 0.05 0.64 ± 0.27 2.54 ± 0.12 15.70 ± 1.17*** 1.88 ± 0.39a 1.58 ± 0.57c 
Praeruptorin D 0.28 ± 0.22** 0.34 ± 0.16 1.32 ± 0.12c 0.48 ± 0.11 2.76 ± 1.95 2.86 ± 1.33 0.64 ± 0.06 0.75 ± 0.15a 
Praeruptorin E 0.56 ± 0.09 1.05 ± 0.43 0.91 ± 0.08b 0.27 ± 0.03a 3.01 ± 0.31* 1.72 ± 0.82 0.59 ± 0.04c 0.61 ± 0.06a 
Protocatechuic aldehyde 1.24 ± 0.71 3.79 ± 0.79*** 1.04 ± 0.15 1.08 ± 0.49b 2.04 ± 0.72 12.20 ± 2.80*** 0.98 ± 0.10a 0.78 ± 0.09c 
Rhein 0.95 ± 0.30 1.46 ± 0.31 3.53 ± 1.45**,a 2.18 ± 1.24 1.16 ± 0.27 3.72 ± 0.29*** 1.56 ± 0.58 1.37 ± 1.00b 
Salvianolic acid B 1.78 ± 0.44** 1.48 ± 0.30 1.58 ± 0.37 0.84 ± 0.45 5.46 ± 2.33*** 2.73 ± 0.81 0.50 ± 0.07b 0.46 ± 0.30b 
Shionone 0.60 ± 0.08 0.66 ± 0.19 0.59 ± 0.05 0.53 ± 0.10 0.47 ± 0.11 1.00 ± 0.30 0.49 ± 0.11 0.46 ± 0.13a 
Sodium danshensu 2.09 ± 0.44*** 1.82 ± 0.34 0.79 ± 0.40b 1.24 ± 0.26a 5.01 ± 1.45*** 4.81 ± 1.09*** 0.41 ± 0.24c 0.62 ± 0.15c 
Tanshinone I 0.12 ± 0.01*** 0.24 ± 0.06 - - 0.22 ± 0.05 0.27 ± 0.04 - - 
Tanshinone IIA 0.22 ± 0.12*** 0.18 ± 0.06 - - 0.23 ± 0.10 0.38 ± 0.12 - - 
Data are the mean ± SD of four independent experiments. 
*p < 0.05; **p < 0.01; ***p < 0.001, herbal treatment vs control vehicle (DMSO or PBS) by one-way ANOVA followed by Bonferroni’s test. 
ap < 0.05; bp < 0.01; cp < 0.001, FBS-free vs FBS-enriched medium at 1 or 25 μM herbal compound by Student’s t test. 
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Figure 4-5. Effects of herbal compounds on the expression of PXR mRNAs in LS174T cells 
cultured in FBS-free (A) or FBS-enriched (B) medium. LS174T cells were seeded in 6-well plates 
and incubated overnight. The cells were treated with 1 or 25 μM herbal compounds for 48 hr. Total 
RNA was isolated, and mRNA levels were analyzed by real-time PCR. Expression of tested genes 
was normalized against that of β-actin. The effect of herbal compounds on PXR mRNA levels is 
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presented as -fold mRNA expression to vehicle control treated cells (value set to 1). Data represent 
the mean ± SD (n = 3) performed in triplicate. .*p < 0.05; **p < 0.01; ***p < 0.001, vs control vehicle 
by one-way ANOVA followed by Bonferroni’s test. 
 
4.3.4 Induction of CYP3A4 mRNA expression by herbal compounds in LS174T Cells 
We investigated the effects of 19 herbal compounds at 1 and 25 μM on the expression of 
CYP3A4 mRNA (a target gene of PXR) in human intestinal LS174T cells cultured in 
FBS-free DMEM using the real-time PCR technique. All herbal compounds at these two 
concentrations did not show remarkable cytotoxicity towards LS174T cells (data not shown). 
As shown in Figure 4-6A, the CYP3A4 mRNA level was significantly induced by rifampicin 
which served as the positive control (12.1-fold at 10 μM), praeruptorin C (15.7-fold at 25 
μM), protocatechuic aldehyde (12.2-fold at 25 μM), praeruptorin A (2.5-fold at 1 and 25 μM), 
praeruptorin D (2.9-fold at 25 μM and 2.8-fold at 1 μM), praeruptorin E (3-fold at 1 μM), 
protocatechuic aldehyde (12.2-fold at 25 μM), rhein (3.7-fold at 25 μM), salvianolic acid B 
(5.4-fold at 1 μM), and sodium danshensu (5-fold at 1 μM and 4.8-fold at 25 μM) when 
compared with the control vehicle. In contrast, aloe-emodin, chrysophanol, cryptoanshinone, 
emodin, eipifriedelanol, morin, mulberroside A, physcion, and shionone insignificantly (p > 
0.05) altered CYP3A4 mRNA expression in LS174T cells. Tanshinone I and tanshinone IIA 
at 1 and 25 μM reduced the expression of CYP3A4 mRNA 3.0 to 4.8-fold, but the 
down-regulation did not achieve statistical significance. 
 
We further investigated the effects of herbal compounds on the expression of CYP3A4 
mRNA in LS174T cells cultured in DMEM containing 10% FBS. As shown in Figure 4-6B, 
the CYP3A4 mRNA levels were significantly induced only by emodin (3.4-fold at 25 μM) 
and physcion (3.6-fold at 1 μM and 4.3-fold at 25 μM). Rifampicin at 10 μM significantly 
induced CYP3A4 mRNA by 3.6-fold (p < 0.05). In contrast, aloe-emodin, chrysophanol, 
emodin, epifriedelanol, morin, mulberroside A, praeruptorin A, C, D and E, protocatechuic 
aldehyde, salvianolic acid B, shionone, and sodium danshensu did not significantly alter the 
expression of CYP3A4 mRNA in LS174T cells (p > 0.05).  
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Figure 4-6. Effects of herbal compounds on the expression of CYP3A4 mRNAs in LS174T cells 
cultured in FBS-free (A) or FBS-enriched (B) medium. LS174T cells were treated with 1 or 25 μM 
herbal compounds for 48 hr. Total RNA was isolated, and mRNA levels were analyzed by real-time 
PCR. Expression of tested genes was normalized against that of β-actin. The effect of herbal 
compounds on CYP3A4 mRNA levels is presented as fold mRNA expression to vehicle control 
treated cells (value set to 1). Data represent the mean ± SD (n = 3) performed in triplicate. *p < 0.05; 
**p < 0.01; ***p < 0.001, vs control vehicle by one-way ANOVA followed by Bonferroni’s test. 
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4.3.5 Effect of FBS addition on the expression of PXR and CYP3A4 mRNA in LS174T 
cells 
Our study demonstrated a remarkable effect of FBS in the medium on PXR and CYP3A4 
mRNA expression by herbal compounds in LS174T cells. Table 4-3 show the differential 
mRNA expression of PXR and CYP3A4 in LS174T cells cultured in FBS-enriched or 
FBS-free DMEM. For the CYP3A4 gene, addition of FBS to DMEM significantly (p < 0.05) 
decreased the inducing effects of rifampicin, praeruptorin A, C, D, and E, protocatechuic 
aldehyde, salvianolic acid B, and sodium danshensu. On the other hand, addition of FBS to 
DMEM significantly (p < 0.05) enhanced the inducing effect of aloe-emodin, emodin, 
physcion, and chrysophanol on the expression of CYP3A4 mRNA in LS174T cells. Similar 
results were observed with all herbal compounds tested on the expression of PXR mRNA in 
LS174T cells when FBS was added to DMEM, except for that the inducing effect of 
praeruptorin C was decreased while the inducing effect of rifampicin and praeruptorin D was 
enhanced.  
 
4.3.6 Correlation analysis of the expression of PXR and CYP3A4 mRNA in LS174T 
cells 
We conducted a correlation study to examine the relationships of PXR and CYP3A4 mRNA 
induction by 19 herbal compounds in LS174T cells cultured in FBS-enriched or FBS-free 
DMEM. The induction of PXR mRNA by herbal compounds at 1 and 25 μM in LS174T cells 
cultured FBS-free medium, but not in cells cultured in FBS-enriched medium, significantly 
(p < 0.05) correlated with that of CYP3A4 mRNA by herbal compounds at 1 μM in LS174T 
cells cultured FBS-free medium. When herbal concentration was increased to 25 μM, the 
induction of PXR mRNA by herbal compounds at 25 μM only significantly (p <0.05) 
correlated with that of CYP3A4 mRNA in LS174T cells cultured FBS-free medium.  In 
FBS-enriched medium, the induction fold of PXR mRNA by herbal compounds at 1 or 25 
μM in FBS-enriched medium, but not in FBS-free medium, significantly correlated with that 
of CYP3A4 mRNA by herbal compounds at 1 or 25 μM. It appeared that addition of FBS to 
the medium did not significantly affect the correlation of PXR and CYP3A4 mRNA induction 
by herbal compounds.  
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4.3.7 Correlations analysis of CYP3A4 reporter gene construct transactivation in 
PXR-transfected HepG2 and Huh7 cells and PXR/CYP3A4 mRNA induction in 
intestinal LS174T cells 
A correlation study demonstrated that there was a significant correlation (p < 0.05) between 
the transactivation of CYP3A4 reporter gene construct by herbal compounds at 0.1 μM (but 
not at 1, 5 and 25 μM) in transiently transfected Huh7 cells and PXR mRNA induction by 
herbal compounds at 1 μM (but not at 25 μM) in LS174T cells cultured in FBS-free medium 
(but not in FBS-enriched medium) (data not shown). However, the correlation did not exist 
between the transactivation of CYP3A4 reporter gene construct by herbal compounds at 
0.01-25 μM in PXR-transfected HepG2 cells and PXR mRNA induction in LS174T cells 
cultured in FBS-free or FBS-enriched medium.  
 
The transactivation fold of CYP3A4 reporter gene construct by herbal compounds at 1 and 5 
μM (but not at 0.1, and 25 μM) in PXR-transfected Huh7 cells significantly (p < 0.05) 
correlated with the induction of CYP3A4 mRNA by herbal compounds at 25 μM in LS174T 
cells cultured in FBS-free medium (but not in FBS-enriched medium) (data not shown). In 
contrast, the transactivation fold of CYP3A4 reporter gene construct by herbal compounds at 
0.01-25 μM in PXR-transfected HepG2 cells did not correlate with the induction of CYP3A4 
mRNA by herbal compounds at 1 or 25 μM in LS174T cells cultured in FBS-free or 
FBS-enriched medium. 
 
4.4 Discussion 
We first investigated the effect of a panel of herbal compounds on PXR activity using a 
luciferase reporter gene assay in two commonly used human liver-derived cell lines, HepG2 
and Huh7. Praeruptorin A and C transactivated the CYP3A4 reporter gene construct in both 
cell lines transfected with PXR, however, differential reporter gene construct transactivation 
effects of other herbal compounds are observed. Morin, tanshinone IIA, salvianolic acid B, 
sodium danshensu, and protocatechuic aldehyde all induced CYP3A4 reporter gene construct 
transactivation in PXR-transfected HepG2 cells, but not in transfected Huh7 cells. HepG2 
cells express lower levels of the major CYPs than liver [541], while the expression of 
CYP3A4 is significantly increased in Huh7 cells during confluent growth over up to 5 weeks 
[542]. Importantly, these two cell lines are different from primary human hepatocytes. Harris 
et al. [543] compared the gene expression profiles of HepG2 cells and human hepatocytes 
and found approximately 31% of the genes expressed in HepG2 cells were unique to the cell 
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line, and many of these coded for transcription factors, signal transduction proteins, growth 
factors, and transporters. Olsavsky et al. [544] recently examined the transcriptomic 
variation of primary human hepatocytes in Matrigel sandwich cultures versus liver cell lines 
including HepG2 cells and Huh7. The human hepatocyte sandwich cultures showed basal 
and post-xenobiotic exposure expression profiles similar to those from liver, but both HepG2 
and Huh7 failed to elicit a comparable response. A recent study revealed a substantial 
number of basal gene expression differences between naive HepG2 cells and primary human 
hepatocytes [545]. 
 
To corroborate the results from our luciferase reporter gene assays, we further examined the 
effects of herbal compounds on the expression of PXR and its target gene CYP3A4 in human 
intestinal Ls174T cells. The PXR mRNA expression in LS174T cells was significantly 
induced by protocatechuic aldehyde, salvianolic acid B, and sodium danshensu. However, 
praeruptorin A, C, D, and E did not induce PXR mRNA at both 1 and 25 μM. For the first 
time, our study has demonstrated that epifriedelanol, morin, mulberroside A, praeruptorin D, 
tanshinone I and tanshinone IIA at 1 μM significantly down-regulated the expression of PXR 
mRNA in LS174T cells. A high concentration of these herbal compounds (25 μM) also 
down-regulated PXR mRNA expression, although it did not achieve a statistical significance. 
Most of these compounds at 1 μM reduced the expression of CYP3A4 mRNA. Several 
compounds have been reported to down-regulate PXR and its target genes. Ketoconazole was 
first reported by Takeshita et al. [546] as a PXR antagonist and was subsequently shown to 
disrupt the binding of coregulators (including both coactivators and corepressors) to the 
surface of PXR in an agonist-dependent fashion [540, 547]. Several synthesized 
ketoconazole derivatives were inhibitors of PXR [548]. L-sulforaphane, a biologically active 
phytochemical abundant in broccoli, is a specific antagonist of human PXR and inhibits 
PXR-mediated induction of CYP3A4 [549]. Ecteinascidin-743 (ET-743) is also an antagonist 
of PXR [98]. In addition, the Toll-like receptor-2 ligand, lipoteichoic acid, down-regulated 
mouse Pxr [550]. Down-regulation of PXR and its target genes by herbal medicines have 
importance implication in and herb-drug interactions and cancer prevention.    
 
The moderate induction of CYP3A4 via PXR-mediated pathway by rifampicin in our study is 
probably due to a lower plasmid transfection efficiency in our tumor-originated cells. In fact, 
there is a negligible induction of PXR by rifampicin in LS174T cells although it induces a 10- 
to 16-fold expression of CYP3A4 mRNA in LS174T cells and human primary hepatocytes 
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[540]. In tumor-derived hepatic and intestinal cells and human primary hepatocytes, the 
induction of PXR is often significantly lower than that of its target gene CYP3A4 by 
rifampicin [540, 551], suggesting the involvement of other nuclear receptors such as CAR, 
GR and HNF-4α. In this study, each herbal compound was tested at concentrations of 0.01, 
0.1, 1, 10, and 25 μM. But some compounds such as emodin and cryptoanshinone did not 
show a dose response in the transactivation of CYP3A4 gene. This did not seem due to 
cytotoxicity, since at these concentrations, the compound showed only minor cytotoxicity 
towards native and transiently PXR-transfected HepG2 cells. This also suggests that other 
factors such as coactivators or corepressors, or other nuclear receptors may be involved in 
the activation of CYP3A4 gene. 
 
In summary, our data demonstrate that cryptotanshinone, emodin, morin, praeruptorin A, C 
and D, protocatechuic aldehyde, salvinolic acid B, sodium danshensu, and tanshinone IIA 
can effectively activate PXR in human hepatic HepG2 and/or Huh7 cells. Chrysophanol, 
physcion and rhein are also potential activators of PXR. Furthermore, emodin, physcion, 
praeruptorin C and E, protocatechuic aldehyde, rhein, salvianolic acid B, and sodium 
danshensu significantly induce CYP3A4 mRNA expression in human intestinal LS174T cells. 
However, epifriedelanol, mulberroside A, praeruptorin D, tanshinone I, and tanshinone IIA 
significantly down-regulate the expression of PXR in human intestinal LS174T cells. These 
results demonstrate that herbal medicines can significantly regulate CYP3A4 in a cell 
type-dependent manner via the PXR-mediated pathway but other NRs may also play a role. 
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CHAPTER 5 GENERAL DISCUSSION 
 
5.1 Major findings of this project 
Firstly, we employed two algorithms, Sorting Intolerant from Tolerant (SIFT) and 
Polymorphism Phenotyping (PolyPhen) to predict the impact of non-synonymous SNPs 
(nsSNPs) on NR activities and disease susceptibility. We identified 442 nsSNPs in a 
systematic screening of 48 human NR genes. Using SIFT, of 442 amino acid substitutions, 
289 (65.38%) were classified as “intolerant”. The PolyPhen program classified 269 (60.86%) 
of them as “probably damaging” or “possibly damaging”. The results from the two 
algorithms were in concordance. Among the 442 mutations, 229 of them have been 
functionally characterized. SIFT predicted 192 of these nsSNPs as “intolerant”, resulting in a 
correct prediction rate of 83.84%, while PolyPhen gave a prediction rate of 76.86%. For 216 
nsSNPs of the androgen receptor gene, 149 nsSNPs have been functionally studied and most 
(121) of them resulted in a reduction of receptor activity. SIFT sorted 187 out of 216 as 
“intolerant” (86.57%) and PolyPhen identified 159 out of 216 as “potentially intolerant” 
(73.61%). These results indicate that both SIFT and PolyPhen are useful and efficient tools to 
predict the functional effects of nsSNPs of human NR genes. 
 
Secondly, we predict the phenotypical impact of nsSNPs of human ABC transporter genes 
and the predicted results were further validated by phenotypical data from site-directed 
mutagenesis and clinical genetic studies. One thousand and six hundred thirty two nsSNPs 
were found from 49 human ABC transporter genes. Using the PolyPhen and SIFT algorithms, 
41.8-53.6% of nsSNPs in ABC transporter genes were predicted to have an impact on protein 
function. The prediction accuracy was up to 63-85% when compared with known 
phenotypical data from in vivo and in vitro studies. There was a significant concordance 
between the prediction results using SIFT and PolyPhen. Of nsSNPs predicted as deleterious, 
the prediction scores by SIFT and PolyPhen were significantly related to the number of 
nsSNPs with known phenotypes confirmed by experimental and human studies. The amino 
acid substitution variants are supposed to be the pathogenetic basis of increased susceptibility 
to certain diseases with Mendelian or complex inheritance, altered drug resistance and 
altered drug clearance and response. 
 
Finally, we investigated the effect of an array of compounds isolated from commonly used 
Chinese herbal medicines on the activity of PXR using a luciferase reporter gene assay in 
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transiently transfected HepG2 and Huh7 cells, two cell lines derived from human liver tumor. 
The effect of herbal compounds on the expression of PXR and its target gene CYP3A4 in 
human intestinal LS174T cells was further determined using real-time PCR and Western blot 
analysis. The study found that praeruptorin A and C, salvianolic acid B, sodium danshensu, 
and protocatechuic aldehyde significantly transactivated the CYP3A4 reporter gene construct 
in both PXR-transfected HepG2 and Huh7 cells. Cryptotanshinone, emodin, morin, and 
tanshinone IIA significantly transactivated CYP3A4 reporter gene construct in 
PXR-transfected HepG2 cells, but not in PXR-transfected Huh7 cells. The PXR mRNA 
expression in LS174T cells was significantly induced by physcion, protocatechuic aldehyde, 
salvianolic acid B, and sodium danshensu. However, epifriedelanol, morin, praeruptorin D, 
mulberroside A, tanshinone I, and tanshinone IIA significantly down-regulated the 
expression of PXR mRNA in LS174T cells. Furthermore, emodin, physcion, praeruptorin C 
and E, protocatechuic aldehyde, rhein, salvianolic acid B, and sodium danshensu 
significantly induced CYP3A4 mRNA expression in human intestinal LS174T cells. 
  
5.2 Genotype-phenotype relationships of human NR genes 
Currently, numerous association studies are undertaken for explaining how common genetic 
variations in the form of SNPs may impact the health and increase the risk of complex 
disease in humans. Due to the large number of SNPs collected in public SNP databases, a 
primary challenge in these studies is the selection of reliable SNPs that have a high 
probability of altered protein structure leading to phenotypic changes. Predicting the 
phenotypic consequences of nsSNPs using algorithms in silico may provide a greater 
understanding of genetic differences in susceptibility to disease and drug response. 
Numerous experiments on the function of SNPs have found that genetic mutations in the 
human NR gene family are responsible for interindividual variation in NR activity and the 
expression levels of enzymes that are governed by NRs, which contribute to disruption of 
signalling pathways, hormone resistance, metabolic dysfunction and are associated with 
several clinically relevant diseases. In this project, we explored the relationship between 
prediction consequences of nsSNPs by computational approaches and real phenotypes 
confirmed by experiments.  
 
A number of haplotypes exist in the human NR family. Haplotypes are considered as better 
predictors for phenotype than individual SNPs. However, it is currently too complicated to 
design a computational method to predict the genotype of haplotype, although a few 
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algorithms have been developed to analyze haplotype frequencies and predict haplotype 
phases based on individual genetic information [516]. 
 
Prediction of the functional impact of nsSNP could be used in early diagnosis of diseases and 
drug discovery. Although a number of complicated in silico approaches have been used to 
predict the function of nsSNPs, the most informative features for these algorithms are amino 
acid sequence alignment [552], the physio-chemical differences based on the basic features 
of amino acids [553], mapping to corresponding protein three-dimensional structures or 
models of protein and protein complexes [554-556], and combinations thereof [557]. 
Different in silico algorithms focus on different aspects of this information, among which the 
SIFT algorithm and the PolyPhen algorithm are the main representatives in this field. 
Significant concordance was observed between the functional consequences of nsSNP 
predicted by SIFT and PolyPhen (Spearman's ρ = -0.601; P≤ 0.001). Defining that the 
variants whose positions with normalized probabilities < 0.05 in SIFT and < 1.5 are predicted 
to be deleterious in PolyPhen are predicted to be deleterious, 65.38 % and 60.86 % of the 
amino acid substitutions are predicted by SIFT and PolyPhen algorithms, respectively, to 
have functional effects on NR activity. They are significantly higher than results from Wang 
et al. [558] who reported that 39-43 % of nsSNPs in human CYP genes were predicted to 
have functional impacts on protein function, and Xi et al. [287] who reported that 20-50% of 
the large number of amino acid substitutions observed in DNA repair genes were supposed to 
impact function. However, the ratio of deleterious nsSNPs in certain genes is slightly higher 
than that in other genes located in the normal human genome. Ng and Henikoff [305] 
reported that 25% of 3084 nsSNPs from dbSNP would impact protein activity using SIFT. 
According to statistics of PolyPhen website, there are 33.2% of 76,434 entries in total 
predicted to be possibly and probably damaging based on the dbSNP build 126. 
 
The prediction accuracy for these in silico algorithms is also investigated. A number of in 
vivo and in vitro experiments have provided directly or indirectly evidence for nsSNPs 
functional effect on alteration of protein stability and NR activity, metabolic dysfunction or 
correlation with diseases. It has been estimated that 68∼73% of amino acid substitutions were 
predicted correctly by SIFT and PolyPhen [305, 558]. Wang et al. [558] identified 68.57% 
and 69.80% of 259 nsSNPs in human CYP genes were correctly predicted as deleterious 
using SIFT and PolyPhen algorithms, respectively. Using SIFT algorithm, Ng and Henikoff 
[305] identified 69% of deleterious nsSNPs (3626/5218) from amino acid substitutions 
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annotated to be involved in disease risk from databases and 63% of deleterious nsSNPs from 
substitutions in lac repressor and lysozyme (Lacl) that affect function. Based on probabilistic 
models developed by the authors, 75% of nsSNPs in a total of 733 amino acid substitutions in 
Lacl that affect function were predicted correctly by Chasman and Adams [559], whereas 
69% of nsSNPs in a total of 1551 allelic variants involved in disease from databases that 
affect function were predicted correctly by Sunyaev et al. [556]. In this study, SIFT and 
PolyPhen predicted successfully the effect of 83.84% and 78.86 of 229 allelic variants in NR 
gene family. These rates of accuracy are higher than those found in previous studies. Notably, 
a higher prediction accuracy (96%) was obtained by Xi et al. [287] using PolyPhen and SIFT 
on the phenotype of APEX1 (multifunctional DNA repair enzyme 1) variants. Although the 
data for evaluation were obtained from benchmarking studies, there maybe exist certain bias 
because of small samples of only 26 substitutions and it should be careful to extrapolate this 
data to other gene family or the whole genome. 
 
5.3 Genotype-phenotype relationships of human ABC transporters genes 
Identifying the functional impact of nsSNPs in genes through site-directed mutagenesis, 
transgenic and gene knockout, and genetic linkage and association studies is laborious and 
often becomes difficult when there are a large number of candidate nsSNPs. In addition, 
these approaches have their intrinsic limitations. For example, although site-directed 
mutagenesis allows DNA modifications by extending oligonucleotide primers which contain 
the desired mutation(s) flanked by bases complementary to target sequences, this technique 
is restrained by the fidelity and template size limitations of in vitro DNA synthesis and the 
success rate for mutagenesis decreases with the number of mismatches introduced by the 
mutagnenic primers.  Approximately 15% of gene knockouts are developmentally lethal and 
the lack of adult mice limits studies to embryonic development and often makes it more 
difficult to determine a gene's function in relation to human health [560]. On the other hand, 
genetic association analysis may result in false positive findings due to problematic 
genotyping technologies and limited number of SNPs tested [561].  Predicting the 
phenotypic consequences of nsSNPs using algorithms in silico may provide a greater 
understanding of genetic basis for differences in susceptibility to diseases and drug response. 
 
In eukaryotes, most ABC genes move compounds from the cytoplasm to the outside of the 
cell or into an intracellular compartment (e.g. endoplasmic reticulum, mitochondria, and 
peroxisome. Most of the known functions of eukaryotic ABC transporters involve the 
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shuttling of hydrophobic compounds either within the cell as part of a metabolic process or 
outside the cell for transport to other organs, or for secretion from the body. ABC transporters 
are involved in many crucial biological processes, including nutrient uptake, lipid trafficking 
and metabolism, cell signalling, xenobiotic defense, ion homeostasis, drug and antibiotic 
excretion, secretion of macromolecules, organ regeneration and repair, antigen presentation 
to cytotoxic T cells, and cell volume regulation [168, 169, 562, 563]. In 49 human ABC 
transporters, at least half of them have a known physiological and pharmacological function 
and 18 are associated with a defined human disease. 
 
ABCB1, ABCC1, ABCC2, ABCC3, and ABCG2 can transport an array of structurally 
distinct anticancer drugs, and their overexpression cause MDR [168, 564]. MDR is a major 
hindrance for the success of clinical chemotherapy. Classic MDR is characterized by 
cross-resistance between a series of chemically unrelated drugs, decreased drug 
accumulation in cancer cells, increased expression of ABCB1, and reversal of the phenotype 
by a variety of different compounds [565]. Mutations of ABCB1, ABCC1, ABCC2, ABCC3, 
and ABCG2 may alter the sensitivity of tumor cells to anticancer drugs. A full understanding 
of the clinical impact of the mutations of ABC transporters is important for the choice of 
proper anticancer drugs and optimal treatment regimens. The knowledge about the 
mechanism of MDR and how ABC transporter mutations affect MDR is useful in predicting 
the human response of chemotherapy. 
 
Drug’s bioavailability depends on a major extent from the expression and activity of drug 
transporters across cellular membranes. In particular, the ABC transporters such as ABCB1 
and ABCG2 have been identified as major determinants of intestinal absorption of many 
substrate drugs. They are expressed in the apical membranes of many barrier tissues such as 
the intestine, liver, blood-brain barrier, kidney, and placenta, thus affecting the tissue 
distribution, disposition and excretion of drugs [210]. Since their expression and function 
exhibit a broad variability, polymorphisms in human ABC transporters could explain in part 
interindividual differences in pharmacokinetics and clinical outcome of drugs [210, 566]. It 
is important to determine how genetic mutations in ABC transporters contributes to the 
variable responses to drugs in patients.  
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5.4 Regulation of human PXR by herbal compounds 
Human CYP3A4 gene has been mapped to chromosome 7 q21.3-22.1 and its 5’-flanking 
region has been found to be about 35.8 kb-pair long [567].  The gene contains 13 exons, 
coding for a 502 amino acid protein with a molecular weight of 57.29 kDa. CYP3A4 is the 
largest human CYP enzyme and consists of a complex array of α-helices and β-sheet 
structures as demonstrated by its recently resolved crystal structure [568]. The CYP3A4 
5′-flanking region is long (35.8 kb), but only 13 kb have been systematically analyzed for 
regulation in hepatocyte or intestinal cells [529]. The promoter region of CYP3A4 includes a 
basal transcription element, AP-3 binding site, a p53 binding motif, a hepatocyte nuclear 
factor-4α (HNF-4α/NR2A1) element, two HNF-5 elements, a glucocoticoid response 
element, a PXR element and an estrogen response element [147, 529, 567, 569, 570]. 
Barwick et al. [571] first identified two AG(G/T)TCA hexamers composing an everted 
repeat (ER6) separated by 6 nucleotides in the proximal region of the CYP3A4 promoter 
(−169/−152) that was later identified as a PXR binding response element [99, 538, 572]. 
Goodwin et al. [526] discovered the XREM located between −7.8 and −7.2 kb upstream of 
the CYP3A4 transcription start site with a functional DR3 NR-binding element 1 (dNR1, 
−7733/−7719). The constitutive liver enhancer module of CYP3A4 (CLEM4) located in the 
region from −11.4 to −10.5 kb is essential for constitutive activation of the CYP3A4 gene in 
HepG2 cells [573]. Liu et al. [551] recently discovered a functional PXR responsive ER6 
element localized within the module (CLEM4-ER6, -11368/-11351) in Huh7 cells. In 
addition, another DR4-type PXR binding cis-element in the 5′-flanking region (eNR3A4, 
-7618/-7603) of CYP3A4 was identified [569]. 
 
CYP3A4 is expressed predominantly in the liver but its high expression in the small intestine 
implicates that it plays am important role in the bioavailability of many substances via 
first-pass metabolism [574]. Almost all herbal medicines are administered orally and thus 
they may alter the expression of intestinal CYP3A4. The present study found that 
praeruptorin E, salvianolic acid B, and sodium danshensu at a physiologically relevant 
concentration (1 μM) significantly induced CYP3A4 mRNA expression in human intestinal 
LS174T cells cultured in FBS-free medium. At a higher concentration (25 μM), praeruptorin 
C, protocatechuic aldehyde, rhein, and sodium danshensu significantly induced CYP3A4 
mRNA in LS174T cells. Praeruptorin A, C, D, and E are major active ingredients in the 
Chinese herbal medicine Qianhu (P. praeruptorum), while protocatechuic aldehyde, 
salvianolic acid B, and sodium danshensu are active components of Danshen (S. miltiorrhiza). 
  148
Qianhu, consisting of the roots of P. praeruptorum and P. decursivum, is widely used in the 
treatment of bronchial diseases such as asthma and as a remedy for angina and pulmonary 
hypertension [575]. Danshen is for the treatment of coronary heart diseases and stroke [576, 
577]. There is a potential for reduced oral bioavailability of drugs that are CYP3A4 
substrates when used in combination with Qianhu or Danshen. To date, there are no clinical 
reports on interactions of these two herbs with CYP3A4 substrate drugs in humans. 
 
Our results showed that protocatechuic aldehyde, salvinolic acid B, sodium danshensu, three 
water-soluble compounds from Danshen, transactivated CYP3A4 reporter gene construct in 
transiently PXR-transfected HepG2 cell (but not in transfected Huh7 cells) and up-regulated 
CYP3A4 mRNA expression in LS174T cells ( 
Figure 4-5). We also found that protocatechuic aldehyde, salvinolic acid B, sodium 
danshensu all increased PXR transcription while they up-regulated CYP3A4 mRNA 
expression in LS174T cells. We consider that these three compounds induce CYP3A4 
through a PXR-mediated pathway in which PXR acts as a transcriptional regulator of the 
CYP3A4 gene and increases CYP3A4 mRNA expression, although the involvement of other 
NRs cannot be excluded. Interestingly, protocatechuic aldehyde, salvinolic acid B, and 
sodium danshensu did not induce hepatic Cyp3a expression in mice [578]. In this regard, 
species differences in PXR-mediated CYP3A4 induction should be taken into account. 
 
Our study further demonstrated that addition of FBS to LS174T cells significantly reduced 
the inducing effect of several herbal compounds on PXR and CYP3A4 mRNA expression. 
The reduced inducing effect is considered to be due to reduced free concentrations of herbal 
compounds that can bind to FBS proteins. In addition, proteins and other compounds such as 
growth factors in FBS may mask the effects of herbal compounds on CYP3A4 and PXR 
mRNA expression through transcriptional and/or posttranscriptional mechanisms. The 
growth factors in FBS suppressed CYP3A4 induction in Caco-2 cells [579], and an increase 
in FBS content in the culture medium resulted in only a slight increase of CYP3A4 induction 
by 1α,25-dihydroxyvitamin D3 in human intestinal Caco-2 and LS180 cells [580]. CYP3A4 
gene regulation is a complex process mediated by numerous transcription factors (PXR, 
CAR, CCAAT/enhancer binding protein α, CCAAT/enhancer binding protein β, GRα, 
HNF-4α, and HNF-3α) and multiple promoter/enhancer elements [581]. Although PXR is a 
critical determinant of xenobiotics-induced CYP3A4 expression, other transacting factors 
such as HNF-4α, SRC-1, SHR, and peroxisome proliferator-activated receptor γ, coactivator 
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1α are essential for maximal transactivation of the CYP3A4 gene (Li and Chiang 2006; 
Tirona and others 2003). It is not a surprise that compounds in FBS might interact with herbal 
compounds or directly interact with PXR, CAR, and the promoter regions of the CYP3A4 
gene.   
 
We found that tanshinone IIA and cryptotanshinone, two highly lipophilic constituents from 
Danshen, transactivated CYP3A4 reporter gene construct in PXR-transfected HepG2 (Figure 
4-2), but down-regulated CYP3A4 and PXR mRNA expression in intestinal LS174T cells ( 
Figure 4-5). Our findings in HepG2 cells are consistent with those reported by Yu et al. [582] 
who found that both tanshinone IIA and cryptotanshinone activated human PXR and 
transactivated the CYP3A4 reporter gene construct in transiently transfected HepG2 cells 
with an estimated half-maximal effective concentration (EC50) of 1.4 and 0.4 μM, 
respectively. Kuo et al. [578] also reported that the ethyl acetate extract of Danshen 
up-regulated the hepatic level of Cyp3a in a murine model. We also found that three 
water-soluble compounds from Danshen, salvianolic acid B, sodium danshensu, and 
protocatechuic aldehyde, transactivated CYP3A4 reporter gene construct. However, Yu et al. 
[582] reported that the water extract of Danshen did not activate PXR in transfected HepG2 
cells, but treatment of LS174T cells with cryptotanshinone or tanshinone IIA resulted in a 
significant increase of CYP3A4 mRNA. Such contrasting results in HepG2 and LS174T cells 
could be due to different concentrations of the herbal compounds used and 
batches/generations of the cell line. Our findings may have implications for Danshen-drug 
interactions. Tanshinone IIA and cryptotanshinone appeared to induce CYP3A4 in a cell 
type-specific manner. LS174T cells have a relatively high expression of PXR and CAR [113, 
583-585], and they may respond to herbal compounds in a different way compared to 
hepatocytes. Recently, Pavek et al. [586] reported that the CLEM4-ER6 motif in the 
5’-flanking region of CYP3A4 interacted with VDR/RXRα heterodimer and partially 
cooperated with DR3 (XREM) and proximal ER6 response element in both basal and 
VDR-mediated inducible CYP3A4 regulation in human intestinal HCT-8, HT-29 and Caco-2 
cells. In contrast, DR4 (eNR3A4) was involved only in the basal transactivation in intestinal 
cells and in the PXR-mediated rifampicin-induced transactivation of CYP3A4 in intestinal 
LS174T cells. These findings clearly demonstrate a specific ligand-induced VDR-mediated 
transactivation of CYP3A4 in intestinal cells that is different from PXR-mediated CYP3A4 
regulation in hepatocytes. 
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The regulation of CYP3A4 expression in cells exposed to xenobiotics and endogenous 
compounds is a complex process. Human PXR, CAR, and VDR control CYP3A4 expression 
by targeting the same cis-acting elements located in the regulatory region of the target gene 
such as ER6 and XREM. The xenobiotic responsive enhancer module is a regulatory region 
of the CYP3A4 gene, and binding causes a cooperative interaction with proximal promoter 
regions of the gene, resulting in increased transcription and expression of CYP3A4. Upon 
ligand binding, the PXR transactivates ER6 upstream of the CYP3A4 gene [99]. The binding 
of PXR/RXR to ER6 causes coactivator proteins such as steroid receptor coactivator-1 and 
transcriptional activation of respective gene to follow. The cross-talk among different NRs 
and intracellular signaling pathways in regulating CYP3A4 gene expression results in a 
distinct response to xenobiotic exposure. This may provide an explanation for the tissue- and 
cell-specific inducing effects of CYP3A4 by different herbal compounds observed in this 
study. 
 
The 35-kb-long human PXR gene maps to chromosome 3q13-q21, consisting of 9 exons and 
encoding a 434-amino-acid protein [587]. Targeted disruption of the mouse Pxr gene 
abolished the induction of Cyp3a by prototypic inducers such as dexamethasone and 
pregnenolone-16-α-carbonitrile [588]. The activity of PXR is tightly regulated by various 
coactivators and corepressors. The silencing mediator of retinoid and thyroid hormone 
receptors (SMRT) and the nuclear receptor corepressor (N-CoR) are two related corepressors 
known to mediate repression of PXR through the recruitment of histone deacetylases 
[589-591]. Small heterodimer partner (SHP/NC0B2) is another copressor of PXR. In the 
absence of ligand, SMRT and N-CoR bind to the unliganded PXR through its NR-interacting 
domains [589, 590, 592]. On the other hand, SRC-1 (SRC1/NCOA1) and 2 (SRC2/GRIP1), 
nuclear receptor interacting protein 1 (NRIP1/RIP140), peroxisome proliferator-activated 
receptor-γ coactivator (PGC-1), and Forkhead transcription factor FKHR (FOXO1) are 
coactivators [593]. These corepressors and coactivators are considered to serve as protein 
platforms for the assembly of corepressor/coactivator complexes necessary for target gene 
transcriptional regulation by PXR. Upon binding to a ligand, PXR undergoes a 
conformational change in the corepressor-binding pocket, leading to the release of 
corepressors and recruitment of coactivators.   
 
The induction of CYP3A4 occurs against the background of constitutive expression.  This 
basal expression is mainly regulated by CAR, PXR and HNF4α in the liver [527-529]. CAR 
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is associated with a co-activator called the steroid receptor co-activator 1 (SRC-1).  The 
CAR/SRC-1 complex dimerises with the RXR before binding with the promoter region of 
CYP3A4.  It is in the 5’-untranlated region of the gene where the CAR/RXR complex binds, 
to a sequence containing two copies of the NR organized as ER6, and controls the expression 
of pre-mRNA. Induction of CYP3A4 can occur via up-regulation of this process following an 
increase in the affinity of complex for the proximal ER6 element. Furthermore, cooperativity 
among the CLEM4-ER6 motif and DR3/prER6 sites in basal transactivation of CYP3A4 has 
been demonstrated to be essential for maximal CYP3A4 transactivation via PXR in Huh7 
cells [551]. Cells such as HepG2, Huh7 and LS174T cells have different basal (constitutive) 
expression of CYP3A4 and this may partly explain the different responses to herbal 
compounds observed in this study. 
 
5.5 Conclusion and future directions 
Our findings from this project suggest that: a) predicting the phenotypic consequence of 
nsSNPs in human NRs and their target genes ABC transporters using computational 
algorithms may provide further understanding of genetic differences in susceptibility to 
diseases and drug response and would be useful hints for further genotype-phenotype studies; 
and b) herbal medicines can significantly regulate PXR and its target gene CYP3A4 and this 
has important implication in herb-drug interactions. Further benchmarking studies are 
warranted to verify our prediction data for NRs and their target genes ABC transporters and 
to explore the clinical impact of herb-CYP interactions via the PXR-mediated pathway. 
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